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A) Principal component analysis (PCA) scores plot for the subset of 314 
negative mode features obtained following filtering and prior to feature 
selection across each class. The distribution of samples in this plot reveals no 
clustering amongst samples. by class Pooled quality control samples, 
represented by yellow circles, clustered towards the center of the plot, 
indicating they are an accurate representation of the average sample analyzed. 
B) Orthogonal Partial Least Squares Discriminant Analysis (oPLS-DA) scores 
plot depicting clustering of samples separated into five classes by day of sample 
collection and injury status using the 26-feature model. Variance between 
classes is captured across the X-axis. C) oPLS-DA scores plot depicting 
clustering of samples separated into a binary model, with the y-axis acting as a 






oPLS-DA cross-validated class prediction plots based on the optimized 26 
feature panel comparing A) sham + naïve controls vs. TBI, B) sham vs. TBI 
and C) naïve vs. TBI samples. For all plots, TBI samples are represented by red 
diamonds and correspond to a predicted class value of 0 while the various 
control samples are represented by green squares and correspond to a predicted 
value of 1. Accuracy, sensitivity and specificity values are given for each 
model. The red dashed line represents a decision boundary between classes. 
The oPLS-DA model details were as follows: A) 34 samples, venetian blinds 
cross-validation (CV), 5 splits, 3 latent variables (LVs); B) 24 samples, 
venetian blinds CV, 4 splits, 2 LVs; C) 26 samples, venetian blinds CV, 5 





Volcano plot of processed metabolomic data set. Each point represents one 
feature. Features with fold change < 2 are colored in grey. Features in 
optimized classification panel are colored in red. Features frequently selected to 
build models but not in final classification panel are colored in blue. Positive 

















Figure 2.4 85 
Example box plots showing significantly dysregulated species used by 
optimized model for classification of samples. A1-A6 show species that 
increased and B1-B3 show species that decreased following injury. A1) FFA 
18:0, [M-H]- = 283.2644; A2) arachidonic acid, [M-H]- =303.2330; A3) 
docosapentaenoic acid, [M-H]- = 329.2483; A4) m/z = 262.8846; A5) 
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Boxplots showing time profile changes of samples at 0, 3 and 7 days following 
TBI. Features are divided into 3 groups: A) Features 14, 128, 271, 272, 277, 
699, 289, 245, 656, 680 and 479 showed an initial increase following TBI; B) 
features 719, 61, 357, 103, 377, 64, 129, 292 and 314 that decreased following 
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Schematic overview of the feature selection process for determining an 
optimized classification model used to differentiate TBI samples (red) from 
controls (green). A) Matched pair data (n=31) were imported into Matlab as a 
62x841 matrix containing relative feature abundances for each sample. B) 
Samples were randomly stratified into 7 or 8 data splits so that a different 
portion of the data were withheld to build each model using random subsets 
cross-validation. C) Using the iPLS-DA feature selection algorithm, a 
classification model was built by iteratively adding the feature that contributed 
to the lowest total error of cross-validation. This process was repeated 10 times 
using 7 data splits and 10 times using 8 data splits. D) The features selected 
most frequently within the 20 classification models were combined to build an 





Offset base peak intensity (BPI) traces for aligned chromatographic separations 
of rodent serum samples in A) negative ionization mode and B) positive 
ionization mode. Colors correspond to individual sample subtypes: TBI 
samples are colored in red, pre-injury control samples are colored in light blue, 
and sham control samples are colored in green. The top black trace corresponds 
to a mean BPI trace of all samples analyzed during the experiment. Lipid 
classes are labeled by anticipated time of elution, and the classes of lipids 











Figure 3.3 116 
Classification model performance comparisons with and without feature 
selection illustrating accuracies of developed classification models to used 
discriminate between TBI samples, represented by red diamonds, and control 
samples, represented by green squares. A) PCA scores plot containing all 
features; B) oPLS-DA model containing all features; C) oPLS-DA scores plot 
for 16 feature model showing performance of classification of all 62 samples, 
including sham controls.  
 
Figure 3.4  118 
Performance of the 5-feature oPLS-DA model. Performance accuracy of 
developed classification models to discriminate between TBI samples, 
represented by red diamonds, and control samples, represented by green 
squares. A) oPLS-DA model for 5 feature model, including only features 56, 
380, 448, 456, and 623, showing performance of classification of all 62 
samples, including sham controls. Sample numbers 1-24 correspond to baseline 
control samples, 25-38 indicate sham control samples, and 39-62 represent TBI 
samples; B) oPLS-DA model showing performance of 5-feature classification 
model on 48 matched pair samples, excluding shams. Sample numbers 1-24 
correspond to baseline control samples and 25-48 represent TBI samples. The 
line at 0.5 on the y-axis represents the decision boundary between TBI samples 
and control samples. 
 
Figure 3.5  121 
Cross-validated class prediction values using 5-lipid classification model when 
yellow foam TBI samples are defined as A) TBI (class = 1) and B) control 
(class = 0). Sample numbers 1-24 correspond to baseline control samples, 25-





Boxplots of selected features from 16-lipid classification panel showing relative 
abundances corresponding to: A) Cholesterol Sulfate: [M-H]- = 465.3035; B) 
CE(22:6): [M+NH4]+ = 706.6345; C) PC(41:2): [M+H]+ = 856.6821; D) 
PC(38:5): [M+H]+ = 808.5873; E) PC(39:6): [M+H]+ = 820.5851; F) PC(40:4), 
[M+H]+ = 838.632.. Dots in the center of the boxes indicate the mean while the 
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Figure 4.1 144 
Principal Component Analysis (PCA) scores plot prior to feature selection. 
Pools, closely clustered together in the center of the plot, were successful 
representations of the combination of all classes of samples analyzed and can 
be used for quality control purposes. No initial separation of A. glacialis 
treatment (green square) and A. glacialis control (red diamond) samples was 
observed. A clear separation of T. pseudonana treatment (light blue) and T. 
pseudonana control (dark blue) samples could easily be approximated by the 
blue ellipses. This indicates that larger differences exist in the response of the 





oPLS-DA models reveal that lipidomes of T. pseudonana and A. glacialis are 
disrupted by Karenia brevis allelopathy. Filled symbols represent lipidomes of 
algae exposed to K. brevis through molecule-permeable but cell impermeable 
membranes, empty symbols represent lipidomes from unexposed algae 
(controls). oPLS-DA model generated from A) 1H NMR spectral data and B) 
from UPLC-MS metabolic features from lipidomes of T. pseudonana (blue 
squares). oPLS-DA model generated from C) 1H NMR spectral data and D) 
from UPLC-MS metabolic features from lipidomes of A. glacialis (yellow 
circles). NMR data were collected and interpreted and figure produced by Dr. 





Volcano plot summarizing the differences in the lipidomic responses of T. 
pseudonana (blue) and A. glacialis (yellow) when exposed to K. brevis 
allelopathy. The relative abundances of 80 metabolites were significantly 
different (p < 0.05 after Bonferroni correction) in T. pseudonana samples upon 
exposure to K. brevis allelopathy. Red lines indicate log2 fold differences of ±1. 
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Lipid coverage following protein precipitation with isopropyl alcohol. 
Representative Base Peak Intensity (BPI) chromatograms for pooled serum 
samples from moderate TBI experiments analyzed in A) negative ion mode or 






Estimated nested cross validation performance of TBI prediction modeling. 
Inner cross validation performance is similar to outer cross validation 
performance, meaning inner cross validation AUC is an unbiased estimate of 
outer cross validation AUC. Each point represents one iteration of cross 
validation. The large X’s represent the average performance of each of the four 









Figure A3 184 
Most commonly selected features to build models for classification of moderate 
TBI sorted by frequency selected– 120 maximum. Features were selected to 





Box plots depicting alterations in features not contained in the 26-feature model 
for the classification of moderate TBI but that were still selected with high 
frequency by omniClassifier. A) eicosapentaenoic acid, [M-H]- = 301.217, #34; 
B) docosahexaenoic acid, [M-H]- =327.2322, #35; C) LysoPE(20:4), [M-H]- = 
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 This dissertation is intended to highlight the recent advancements in the field of 
lipidomics, particularly in reference to the discovery of novel biomarkers of traumatic 
brain injury (TBI). Lipidomics falls under the umbrella of the related ‘omics technique 
known as metabolomics and refers specifically to the study of the lipidome, or collection 
of all lipophilic metabolites in a biological system. Lipids play critical roles in cellular 
structure and function, including acting as signaling molecules, regulating energy storage, 
and maintaining membrane integrity. The use of omics’ techniques has led to the 
proposal of a number of biomarkers for the study of TBI, though most have stemmed 
from targeted proteomic approaches, with researchers focusing on a few proteins in the 
brain and central nervous system that are upregulated as a consequence of TBI. The 
response of the lipidome to TBI is less understood, so a non-targeted approach is 
suggested here for the purpose of generating hypotheses regarding lipidomic responses to 
TBI using data-driven, discovery-oriented techniques.  
 Research interest into TBI has been accelerated due to heightened awareness of 
the growing concussion epidemic in the military, sports, and general population. With 
diagnosis of subtle cognitive dysfunction typically based on the presence of subjective 
self-reported symptoms, the number mild traumatic brain injuries (mTBIs) is vastly 
underestimated, as many injuries may go unreported or misdiagnosed due to lack of 
perceived symptoms. Chapter 1 introduces the commonly utilized techniques for clinical 
diagnosis of TBI and outlines the known pathophysiology associated with the onset of 
injury. Ranging from simple grading schemes that measure a patient’s verbal, motor and 
xvii 
 
eye-opening responses to more advanced radiologic imaging and neuropsychological 
testing modalities, the field of mTBI diagnostics is growing rapidly. However, a 
substantial gap remains between the literature and clinical translation, indicating a need 
for further scientific collaboration. 
 Biomarker discovery studies have been enabled by the advent of sophisticated 
instrumentation, fueling the growth of the fields of metabolomics and lipidomics. Such 
studies often involve careful measurement of a large number of molecular targets, so 
advanced techniques are required beyond simple single-target assays. Mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) are the two most commonly utilized 
platforms for metabolomics analysis, and each offers complementary advantages to 
research efforts. MS-based techniques are used throughout this dissertation in order to 
study the lipidomic response within the serum of rodents incurring TBI induced by 
controlled cortical impact. 
 Two distinct severities of injury are investigated and modeled in chapters 2 and 3. 
Chapter 2 first focuses on an injury of moderate severity in an effort to measure the 
response of lipids to injury. A standard metabolomics workflow was utilized, and a 
number of novel biomarker candidates for TBI were identified in the serum lipidome of 
adult male Sprague-Dawley rats in the first week following injury. Serum samples were 
analyzed in positive and negative modes by Ultra Performance Liquid Chromatography 
Mass Spectrometry (UPLC-MS). A predictive panel for the classification of injured and 
uninjured sera samples, consisting of 26 dysregulated species belonging to a variety of 
lipid classes, was developed with a cross-validated accuracy of 85.3% using 
omniClassifier software to optimize feature selection. Polyunsaturated fatty acids 
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(PUFAs) and PUFA-containing diacylglycerols were found to be upregulated in sera 
from injured rats, while changes in sphingolipids and other membrane phospholipids 
were also observed, many of which map to known secondary injury pathways. 
Cholesterol sulfate, a sterol sulfate that plays a stabilizing role in cellular membranes and 
serves as a precursor in the synthesis of other sulfonated adrenal steroids, was found to be 
significantly decreased in the TBI cohort. Overall, the identified biomarker panel presents 
a number of viable molecular candidates representing lipids affected by of TBI 
pathophysiology. 
 In chapter 3, we proposed to study mild injury at an early acute time point (t=24 
h). Using a matched pair study design to improve statistical power, a panel of 16 lipid 
metabolites was developed with a classification accuracy of 88.5%, a small improvement 
from the previous study despite the use of a less complex metabolite panel (reduction by 
50% of the number species studied) and the occurrence of a milder form of injury in 
which the average effect size of lipid alterations was reduced. These promising results 
demonstrate the feasibility of utilizing non-targeted lipidomics to detect mild, concussive 
events in serum.  
 The broad applicability of non-targeted lipidomics experiments is then 
demonstrated in chapter 4 through the study of phytoplankton competitor responses to 
exposure to Karenia brevis, the dinoflagellate responsible for forming harmful algal 
blooms commonly referred to as red tides. MS-based analysis of phytoplankton lipidomes 
led to the identification of 80 distinct lipid metabolites whose concentrations differed 
significantly in T. pseudonana following exposure to K. brevis allelopathy. These 80 
metabolites represent nine major lipid classes, of which members of five 
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(phosphatidylcholines [PCs], sulfoquinovosyldiacylglycerols [SQDGs], 
monogalactosyldiacylglycerols [MGDGs], digalactosyldiacylglycerols [DGDGs], and 
phosphatidylglycerols [PGs]) were generally less abundant when T. pseudonana was 
subjected to K. brevis allelopathy, whereas members of four classes (non-SQDG 
sulfonated lipids [SULFs], free fatty acids [FFAs], primary fatty acid amides [PFAAs], 
and phosphatidylethanolamines [PEs]) were generally more abundant. In contrast, for the 
other competitor, A. glacialis, concentrations of only six metabolites were significantly 
affected by allelopathy, reinforcing the hypothesis that A. glacialis maintains a more 
robust metabolism in response to K. brevis allelopathy due to an evolved resistance 
stemming from periods of prior co-habitation. 
 A majority of the lipids formed (PFAAs, FFAs, and SULFs) by allelopathic 
exposure were either metabolic breakdown products or metabolic precursors of PCs and 
SQDGs, whose pools shrunk in T. pseudonana upon exposure to allelopathy. Globally, 
concentrations of membrane-associated lipids (MGDG, DGDG, SQDG, PC) were 
significantly suppressed for T. pseudonana exposed to allelopathy, leading membranes of 
living cells to become more permeable. Increased membrane permeability as well as 
decreased photosynthetic capability both likely occurred due to decreases in the 
concentrations of membrane- and thylakoid-associated lipids. K. brevis allelopathy 
appears to target lipid anabolism, affecting multiple physiological pathways. This 
suggests that exuded compounds have the ability to significantly alter competitor 




 Finally, chapter 5 explores the potential future work associated with the projects 
contained within this dissertation. Critical points of exploration include validation of 
proposed biomarkers in another cohort of rats and examination of altered response 
patterns based on sex, strain, and age of the animals. Use of human samples for the 
purposes of clinical translation is also proposed. Limitations of the current work are 
examined, and suggestions are made for future experiments to better understand efflux 
pathways for biomarker clearance and answer questions regarding specificity of the 
proposed biomarkers to the brain and brain injury.
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 A substantial portion of the population will sustain a traumatic brain injury (TBI) 
at some point in their lifetime, and heightened awareness of the potentially devastating 
effects of even mild injuries, often referred to as concussions, in the setting of military 
and sports has led to increased research efforts towards the development of objective 
diagnostic modalities. This chapter outlines the different mechanisms of injury and 
subsequent pathophysiological changes that may result. Additionally, the strengths and 
limitations of existing diagnostic modalities for TBI are examined. Non-targeted 
lipidomics is suggested as a tool to objectively determine the presence of injury through 
the measurement of all lipids in a biological system and can be used to guide research 
efforts towards the development of novel biomarkers of injury. Lipidomics can also be 
broadly applied to understand the role of lipid metabolism involved in other biological 
systems, such as the allelopathic effects exerted by Karenia brevis on phytoplankton 
competitors.  
 
1.2 Traumatic Brain Injury Epidemiology 
Traumatic brain injury (TBI) is a complex, heterogeneous disease that affects 
millions of people, with an average of 1.4 million TBIs occurring annually in the United 
States alone. In the US, injury was the leading cause of death for the 1-44 age group in 
2009, and TBI was diagnosed in at least 1/3 of these cases.2 Incidence rates of TBI are 
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similar in other countries, though it is difficult to make direct comparisons due to 
differences in health care and admission criteria.3,4 The direct costs associated with TBI, 
including medical treatment and deaths, have been estimated at over $9 billion annually. 
On top of that, loss of productivity and wages due to TBI-related work absences accounts 
for over $51 billion, bringing the economic burden of TBI to over $60 billion annually in 
the US alone.5  The majority of all reported cases are classified as mild TBI (mTBI), 
though cognitive deficits are still present a year post-injury in about 10% of cases.6 
 About 80% of TBI cases are diagnosed in emergency departments, with head 
injuries accounting for 1.4% of emergency department visits, and 4.8% of injury related 
visits.3 As many patients sustaining TBIs, especially mild, may not report to hospitals for 
diagnosis or treatment, it is expected that the total number of TBI cases actually exceeds 
these totals, with estimates ranging from 11%7 to 75%8 of TBIs going undiagnosed. 
Approximately 52,000 people die of TBI related injury annually in the US, accounting 
for about 30% of injury related deaths, though death rates have been steadily declining 
since 1989.3, 9, 10 The leading causes of TBI include falls, struck-by or struck-against 
events, and motor vehicle crashes. People in the early and late stages of life are most 
vulnerable to fall related TBI. Males (548 per 100,000) have a higher incidence of TBI 
than do females (386 per 100,000).3 Heterogeneity within mechanism of injury and 
amongst persons experiencing TBI is a primary impediment in the design of effective 
treatments and is thought to be a major reason for the failure of clinical trials.11 Factors 
such as age, sex, and previous TBI exposure may all affect the extent of damage and 
clinical manifestation of symptoms of TBI.  
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1.3 Primary Injury Mechanisms 
In addition to the variability in the affected clinical population, the type of injury 
mechanism (fall, penetrating, blast, etc.) contributes to the heterogeneity of injury 
pathology. Mechanisms for primary injury, damage which evolves acutely as a direct result 
of injury to the brain, include blast, focal injury, contusions, and rotational acceleration/ 
deceleration forces.12 Primary damage typically stems from contact and/or inertial forces 
occurring at the moment of injury.   
1.3.1 Focal Injury 
The term focal is used to describe injuries that are caused by direct focused contact 
to the head. The blunt force of the injury results in deformation of the brain tissue and leads 
to localized damage at or near the injury site. Focal injuries are believed to be responsible 
for the majority of injury related deaths and are often characterized by contusions, skull 
fractures, lacerations and hemorrhage.13 Animal models of focal injury are designed to 
produce consistent injury by directly injuring the brain while carefully controlling the 
injury parameters. In vivo studies serve as foundational research for guiding clinical 
studies. The controlled cortical impact (CCI) and fluid percussion injury (FPI) models are 
the most commonly used models to induce focal injury.  
1.3.1.1 Controlled Cortical Impact 
CCI injuries are induced using an air-driven pneumatic piston to impact the exposed 
cortex with intact dura mater following a craniectomy, rapidly compressing brain tissue. 
CCI can be used to model injuries of different severities by varying mechanical parameters 
such as impact velocity, dwell time and depth of impact. The ease with which these 
mechanical parameters can be changed makes CCI a useful pre-clinical model.14 For 
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example, by varying these parameters, CCI can be used to model mTBI, where there is 
little damage, as well as more severe injuries, where large cortical areas are destroyed.15  
1.3.1.2 Fluid Percussion Injury 
The FPI model rapidly applies a pressurized column of liquid to the intact dura 
matter following craniectomy, causing the brain to move within the skull. The resulting 
lesion is less localized compared to CCI, and hemorrhage, brain swelling and progressive 
grey matter damage are seen.16 By controlling the pressure of the liquid, FPI can also be 
used to model different severities of TBI. 
1.3.2 Diffuse Injury 
Diffuse injuries are caused by inertial forces or acceleration/ deceleration of the 
brain within the skull, leading to widespread microscopic damage across large areas of 
the brain. These forces are often seen in clinical TBI following car accidents or falls, in 
addition to the focal injury at the contact site.17 Acceleration/ deceleration forces are 
difficult to model in rodents, though the weight drop and blast injury models may 
substitute as examples of  diffuse injury, even if they are not caused by the same 
mechanism of action, e.g. rotation of the head.  
1.3.2.1 Weight Drop 
The weight drop model involves the release of a weight dropped from a known 
height onto the closed skull. Injury severity can be altered by varying the mass of the 
dropped weight and the height from which it is dropped. A stainless-steel disc is mounted 
to the skull midline to prevent skull fracture. This model produces general brain movement 
and has been shown to result in diffuse axonal injury (DAI).18  
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1.3.2.2 Blast Injury 
While blast injuries also fall within the diffuse subcategory, there are a variety of 
different mechanisms of damage resulting from injuries of this type. Rather than high levels 
of brain deformation, blast is characterized by small deformations delivered at relatively 
much higher rates than the other modalities described. Blast TBI can be modeled pre-
clinically using shock tubes driven by compressed air or helium.19,20  
 
1.4 Secondary Injury Mechanisms 
In addition to the primary injury imparted by the TBI, a complex secondary injury 
cascade follows, which can lead to necrotic and apoptotic neuronal and glial death.  
Necrosis occurs when the acute trauma causes cell death directly in the injured area of the 
brain and is associated with the generation of free radicals and excitotoxins.  It is often 
characterized by mitochondrial and nuclear swelling, rupture of the nuclear and 
cytoplasmic membranes, and enzymatic degradation of deoxyribonucleic acid (DNA). The 
process is very rapid, and because neuronal tissue has little regenerative ability, necrotic 
cell death is very difficult to prevent.21 Necrosis and apoptosis of neurons has also been 
observed in the days and weeks following injury, and it is generally thought to occur 
continuously after injury.22,23 Secondary injury cascade mechanisms also include oxidative 
stress, glutamate excitotoxicity, inflammation, and cytotoxicity of metabolites formed in 




1.4.1 Glutamate Excitotoxicity and the Neurometabolic Cascade 
A significant increase in the release of neurotransmitters and other excitatory amino 
acids (EAAs), specifically glutamate, is a significant part of the secondary injury cascade. 
The neurometabolic cascade is a series of events resulting from TBI, disrupting 
homeostatic brain function to different degrees depending on injury severity. Release of 
neurotransmitters and ionic fluxes occur immediately following TBI.25 Disruption of 
neuronal membranes, axonal stretching and voltage dependent potassium channel openings 
following the primary injury lead to membrane depolarization and efflux of potassium ions 
(K+).26 The resultant non-specific release of excitatory neurotransmitters such as glutamate 
overwhelms the surrounding glial cells’ ability to regulate excess K+, leading to the release 
of additional EAAs, activation of the respective receptor channels and further ion 
imbalance.27 The binding of excitatory neurotransmitters to glutamatergic receptors leads 
to further membrane depolarization, calcium ion influx, and excitotoxicity. Efflux of 
potassium causes the sodium-potassium pump to work harder to restore equilibrium 
intracellular concentrations, requiring energy in the form of adenosine triphosphate (ATP) 
and vastly increasing glucose metabolism.28  
1.4.2 Energy Crisis in the Brain 
This increase in glucose utilization occurs almost immediately in the injured cortex 
and neighboring hippocampus, though it may persist for hours in distant brain areas 
following severe injury. To combat this increased energy demand, the brain responds by 
increasing glycolysis, the breakdown of glucose into pyruvate, which leads to increased 
lactate production.29 The resulting lactate accumulation leads to neuronal dysfunction by 
inducing acidosis, membrane damage, cerebral edema, and altering blood-brain barrier 
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(BBB) permeability.30 The hyperglycolysis demands a concomitant increase in cerebral 
blood flow (CBF), but instead CBF may be reduced by up to 50%, furthering the brain’s 
energy crisis by reducing the energy substrates and oxygen supplied to the brain.31 
Following this period of hypermetabolism, in an effort to combat the energy crisis, the 
brain goes into a period of decreased metabolism, reducing cerebral glycolysis and CBF 
while calcium ion influx continues to disrupt mitochondrial oxidative metabolism.32 
1.4.3 Mitochondrial Dysfunction 
Calcium can flow through the open N-methyl-D-aspartate (NMDA) receptor 
channels, and an increase in intracellular calcium is observed within minutes after injury 
and sustained for days.33 This increase in calcium leads to overactivation of degradative 
enzymes including phospholipases, causing destruction of cellular membranes. Lactic acid, 
free radicals and inflammatory mediators are also generated upon initiation of the 
neurometabolic cascade. 
Mitochondria are small organelles found within most cells and are responsible for 
cellular respiration and energy production. Within mitochondria, carbohydrates and fatty 
acids are converted into ATP. Neurons rely heavily on mitochondrial oxidative metabolism 
and ATP production, which is known to be disrupted following TBI.34 Damage to 
mitochondria reduces ATP production, again signaling the activation of glycolysis despite 
a decrease in lactate metabolism. Ischemic necrosis primarily results from anaerobic 
inactivation of the oxidative phosphorylation process. Mitochondrial cytochrome c release 
has also been demonstrated in TBI, resulting in increased neuronal apoptosis.35 Persistent 
accumulation of intracellular calcium, especially in the mitochondria, is associated with 
8 
 
more severe injuries and may also activate cell death pathways and disrupt neurofilaments 
(NFs) and microtubules.36 
1.4.4 Oxidative Stress 
While reactive oxygen species (ROS) and reactive nitrogen species (RNS) are 
generated during normal physiological processes, their production is vastly increased 
following TBI, overwhelming antioxidant defenses and mediating damage to vital cell 
structures such as cell membranes and mitochondria.37 Overproduction of ROS can lead to 
damage to both DNA and proteins as well as lipid peroxidation (LP) due to oxidative stress 
in mitochondria. 
Much research has focused on the oxidative stress mechanism in TBI involving the 
peroxidation of lipids by free radicals. The brain has a number of characteristics that make 
it especially susceptible to free radical-mediated oxidative stress, including a high oxygen 
consumptions rate, elevated levels of polyunsaturated fatty acids (PUFAs), and high iron 
concentrations in the substantia nigra and striatum, which can catalyze LP.38 High 
metabolic rates in brain cells also stimulate a high baseline ROS production.39 Low energy 
stores and a reliance on aerobic glucose metabolism leaves the brain highly vulnerable to 
ischemic injury. Neurons are susceptible to ischemia, hypoxia, or hypoglycemia, and a 
major consequence of oxidative stress is damage to cellular macromolecules.40 
1.4.5 Edema 
Edema, or swelling of the brain, is one of numerous secondary injury events 
associated with TBI. Edema can be caused by BBB disruptions leading to accumulation of 
extracellular fluid (vasogenic) or by sustained collection of intracellular fluid 
(cytotoxic/cellular).41 A third category, interstitial, may occur when outflow of 
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cerebrospinal fluid (CSF) is obstructed, though there is considerable overlap between the 
types of edemas.42 This can result in increased intracranial pressure (ICP), requiring a 
craniotomy to relieve built up pressure in the skull in severe cases.  
1.4.6 Inflammation 
Progressive and prolonged neuroinflammation is amongst the major secondary 
injury pathways hypothesized to play a significant role in TBI. Although the brain was 
once believed to be an immune privileged organ (unable to elicit and not susceptible to 
inflammatory responses), it is now clear that that inflammation represents a key 
pathology in TBI.43 This process includes glial activation and leukocyte recruitment as 
well as upregulation and secretion of molecules such as cytokines and chemokines. 
Involving both pro- and anti-inflammatory mediators, inflammation following TBI can be 
either beneficial or detrimental, depending if the process is controlled and regulated.44 
Cytokines are polypeptides normally present in healthy tissue at non-detectable levels but 
are rapidly upregulated in response to TBI and other pathologies.45  
 Interleukins (ILs) are a family of cytokines produced by leukocytes that are 
necessary for regulating immune responses. The IL-1 family of cytokines plays a key role 
in initiating the immune response, and IL-1 has been shown to be elevated in the CSF 
and brain parenchyma in both rodents and humans following brain injury.46,47 Belonging 
to the neuropoitin family of cytokines, IL-6 has also been reported to be elevated in CSF 
and serum in the setting of severe BBB dysfunction.48 In addition, IL-10 possesses 
neuroprotective effects including activation of microglia and suppression of pro-
inflammatory cytokines.49,50 Administration of IL-10 in rats promoted neurological 
recovery, though an increase in its concentration in the CSF of children with brain injury 
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was associated with negative outcomes, highlighting the conflicting roles of 
inflammation in brain injury.51,52 More recent studies of ILs have confirmed their role as 
potential biomarkers of BBB dysfunction and severe TBI.53,54 IL-1 can also alter lipid 
metabolism and stimulate the production of eicosanoids, ceramides (Cers) and further 
accumulation of ROS.55 
 
1.5 Clinical Diagnostic Modalities 
1.5.1 Glasgow Coma Scale 
Clinical diagnosis of TBI is typically based on self-reported symptoms, observer 
report, imaging, and/or the Glasgow Coma Scale (GCS), a simple grading scheme which 
serves to separate injury into subtypes (mild, moderate, and severe).56 The GCS combines 
measures of motor, verbal and eye movement ability, yielding a final score of 3-15. 
Motor skills are scored from 1-6, verbal 1-5 and eye opening 1-4 to account for a total of 
15 points. Mild injuries (score 13-15) account for nearly 80% of injuries, while moderate 
(9-12) and severe (< 9) each account for approximately half of the remaining cases. As 
substance use, e.g. alcohol, is commonly present upon admission, initial GCS scores may 
not be an accurate representation of cognitive deficits.57 
1.5.2 Self-reported Symptoms 
Self-reported symptoms are a primary method for evaluating mTBI. Symptoms 
may include headache, nausea, dizziness, loss of consciousness, balance impairment, 
blurred vision, light or noise sensitivity, memory deficits, drowsiness, inability to sleep, 
irritability and confusion, amongst others. Sideline assessments such as the Sport 
Concussion Assessment Tool 5th Edition (SCAT5) for sports-related concussion 
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diagnostics include reporting of these symptoms.58 However, because athletes may have a 
tendency to underreport symptoms in an effort to stay on the field, more objective 
diagnostic criteria are likely required for accurate assessment.59  
1.5.3 Imaging Modalities 
Advanced imaging techniques such as computerized tomography (CT) and 
magnetic resonance imaging (MRI) are capable of detecting intracranial lesions, acute 
hemorrhage and skull fracture; however, scans are often negative for mTBI due to a lack 
of macrostructural damage.60,61 Diffusion Tensor Imaging (DTI) is an advanced MRI 
modality that measures the diffusional patterns of water in tissue.62 The uniform collinear 
structure of normal white matter allows DTI to detect microscopic abnormalities, 
enabling the assessment of traumatic axonal injury in the absence of macroscopic tissue 
damage.63 Measurements such as fractional anisotropy (FA), mean diffusivity, axial 
diffusivity, and radial diffusivity describe the magnitude and direction of water diffusion 
in tissue. Most commonly FA values are reported, and abnormally low values for FA 
have been associated with TBI.64, 65, 66 Functional magnetic resonance imaging (fMRI), 
which measures cortical responses to controlled stimuli through changes in blood flow, 
also offers promise for detection of TBI in clinical populations.67,68 Blood-oxygen-level-
dependent (BOLD) imaging signals measure activity in the brain, and an increase in brain 
activity or blood flow in one region leads to a reduction in deoxyhemoglobin and 
reduction in signal in another. A study of concussed patients showed increased activation 
in the dorsal-lateral prefrontal cortex and cerebellum when performing spatial memory 
tasks, consistent with the majority of previous reports.66 
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1.5.4 Balance Assessments 
The ability to maintain both static and dynamic balance has been shown to be 
disrupted following TBI.69,70 In fact, balance deficits present in close to 30% of sports-
related concussion cases, trailing only headache, dizziness, confusion, disorientation and 
blurred vision in terms of frequency of occurrence.71 Romberg’s test of balance and 
postural stability was long considered the hallmark for balance assessment.72 Created in 
1846, Romberg’s test measures postural equilibrium in the absence of vision, leaving 
only somatosensory or proprioceptive cues and the vestibular system to maintain balance. 
However, the test lacks objectivity and sensitivity for mild balance deficits exhibited as a 
consequence of concussion, especially in elite athletes. A variety of balance tests 
integrating technology have been designed to measure balance deficits more sensitively, 
though these require sophisticated measurement of force and sensory information 
integration. The balance error scoring system (BESS) was thus developed to provide a 
more cost-effective approach to quantifying balance deficits. Here balance is measured 
on two differing stability surfaces across multiple stances (single leg, double leg, tandem) 
for 20 seconds each with eyes closed and hands on hips. Errors are counted to a 
maximum of 10 per trial. Concussed college football players experienced an average 
increase in total errors of 5.7 from their pre-injury baselines (average 12 errors) 
immediately following the game/practice in which injury occurred, though this had 
dropped to only 2.7 points by 1-day post-injury. Overall, most players returned to 
baseline balance performance after 3-7 days.73 Test scores may be affected by type of 
sport played, history of ankle injuries, and fatigue, but incorporation of the BESS in 
concussion evaluation can increase sensitivity and specificity of evaluation.74 
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1.5.5 Neuropsychological Testing 
Neuropsychological (NP) testing can also be used for diagnosis and clinical 
management of concussion and more severe TBI. The Diagnostic and Statistical Manual–
5th Edition (DSM–5) diagnostic criteria for post-concussive syndrome (PCS) requires 
evidence of sustained cognitive impairment, which can be detected in concussed athletes 
by NP assessment.73,75 Attention, information processing speed, working memory, recall 
and other related skills are measured through a variety of tests designed to yield 
diagnostic feedback within 20-30 minutes. NP assessments have been shown to be 
sensitive enough to measure cognitive performance decreases in the days following 
injury, providing an additional diagnostic tool beyond self-reported symptoms.76 
Computerized tests such as Immediate Post-Concussion Assessment and Cognitive 
Testing (ImPACT)77,78, Automated Neuropsychological Assessment Metrics (ANAM), 
Symbol Digit Modalities Test (SDMT),79 and Display Enhanced Testing for Cognitive 
Impairment and Traumatic Brain Injury (DETECT)80 allow for the detection of transient 
cognitive deficits that result from mTBI by comparing performance post-injury with pre-
injury baseline assessments. To better track and understand TBI, The US Naval Academy 
utilized the ANAM test to collect over 4800 baseline scores for comparison of post-
concussive effects.81 In addition to symptoms reporting, NP testing has been utilized for 
return to play decisions in college athletics, as well as in professional football, baseball 
and hockey.82-85 However, these tests are typically limited by practice effects, test-retest 
reliability, test duration, and sensitivity/specificity issues. Additionally, no direct 
comparison between tests exists to document interpretation of results, and none have yet 




Biomarkers are defined as indicators of a medical state that can be measured 
accurately and reproducibly.89 Biomarkers of TBI offer the ability to supplement or 
supplant prohibitively expensive and sometimes ineffective diagnostic modalities, and 
there is a wealth of scientific literature showing their potential utility in the diagnosis and 
prognosis of TBI. The ideal biomarker can be measured non-invasively, such as through 
the use of easily collected biological fluids like urine and blood.90 To create more 
objective measures of brain injury diagnosis, research efforts have been focused on the 
identification of blood-based biomarkers, with a heavy emphasis on targeted studies 
focusing on a small number of neuronal, axonal or astroglial specific proteins as well as a 
variety of inflammatory mediators which are up-regulated as a consequence of TBI.91 
1.6.1 Protein Biomarkers of TBI 
1.6.1.1 Axonal Proteins and Neuronal Proteins 
Although found in the cytoplasm of neurons, NFs are particularly abundant in 
axons, forming their cytoskeletal components. NFs are heteropolymers found in the CNS, 
including neurofilament light (NFL), medium (NFM), and heavy (NFH), as well as α-
internexin polypeptides.92 Detection of markers of axonal injury and degeneration such as 
NFL in the blood or CSF offers an alternative means to diagnosis of injury. NFL is most 
abundant in large myelinated axons that project deep into the brain and spinal cord. NFL 
has been suggested to be the most sensitive and specific marker of axonal injury, and its 
concentration has been shown to be elevated in the CSF of boxers as well as the serum of 
college football players over the course of a full season.93,94 After injury, calcium 
activates calcineurin, altering the phosphorylation states of NFs.95 Quantified by an 
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enzyme-linked immunosorbent assay (ELISA), higher levels of phosphorylated 
neurofilament heavy (pNFH) were seen in cases of DAI and were also associated with 
poorer outcomes on the Glasgow Outcome Scale in children sustaining TBI.96 Because 
pNFHs are resistant to calpain and other proteases, they should remain undegraded in 
peripheral biofluids and may be useful biomarkers of TBI at clinically relevant 
timepoints.97 
Neuronal proteins such as Ubiquitin C-terminal hydrolase (UCH-L1) and neuron 
specific enolase (NSE) have also been proposed as potential biomarkers of TBI, with 
UCHL-L1 having been identified in both rat and human models.98,99 UCH-L1 is a 25 kDa 
cysteine protease typically expressed in neurons. Present in almost all neurons, UCH-L1 
makes up about 2% of total soluble brain protein.100 As the name suggests, it hydrolyzes 
the C-terminal of ubiquitin or unfolded polypeptides, and data suggest that it plays an 
important role in the removal of misfolded proteins during normal conditions and 
following injury. Mean CSF levels of the protein were found to be highly elevated in 
patients with severe TBI as measured by ELISA.101 UCH-L1 was also found to be 
elevated in serum of severe TBI patients in the acute phase, typically defined as <24 h 
post-injury, and elevation of UCH-L1 persisted for over a week post-injury.102 
NSE, an iso-enzyme of enolase, is a glycolytic pathway enzyme that is highly 
expressed in the neuronal cytoplasm.103 It is also highly specific to neuronal cell death. A 
two-fold increase in NSE was observed across 85 patients sustaining severe TBI 
compared to normal reference values, and NSE serum levels were also correlated with 
injury severity and CT findings.104 However, NSE concentrations were unable to 
differentiate mTBI patients (GCS 13-15) presenting with symptoms from an 
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asymptomatic head contusion group (GCS = 15).105 These results indicate that the utility 
of NSE as a biomarker may be limited to severe TBI.  
Alpha-II spectrin is a 240 kDa structural protein abundant in axons, and spectrin 
breakdown products (SBDPs) have also been implicated as biomarkers of TBI.106 The 
cytoskeletal protein α-II spectrin is involved in both apoptotic (caspase-3-mediated) and 
necrotic (calpain-mediated) cell death. Calpain cleaves the protein to breakdown products 
SBDP150 and SBDP145, whereas capsase-3-mediated cleavage results in the formation 
of SBDP120.107 Increased CSF concentrations of SBDPs have been found in both rat and 
human severe TBI samples.108,109  
Tau, a natively unfolded protein, binds to and stabilizes microtubules in brain 
cells.110 Tau is subject to a number of post-translational modifications, including 
phosphorylation.111 Buildup of phosphorylated-tau (p-tau) protein is a hallmark of 
Alzheimer’s disease (AD).112 Following injury, tau is cleaved by calpain-1 and capsase-3, 
forming cleaved tau (c-tau), which can diffuse through a disrupted BBB into serum and 
CSF.113 Concentrations in CSF are 10 times higher than in plasma due to clearance rates, 
making CSF a better sample source than blood.114 In a study of severe DAI, levels of c-
tau were shown to rise nearly 1000-fold by 1 h and 40,000-fold at 24 h post-injury.115,116 
A recent study showed a measurable increase total tau in the plasma of concussed hockey 
players compared to preseason baselines.117 Tau, and other proteins localized to the 






1.6.1.2 Astroglial Proteins 
Because glial fibrillary acidic protein (GFAP) is not found outside the nervous 
system but only in the astroglial cytoskeleton, it is considered a very promising candidate 
for selective TBI diagnosis.  During brain injury, astroglial cells enter a reactive state and 
increase production of GFAP, while levels of the protein do not spike without brain 
injury even when other injuries are present.118 Patients with mTBI were also found to 
have elevated concentrations of GFAP breakdown products.119 Additionally, GFAP 
histological staining is commonly used as a technique to quantify reactive astrocytes and 
identify pathologies associated with TBI.120 A panel combining UCH-L1 and GFAP was 
recently developed to determine the need for CT scan in the setting of TBI, but again this 
is limited to detection of injury that results in visible hemorrhage, intracranial lesions and 
other macrostructural damage, which does not typically result from mTBI.121  
S100β is a calcium binding protein involved in signal transduction and is a 
structural damage marker of CNS injury.122 S100β is found predominantly in astroglia 
and Schwann cells, but it is not brain specific as it is also found in adipocytes, epidermal, 
chondrocytes, and Langerhans cells.123,124 Its concentration has been found to increase 
after injury, but it has a biological half-life of only 2 h and thus must be measured quickly 
after injury in order to be detectable.125 It is also upregulated in the setting of infection, 
bone fractures and other non-TBI related disease states, indicating that general trauma 




1.6.2 Lipophilic Molecules 
Lipids are generally defined as organic molecules that are soluble in organic 
solvents such as methanol, isopropyl alcohol (IPA), or hexane.127,128 Lipids can be 
subdivided into 8 distinct classes based on their structure: 1) fatty acyls, 2) glycerolipids, 
3) glycerophospholipids, 4) sphingolipids, 5) sterol lipids, 6) prenol lipids, 7) 
saccharolipids, and 8) polyketides.129 The primary component of all lipids, or the smallest 
basic subunit, is a fatty acid, an amphiphilic organic molecule with a neutral hydrocarbon 
tail at one end and a terminal, polar carboxyl head at the other. Lipids’ primary functions 
include energy storage (primarily as triglycerides), acting as first and second messengers 
in signal transduction, and playing a critical role in cellular membrane composition, 
metabolism.130 Outside of the cell, a primary messenger, or chemical signaling molecule, 
binds to the surface of the cell membrane receptors. Sensing this ligand binding, the cells 
respond by activating enzymes in the lipid bilayer, causing the cleavage of lipids in the 
membrane. Referred to as secondary messengers, these molecules can then bind to 
intracellular enzymes and cause the activation of a desired intracellular process. Fatty 
acid amides, such an anandamide and oleamide, commonly serve as signaling molecules 
in vivo. Concentrations of these signaling molecules, belonging to a class of lipids known 
as N-acylethanolamines, are tightly regulated by enzymatic synthesis and degradation, 
though their biological role is mediated through receptor binding.131 For instance, the 
binding of vitamin D3 to the lipid membrane induces sphingomyelinase activity, 
initiating a sphingomyelin (SM) signaling pathway through the generation of ceramides 
by hydrolysis, which serve as second messengers in many biological processes.132, 133 The 
hydrocarbon chain of each fatty acyl typically varies between 12 and 26 carbon units in 
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length, with even numbered chains composing the vast majority of endogenous molecules 
in mammalian species, although odd chain fatty acids (OCFAs) may be found more 
commonly in plant-based organisms. The difference in fatty acid composition in animals 
arises from their synthetic pathway, in which the coupling of 2-acetyl-CoenzymeA (CoA) 
molecules leads to the generation of exclusively even chain fatty acids (ECFAs). The 
synthetic process is initiated by the transfer of acetyl-CoA from the mitochondria to the 
cytosol.134 
Fatty acid synthesis starts with the irreversible conversion (carboxylation) of 
acetyl-CoA to malonyl-CoA through the hydrolysis of ATP. The intermediates are then 
linked to an acyl carrier protein (ACP), forming acetyl-ACP and CoA. Malonyl 
transferase (C3H4O4) is highly specific, ensuring that the fatty acid chain will be 
lengthened by exactly 2 carbon units per elongation cycle, while acetyl transferase can 
transfer a non-acetyl (C2H4O2) group at a reduced rate. The acetyl-ACP and malonyl-
ACP complexes condense to form acetoacetyl-ACP, releasing energy through a 
decarboxylation. The keto group at C3 is then reduced to a methylene group, with 
nicotinamide adenine dinucleotide phosphate (NADPH) acting as the reducing agent. The 
resultant D-3-hydroxybutyrl-ACP is dehydrated to form crotonyl-ACP, which is 
ultimately reduced to butyryl-ACP again using NADPH as the reducing agent, 
completing the first elongation cycle. The condensation reaction with malonyl-ACP, 
reduction, dehydration, and reduction processes can then be repeated to further elongate 
the fatty acid hydrocarbon chain. The enzymes that initiate fatty acid synthesis 
collectively form a single polypeptide chain called fatty acid synthase. This process stops 
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at palmitate (16:0), and double bonds as well as further elongation occurs via other 
enzymes.  
 Two separate systems exist for the synthesis of fatty acids: 1) the non-
mitochondrial system which produces only palmitic acid (16:0) and is a true de novo 
synthesis, and 2) the mitochondrial system which produces stearic (18:0), palmitic, 
arachidic (20:0), myristic (14:0) and lauric (12:0) from the elongation of shorter chain 
fatty acids.135  
While it was initially hypothesized as such, the β-oxidation degradation pathway 
is not in fact simply a reversal of the synthetic pathway. Degradation instead takes place 
in the mitochondria, and intermediates are covalently linked to the sulfhydryl group of 
CoA rather than that of the ACP as in synthesis. Nicotinamide adenine dinucleotide 
(NAD+) and flavin adenine dinucleotide (FAD) act as the oxidants. The steps of the 
synthetic pathway are reversed, and the enzymes that catalyze the reaction are thus 
appropriately named ketoacyl reductase, hydroxyacyl dehydratase, and enoyl 
reductase.136 
1.6.3 Lipid Biomarkers of TBI 
1.6.3.1 Markers of Lipid Peroxidation 
While brain specificity is a key characteristic for a number protein biomarker 
candidates of TBI, the inability to detect changes in their concentrations within biofluids 
in the setting of mTBI has led to questions over their utility.137 Lipids constitute more 
than half of the dry weight of the brain, and a lipophilic barrier (the BBB) composed of 
endothelial cells acts to prevent the flux of molecules between the blood and brain. While 
CNS-specific proteins have proven to be outstanding markers of severe TBI, lipophilic 
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molecules can more easily permeate an intact BBB, and therefore serve as attractive 
targets for biomarker research into mTBI. Thus, changes in lipid profiles should be more 
readily detectable in biological matrices such as serum and plasma in mTBI where little 
or no disruption of the BBB is believed to occur.  
Early lipidomic studies focused on markers of inflammation and oxidative stress, 
such as malondialdehyde (MDA), 4-hydroxynonenal (4-HNE) and thiobarbituric reactive 
substances (TBARS), produced by the autooxidation of PUFAs.138,139 This research 
investigated the role of the oxidative stress mechanism in TBI, involving the peroxidation 
of lipids by ROS. The brain is especially susceptible to free radical-mediated oxidative 
stress due to its elevated PUFA content.38,39   
Following TBI, ROS react with proteins and lipids in the brain, inducing 
oxidative damage. Autooxidation proceeds via a process consisting of initiation, 
propagation and termination, beginning with the abstraction of a hydrogen atom from the 
carbon adjacent to a double bond where a new hydroxyl bond can form.140 Oxygen is 
then added to the carbon radical via a number of free radical sources, after which 
cyclization, rearrangement of atoms or termination of the process is likely to occur. 
Lipids are essential components of cell membranes and also represent the primary targets 
of free radical mediated oxidative damage. In addition to its role in TBI pathophysiology. 
LP has been implicated in a host of other diseases such as cancer141, diabetes,142  and 
AD.143  
The LP process leads to fragmentation of PUFAs, with MDA and 4-HNE being 
the most abundant products and acrolein (2-propenal) as the most reactive product.24  
These cytotoxic aldehyde end products can bind to amino acids such as lysine, histidine, 
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and cysteine to form “protein carbonyls,” disrupting cellular protein function.144 A wide 
range of aldehydes are formed in biological systems from the oxidation of both linoleic 
acid and arachidonic acid (AA).145 These cytotoxic aldehydes were discovered in the 
early 1960s and can be used as an index of LP.146 A study of mTBI in rats showed that 
MDA rose immediately from non-detectable levels in controls, reaching maximum values 
within 2 h.138 Intense immunostaining for 4-HNE was apparent in rat brain tissues within 
1 h of TBI, increasing up to 24 h and persisting until 96 h post-injury.139  
MDA and like compounds can react with thiobarbituric acid (TBA) to form adducts 
with a measurable colorimetric change.24 TBI has been shown to significantly increase 
TBARS levels in rat brain tissue homogenate.147 Significant changes in concentration were 
found in human plasma at 30 h and 72 h post-injury, and increased TBARS compared to 
healthy controls were observed as early as 12 h post-injury.38 Significant differences in 
TBARS levels have also been observed in TBI survivors vs. non-survivors, and a 
correlation between graded head injury and erythrocyte TBARS levels has been 
established.148,149 However, other studies indicated that TBARS were not specific markers 
of LP, and levels of both MDA and TBARS remained unchanged in patients after isolated 
head injury.150 Additionally, when MDA and 4-HNE bind to proteins, the LP products will 
not react with TBA and will not be detected. Therefore a major criticism is that the assay 
only measures the unbound portion, which is relatively minor.38 It has become increasingly 
evident that oxidation of membrane lipids is a primary consequence in certain sub-
populations incurring a TBI, and further study into products detectable in readily accessible 
biological fluids such as serum and CSF could form the basis of future biomarker studies. 
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Oxidation of PUFAs also leads to the formation of a biologically active series of 
lipid mediators, a subclass of eicosanoids known as prostaglandins.151 Based on the 20-
carbon prostanoic fatty acid, prostaglandins are formed by enzymatic oxidation of PUFAs, 
specifically AA. This process is catalyzed in the brain by the highly expressed 
cyclooxygenase (COX)-2 enzyme.152 This enzyme does not attack arachidonoyl residues 
of phospholipids, rather only free fatty acids (FFAs).  The non-enzymatic, free radical-
catalyzed peroxidation of AA esterified to phospholipids leads to the formation of F2-
isoprostanes, prostaglin-F2α-like compounds (PGF2α).153 Interestingly, F2-isoprostanes 
were discovered as bi-products of improper storage of arachidonoyl-containing lipids in 
plasma and are stable products of the oxidation of AA. They are produced in vivo 
independent of COX activity. An F2-isoprostane with inverted stereochemistry at the side 
chain hydroxyl group, 8-iso-PGF2α  or 8-epi-PGF2α is considered the most reliable marker 
of LP, and most studies of lipid biomarkers of TBI have focused on measurements of this 
molecule.122,154,155 While isoprostanes can be markers of improper sample storage 
conditions, their formation by autoxidation of lipids is completely inhibited at -70°C.156   
 F2-isoprostanes are relatively stable molecules that can be used to measure 
oxidative stress.  Though similar in structure to prostaglandins, isoprostanes are typically 
found in blood at concentrations one to two orders of magnitude higher.155 Autoxidation 
can involve the non-enzymatic oxidation of either free or esterified PUFAs with free 
radicals and is catalyzed by transition metals.  However, in vivo the majority of 
isoprostanes are formed via the oxidation of  AA in the SN2 position of phospholipids, 
because these fatty acids at these ester sites are much more readily oxidized than unbound 
fatty acids.157 8-iso-PGF2α is also found in plasma as a FFA, but it is not formed directly 
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from the oxidation of free AA. Rather it is still formed in situ and subsequently cleaved 
from the ester site, though the esterified species are always more prevalent.153 Numerous 
studies have demonstrated the utility of these lipid mediators as potential biomarkers of 
TBI. F2-isoprostanes were increased in CSF after severe TBI in young children.158 8-iso 
PGF2α  was increased in brain extracts at 6 h and 24 h post injury, as were fluorescent end 
products of LP.159 8-iso PGF2α  was increased in both the CSF and serum of a clinical 
cohort after severe TBI.160  
Containing a tetrahydrofuran ring but formed under similar conditions, isofurans 
were increased in the CSF of patients after severe TBI, as were F4-neuroprostanes, the 
oxidized products of docosahexaenoic acid (DHA).161 The 8,12-iso-iPF2a-VI isomer has 
also been shown to be increased at acute timepoints following moderate TBI using the 
FPI model to induce injury in rats.162  
1.6.3.2 Fatty Acids 
FFAs have been shown to exhibit measurable increases as a consequence of TBI, 
likely stemming from the activation of phospholipase A2 (PLA2), resulting in their 
cleavage from membrane phospholipids.163 In one study, free AA and DHA were 
increased within 30 min, and this was followed by hydrolysis of DHA containing 
phospholipids. Increases in FFAs were still observed at 24 h, with increases in DHA and 
stearic acid being most significant.164 Similarly AA, DHA, and myristic acid were all 
shown to be increased in CSF of humans after TBI of varying severity, and higher levels 
of these FFAs were associated with poorer outcome.165 Other studies have demonstrated 
increases in a variety of other fatty acids in serum following TBI, including decanoic and 
octanoic acid, and these increases were strongly associated with injury severity.166,167 
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Additionally, depletion of PUFAs such as DHA appears to have detrimental effects on 
recovery, as depletion of DHA in the brain resulting from diet led to slower recovery and 
worse outcomes in mice.168 DHA supplementation also appears to attenuate increases in 
the protein biomarker NFL following injury in a population of American football players, 
and similar results were demonstrated for DHA administered pre-injury in a pre-clinical 
population.169,170 These studies indicate that DHA in the brain may provide resilience 
against propagation of injury. 
1.6.3.3 Phospholipids 
Phospholipids are the building blocks of both plasma and intercellular 
membranes, and they also compose about 25% of the dry weight of the brain.171 
Glycerophospholipids such as phosphatidylcholines (PCs) and 
phosphatidylethanolamines (PEs) comprise the majority of phospholipids in mammalian 
cell membranes.172 These two types of lipids are also the most abundant in mitochondria, 
with PE species being highly enriched in the inner leaflet. PCs and PEs also play a 
critical role in the formation and stability of lipoproteins. Several studies have 
investigated the role of membrane phospholipids in TBI. Using CCI injury in a mouse 
model, lower levels of cortical and cerebellar PCs, SMs and PEs have been discovered, 
while hippocampal PCs, PEs, and SMs were elevated. Levels of ether PCs were found to 
be lower in the cortices and plasma of injured animals, while PUFA containing PCs, 
especially those containing esterified DHA, were lower in cortices, hippocampi, and 
plasma of injured animals.173  Increased levels of PCs and PEs in CSF have been 
associated with worse outcome in severe TBI patients.174Another group discovered that 
ether containing PE species were elevated at 24 h, while AA and DHA containing 
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phospholipids significantly decreased at chronic stages, including lower levels of PCs, 
PEs, phosphatidylinositols (PIs), and SMs at 24 months post-injury, indicating that TBI 
results in long term, significant decreases in circulating phospholipids.175  
Overall, many of the studies describing alterations in lipid profiles have been 
conducted in brain tissue using 2-dimensional sections to study changes at the injury site. 
One study using mass spectrometry imaging (MSI) demonstrated that the potassiated 
adduct of the most abundant PC species PC(16:1/16:0) was significantly decreased in the 
brain of a rat injured by CCI, with a corresponding increase in the sodiated adduct, likely 
influenced by the loss of Na+/K+-ATPase activity and ionic fluxes caused by injury.176 
Recently, the first 3-dimensional study of brain lipid alterations stemming from TBI 
demonstrated that one species, PC(42:9), was uniquely expressed in injured tissue while a 
different PC species (m/z 797.59) showed increased distribution in the ventricular 
system.177 The data collected were limited to positive mode, where PCs are highly 
abundant and dominate the spectra, indicating that more can be learned by mapping the 
complete spatial distribution of lipid alterations in the brain following TBI.  
Phosphatidic acids (PAs) are lipid messengers involved in protein synthesis via 
the mTOR signaling pathway.178 PAs have been shown to be elevated in the CSF within 
24 h post-injury.179 Through direct analysis of brain tissue, dramatic increases in lysoPA 
and lysoPA precursors in the brain were discovered within 1 h post-injury.180 Levels of 
lysoPA have also been shown to increase in CSF and blood within 24 h post-injury, 
making these molecules interesting biomarker candidates. 
Like many other lipids, diacylglycerols (DGs) play a variety of roles within the 
cell, including serving as intermediates in lipid metabolism, functioning as components 
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of cell membranes, and acting as second messengers in signal transduction, stimulating 
protein phosphorylation.181,182 DGs have been shown to be increased in the cerebellum 
and the injured frontal right motor cortex 1 day post-injury, with DHA containing DGs 
showing the largest increase.164 DGs were also increased following CCI in the brain 
extracts of rats at 4 days post-injury in all frontal and occipital cortical areas, while they 
were even further increased in all cortical areas over one month post-injury. The highest 
measured increases were associated with DHA, stearic acid and AA containing DGs.183 
Increases in DGs at injury site have also been demonstrated in tissue, likely 
resulting from increases in phospholipase C (PLC) activity. Subsequent degradation of 
phospholipids including decreases in two DHA-containing PEs (16:0_22:6, 18:0_22:6), 
PC(34:1), and an AA containing PI species, PI(16:0_20:4), were observed at 3 days post-
injury.184 Another group showed that DHA containing membrane lipids PE(18:0_22:6), 
PE(p18:0_22:6) and PS(18:0_22:6) were decreased in the acute phase, while they were 
gradually increased in the chronic repair phase.185 Accordingly, LysoPE(22:6) was 
increased initially but decreased at later time points.  
Changes in lipid concentrations have be used to objectively classify TBI samples 
from controls through the combination of multiple related biomarkers into a single 
diagnostic panel. In one such study, a panel of 6 lipids was able to discriminate between 
athletes with mTBI and non-injured teammates at each of the time points measured (<6 h, 
2d, 3d, and 7d post-mTBI). This panel consisted of 2 PUFA-containing PE species, 
lysoPC(20:4) and a number of fatty acids- FFA(18:0), FA 2-OH C16:0, and 
tauroursodeoxycholic acid- with the direction of change being species specific.186 The 
ability of these 6 lipids to classify injury in both the initial college athlete cohort as well 
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as a separate independent cohort indicates the utility of lipid biomarkers to detect changes 
associated with TBI and make predictive assessments of TBI using objective methods.  
Cardiolipins (CLs) are a class of diphosphatidylglycerol lipids that have been 
implicated as biomarkers of oxidative damage stemming from TBI.187,188 CLs consist of 
two phosphate head groups, three glycerol molecules and four total fatty acyl chains. CLs 
are exclusively present in the mitochondria of eukaryotic cells and are highly enriched in 
the mitochondrial inner membrane.189 The diversity of CLs in the brain compared to other 
tissues allows for the selection of these molecules as target biomarkers of TBI. Brain CLs 
typically possess high PUFA content, resulting in LP induced by hydrogen peroxide or 
other sources of free radicals. The exclusive presence of these PUFA containing CLs in 
brain mitochondria reveals the potential susceptibility of brain CL to oxidative stress. 
Detection of these specific molecules at elevated levels in locations outside of the brain, 
e.g. in blood, may be indicative of a BBB breach. Highly unsaturated CLs, each 
containing at least one AA residue, were particularly susceptible to this trend. Applying 
oxidative lipidomics to study lipids in the brain after TBI, it was shown that CLs were 
selective targets for oxidative, while PCs and PEs were unaffected acutely, despite their 
high abundance. While all major phospholipid classes contain readily oxidizable PUFA 
residues, only the formation of oxidized CLs was observed at early acute timepoints 
while only minor oxidation of other species, mainly minor anionic phospholipids, was 
observed at 24 h post-injury.190 Preventing CL oxidation in the brain has also been shown 
to reduce neuronal death, behavioral deficits and cortical lesion volume.191 Similarly, 
other anionic phospholipids such as phosphatidylserines (PSs), sulfatides and PIs, have 




Representing one of 8 major classes of lipids, sphingolipids such as SMs and 
ceramides were named for the tissues in which they were first discovered but are not 
necessarily unique to neuronal tissues.193 They play key roles in signaling  pathways such 
as cellular senescence, proliferation, differentiation and cell cycle arrest as well as 
programmed cell death.194  SM is a phospholipid enriched in the brain that plays a large 
role in structural organization, tightly packing with saturated fatty acids and cholesterol 
in the intracellular membrane to form membrane rafts.195 While sphingolipids compose 
22% of the dry weight in white matter, their abundance is much lower in plasma (5%), 
though they are major components of plasma membranes.196,197 Therefore, changes in 
circulating levels of sphingolipids are hypothesized to relate to changes originating in the 
brain. Many sphingolipids also modulate cellular calcium homeostasis, which is a critical 
outcome of TBI pathophysiology.198 Playing a role in signaling pathways, sphingosine 
receptors modulate both pro- and anti-inflammatory cascades. Sphingosine-1-phosphate 
(S1P) receptors have been related to microglial activation and vascular dysfunction using 
a mouse model of cerebral ischemia.199  Sphingosine-1-phosphate receptor subtype 1 
(S1P1), the most abundant S1P receptor, can trigger microglial activation, leading to 
ischemic brain damage.200 It has been shown to act via regulation of macrophage 1 
(M1)/M2 polarization, which modulates both pro- and anti-inflammatory cascades.201 
Other S1P receptors exert pathogenic roles in cerebral ischemia through microglial 
activation and vascular dysfunction. Another study of CCI injury in rats demonstrated 




 Much of the endogenous SM in a cell exists in lipid rafts, which are the sites of 
ceramide generation and signal transduction. Ceramides serve as precursors for the 
synthesis of complex sphingolipids and also promote non-lamellar phase formation. 
Ceramides undergo transmembrane movements much faster than do SMs, moving across 
the lipid bilayer and facilitating the movement of other lipids.203 The release of ceramides 
as secondary messengers can be indicative of cell growth suppression or the onset of 
apoptotic or necrotic cell death.204 Numerous studies have demonstrated increases in 
ceramides in the brain associated with TBI pathophysiology. For instance, Hankin et. al. 
showed an increase in Cer(d18:1/18:0) in the hippocampal region following ischemia/ 
reperfusion injury in rats.176 Roux et. al. also demonstrated an increase of the same 
molecule as early as 1-day post-injury, while low mass SMs were increased near the 
injury site and decreased in the rest of the brain. Intermediate mass ceramides and SMs 
showed opposite trends (SM decrease, Cer increase), as was seen throughout the whole 
brain.184 Interestingly, other studies of TBI resulted in increases in a variety of ceramides 
including Cer(34:1), Cer(36:2), Cer(36:1), and Cer(38:1), specifically in the dorsal half of 
the section containing the injury site following CCI, and their concentrations were shown 
to decrease with treatment with a peptide agonist, indicating that prevention of ceramide 
dysregulation after injury may result in better outcomes.205 However another study 
demonstrated a uniform decrease in all measured ceramides in the mouse brain after blast 
injury.206 Decreases in brain ceramides are likely related to the utilization of ceramides 
for SM synthesis.207 These mixed results demonstrate the difficulty in studying the 
chemical response to heterogenous injury subtypes and severities, given the complex 
interplay of beneficial and detrimental inflammatory pathways.  
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 Gangliosides are glycosphingolipids located in the outer leaflet of neuronal 
membranes. They are composed of a ceramide and an oligosaccharide with sialic acid(s) 
linked to the sugar chain and represent approximately 6% of the total brain lipid. A 
number of studies have looked at changes in gangliosides in addition to the previously 
discussed ceramides and SMs since these lipids are much more highly concentrated in the 
CNS.184,206 Ganglioside monosialic 1 (GM1) is highly abundant, composing 21% of total 
gangliosides, while GM2 represents just a fraction of this at < 0.5%. An increase in the 
ganglioside GM2(d18:1/C18:0) was discovered after blast injury in mouse brain tissue. 
These changes were localized to the hippocampus, thalamus, and hypothalamus, and 
increases were observed at early acute timepoints (<24 h) but had normalized by 72 h.206 
Overall, the dysregulation of sphingolipids stemming from onset of TBI requires further 
investigation, but offers promise due to their heightened association with the CNS. 
1.6.3.5 Sterols 
 The sterol class of lipids, including cholesterol, steroids and bile acids, may be 
vitally important to the regulation of neurological disorders. Disproportionate to the 
relative mass of the brain, greater than 25% of total cholesterol is found within the brain, 
where it plays a critical role in membrane function and serves as the precursor for the 
synthesis of neurosteroid hormones such as progesterone and pregnanolone.208 Lecithin: 
cholesterol acyltransferase forms the majority of cholesteryl esters (CEs) in circulation, 
transferring long chain fatty acids from PC species to esterify the free cholesterol.209 
Cholesterol may also be metabolized to a variety of other end products, such as 
cholesterol sulfate (CS), which regulates membrane packing efficiency and is found in 
higher abundance in DHA rich membranes.210 Altered cholesterol metabolism in the 
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brain may be linked to genotype. Apolipoprotein E (ApoE) is critical to maintenance, 
growth and repair of neurons, and is responsible for sterol transport. A specific allele, 
ApoE4, was also associated with large changes in both sterol and sphingolipid content in 
the brains of AD patients.211 The ApoE4 allele has long been associated with early onset 
and faster progression of AD, and may also play a role in determining outcome in TBI.212  
 
1.7 Tools for Measuring Biomarkers 
Metabolomics is the comprehensive study of all small molecules in a biological 
system related to the organism’s metabolism.213 Lipidomics, a subset of the 
metabolomics field, involves the study of all lipids within such systems.214 Both methods 
of research are commonly used to generate data for the purpose of biomarker discovery. 
Biomarker studies can be classified as either targeted or non-targeted, each involving 
slightly different approaches.215 Typical non-targeted studies are data-driven and focus on 
the study of the full complement of molecules in a given biological system, attempting to 
discover which analytes are influenced most by the presence or absence a given disease 
state or condition. Workflows involve a number of steps, including sample collection, 
preparation, analysis and subsequent chemical identification of target molecules. Once 
identified, biomarkers can be mapped to their metabolic pathways to relate these products 
to their role in a specific disease state such as TBI.216  
Targeted studies follow a slightly different approach, as a smaller number of 
molecules known to be involved in the onset of disease are selected prior to sample 
analysis. For instance, class-specific changes in lipids are investigated using mass 
spectrometry (MS) through the development of product ion scans, multiple reaction 
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monitoring (MRM), or neutral loss scans in order to identify and quantify one or more 
target molecules within a specific lipid class. Based on the method of data acquisition, 
unknown targets cannot be identified using these studies as the approach is limited to the 
preselected molecules of interest.217 Targeted studies are advantageous when a defined 
pathophysiological outcome can be used to generate a hypothesis about how specific 
analytes will be affected by the occurrence of a disease. Based on the limited research 
guiding lipid biomarkers of TBI, the work contained within this thesis was generated 
using non-targeted approaches, which are described in more detail below. 
1.7.1 Sample Collection and Storage 
 While preliminary experiments must investigate direct changes in the affected 
brain tissue to discover injury specific changes in biomarker composition, collection must 
be done post-mortem, which presents an obvious challenge for the diagnosis of 
concussion in living patients. Because of this, collection of peripheral biofluids is 
necessary for clinically useful biomarker studies and the potential development of future 
diagnostic tools. Biofluids such as blood (including whole blood, serum, or plasma), 
urine, CSF and saliva have all been implemented successfully for use in discovery-based, 
data-driven lipidomics approaches.218,219,220,221 To ensure reproducibility of results it is 
imperative that all samples be collected using identical methods and stored under the 
same conditions to ensure the only variable being investigated relates to the biological 
question of interest. Typically, samples are stored at low temperatures (e.g. -80° C) to 
prevent degradation from storage for long periods of time.222,223  
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1.7.2 Sample Preparation 
Many sample preparation techniques have been developed and compared for use 
in lipidomic biomarker studies.224 Biological fluids such as blood samples contain large 
amounts of both lipid and protein, which must be separated in order to conduct MS 
analysis. Typical separation techniques can be classified as either protein precipitations or 
liquid/liquid extractions. Protein precipitation methods are simpler, allowing for higher 
throughput studies. Typically, an excess (≥3:1 v/v) of organic solvent such as methanol 
or IPA is added to a small amount of aqueous sample.224 Upon centrifugation, the 
proteins that were soluble in the aqueous biofluid are precipitated out of solution, and the 
lipophilic portion of the samples is collected within the supernatant. Based on chemical 
interactions, methanol is a useful solvent for extracting cell-membrane lipids (e.g. 
phospholipids, and cholesterol) and is commonly used in metabolomics experiments.225 
However, these simple methods often lead to incomplete extraction of lipids, specifically 
neutral lipids, and truly quantitative experiments should use liquid/liquid extraction 
approaches such as the Folch226 or Bligh-Dyer227 methods, which combine chloroform, 
methanol, and water to form distinct aqueous and organic phases into which the proteins 
and lipids can be partitioned. These extractions are advantages for the study of a more 
diverse range of lipids. Alternative extractions utilizing methyl tert-butyl ether (MTBE) 
have been proposed, which offer similar extraction efficiencies but place the organic 
phase on top of the aqueous phase due to solvent density, allowing for easier collection of 
the lipid layer of interest.228 
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1.7.3 Instrumental analysis 
The increasing popularity of metabolomics and lipidomics biomarker studies has 
been aided by advancements in technology and instrumentation.229 Since the mixtures 
being analyzed in non-targeted metabolomics studies are highly complex, MS and 
nuclear magnetic resonance (NMR) are the two most widely utilized techniques in the 
field.230 
1.7.3.1 Mass Spectrometry 
 Biomarker discovery studies have been enabled by the advent of sophisticated MS 
instrumentation, fueling the growth of the fields of metabolomics and lipidomics.229 
Metabolomics studies often involve careful measurement of a large number of molecular 
targets, so advanced techniques are required beyond simple single-target assays. MS and 
NMR are the most commonly utilized platforms for metabolomics analysis, and each 
offers complementary advantages to research efforts.231 MS studies are very fast, 
depending on the front-end separation, and offer unparalleled sensitivity.232 MS 
techniques, principally liquid chromatography-mass spectrometry (LC-MS) and tandem 
mass spectrometry (MS/MS), are used throughout this thesis to study the serum and brain 
tissue of rodents incurring TBI induced by CCI as well as the cell extracts of 
phytoplankton competitors.  
Different ionization modes and techniques can be used to analyze a wide range of 
target molecules, and a primary advantage of MS studies relates to sensitivity, which can 
reach into the pico- to femtomolar concentrations.232 MS is also the preferred technology 
for targeted experiments due to the ease of separations coupling and the existence of a 
wide variety of analytical methods suited to single target analysis.233 MS instrumentation 
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consists of three main components: an ionization source, a mass analyzer and a 
detector.234 Ion sources produce gaseous ions from the sample, and commonly utilized 
sources include electrospray ionization (ESI) and matrix assisted laser desorption 
ionization (MALDI). Many other sources exist, including electron impact (EI), chemical 
ionization (CI), desorption electrospray ionization (DESI), fast-atom bombardment 
(FAB), secondary ion mass spectrometry (SIMS), etc. Different ionization modalities as 
well as the use of multiple polarities, allows for the ionization of a wider variety of 
molecules. Once in the gaseous state, the mass analyzer then separates ions on the basis 
of their mass to charge ratio (m/z). Common mass analyzers include quadrupole, time-of-
flight (TOF), ion trap, or Fourier transform ion cyclotron resonance (FT-ICR) 
analyzers.231 These ions are then detected based on m/z and their relative abundance is 
recorded. Common mass detectors include electron multipliers, photomultipliers, Faraday 
cups, and Orbitraps, which function as both a mass analyzer and detector.235,236  
 The front end of the mass spectrometer can be coupled to a separation technique, 
such as gas chromatography (GC) or liquid chromatography (LC) in order to separate the 
components of complex mixtures by time of elution, or retention time (RT). This ensures 
that all the ions are not detected simultaneously, which may lead to inaccuracy in relative 
quantification based on ion suppression. Additionally, separation prior to detection 
minimizes overlapping structural isomers as well as difficulty in accounting for isotopes 
from precursors of consecutive nominal masses.237 A variety of front-end separation 
techniques take advantage of chemical interactions between the stationary phase and 
eluting analytes, including normal phase and reversed phased LC separations, which can 
separate a variety of lipid classes based on time of elution. Normal phase LC separates 
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mixtures based on head group polarity, but the presence of water in the solvent can alter 
analyte affinity to silica.238 Reverse phase LC instead separates complex mixtures based 
on lipophilicity, such that fatty acyl chains determine the elution order while many 
classes of lipids may overlap in RTs, such as PEs and PCs.  
1.7.3.2 Nuclear Magnetic Resonance 
NMR offers distinct advantages over MS, as it is directly quantitative and does 
not require separation or derivatization steps. Additionally, NMR offers enhanced 
reproducibility and is non-destructive to samples. However, NMR instruments require 
highly skilled technicians to operate, are often more expensive to acquire and maintain, 
and require large amounts of space.231 Though less than the capabilities of MS, 
approximately 100-200 metabolites can be measured in a single NMR experiment, 
depending on spectral resolution.   
No single technique can quantify and identify all types of molecules within a 
sample, so a combination of techniques can be advantageous when studying complex 
biological systems. As complementary techniques, MS and NMR make a powerful 
impact, as is demonstrated in the fourth chapter of this thesis, relating to the study of the 
effects induced by Karenia brevis exposure.239  
1.7.4 Chemometric Analysis 
Advanced chemometric methods, such as Principal Component Analysis (PCA) 
and Partial Least Squares Discriminant Analysis (PLS-DA) can be used to identify 
important changes in individual components of complex mixtures, referred to as features 
and defined by their RT and m/z until chemically identified in data-driven experiments.240 
By projecting complex datasets into lower dimensional space (e.g. 2D or 3D), changes in 
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composition can be identified and readily visualized. PCA can be used to visualize 
inherent differences in the data and is classified as an unsupervised method. Variance 
captured will be based on inherent differences in the data, as class information is not 
considered in PCA analysis.241 PLS-DA instead is a supervised approach, in that the class 
information is contained within the dataset being investigated and used to construct the 
multivariate models. The maximum variance between classes (or sample types) will be 
captured and defined by a hypothetical decision boundary. A sample’s score will be a 
sum of each feature’s relative abundance multiplied by its weighted contribution to the 
model, defining a sample as a point in Euclidean space.242 Only features that contribute to 
accurate classification of different sample types will be selected by feature selection 
methods, ensuring that maximum variance is captured using the simplest possible 
multivariate model. Samples with similar scores on the statistical model can be classified 
collectively as a group will be separated by less Euclidian distance, allowing for 
clustering of similar and separation of different samples. Features can be combined 
linearly to calculate a score for a multi-feature model, which is then used to create a 
classification panel for distinction of sample types. Other common classifiers used for 
feature selection operate under similar principles but may offer inherent advantages based 
on the specific dataset being analyzed. Examples include Bayesian, K-nearest neighbors 
(KNN), logistic regression, support vector machines (SVMs), and random forest 
algorithms.243  
1.7.5 Chemical Identification and Pathway Mapping 
NMR offers the advantage of providing clear structural information for analytes, 
this technique is inherently limited by moderate sensitivity and overlapping signals in 1H 
39 
 
NMR spectra of lipids. Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
is the most powerful tool for structural identification of lipid mediators due to high 
sensitivity and specificity provided by the combined separation of complex mixtures and 
unique fragmentation patterns.244 Lipids can be categorized into 8 distinct classes, and 
these classes such as phospholipids, a main focus of study in the field of TBI biomarkers, 
can be similarly subdivided using MS/MS fragmentations patterns to identify distinct 
polar headgroups.129,245 Negative mode data are more useful for chemical identification of 
lipids, as esterified fatty acid chains can be determined, reducing the number of possible 
structural isomers to a single molecule.246 The feature selection methods described above 
coupled to chemical identifications leads to the discovery of a host of potential biomarker 
candidates. Chemical identification of these unknown features in non-targeted 
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CHAPTER 2: DISCOVERY OF LIPIDOME ALTERATIONS 
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Traumatic brain injury can occur across wide segments of the population, 
presenting in a heterogeneous manner that makes diagnosis inconsistent and management 
challenging. Biomarkers offer the potential to objectively identify injury status, severity, 
and phenotype by measuring the relative concentrations of endogenous molecules in 
readily accessible biofluids. Through a data-driven, discovery approach, novel biomarker 
candidates for TBI were identified in the serum lipidome of adult male Sprague-Dawley 
rats in the first week following moderate injury induced by controlled cortical impact. 
Serum samples were analyzed in positive and negative modes by Ultra Performance Liquid 
Chromatography Mass Spectrometry (UPLC-MS). A predictive panel for the classification 
of injured and uninjured sera samples, consisting of 26 dysregulated species belonging to 
a variety of lipid classes, was developed with a cross-validated accuracy of 85.3% using 
omniClassifier software to optimize feature selection. Polyunsaturated fatty acids (PUFAs) 
and PUFA-containing diacylglycerols were found to be upregulated in sera from injured 
rats, while changes in sphingolipids and other membrane phospholipids were also 
observed, many of which map to known secondary injury pathways. Overall, the identified 
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biomarker panel offers viable molecular candidates representing lipids that may readily 
cross the blood-brain barrier and aid in the understanding of TBI pathophysiology. 
 
2.2 Detection of Traumatic Brain Injury 
2.2.1 Background 
The Centers for Disease Control estimate that TBI is the primary cause of over 
50,000 deaths and 300,000 hospitalizations in the United States annually.1 Many more 
injuries remain misdiagnosed, undetected, or unreported.2,3 Heightened awareness of TBI 
in the military, athletics, and the general public has led to increased efforts towards the 
development of objective diagnostic measures and clinically relevant treatment options. 
Assessment tools such as the GCS, radiologic imaging, and symptoms reporting are 
commonly used and provide valuable information about potential injury status. However, 
they do not capture the heterogeneous physiologic and neurochemical response, making 
TBI diagnosis and treatment a challenge.4 The GCS combines measures of motor, verbal 
and eye opening responses to stratify injuries into three severities. Mild injuries (score 13-
15) account for nearly 80% of injuries, while moderate (9-12) and severe (< 9) each account 
for approximately half of the remaining cases.5 Injury severity affects the time-course and 
extent of BBB breakdown, and while the BBB is disrupted in severe TBI, damage is 
minimal or non-existent in milder injuries.6 Injury severity also has a major effect on the 
extent of impairment resulting from primary and secondary injury cascades, leading to 
worse prognostic outcomes and increased mortality in more severe injuries, which were 
the focus of the vast majority of early research.7,8,9 However the ultimate goal of current 
innovative diagnostic modalities should focus on the detection of less severe injuries, 
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specifically mTBI, as diagnosis of these injuries remains elusive even today. Therefore, 
preliminary studies aimed at understanding moderate TBI pathophysiology may provide 
valuable insights into the molecular mechanisms and metabolic responses more closely 
associated with mTBI.  
2.2.2 Biomarkers for the Diagnosis of TBI 
Biomarkers offer the potential to both sensitively and specifically identify the 
severity and phenotype of TBI, track pathology and metabolic state, and aid in 
mechanistically-based treatment decisions. The vast majority of proposed TBI biomarkers 
are astroglial and neuronal proteins, such as GFAP, S100β, UCH-L1 and tau/p-tau10,11 that 
may not readily cross the BBB, although the recently discovered glymphatic system may 
partially explain their brain-to-blood transport.12,13 While some of these proteins have 
proven useful in the diagnosis of severe TBI, they have not yet been shown to be sensitive 
enough to consistently detect TBI across the full range of severities.14 Furthermore, while 
the BBB is disrupted in severe TBI, it remains predominantly impermeable in milder 
injuries, partially explaining why many biomarkers of severe brain injury do not translate 
well to mTBI diagnostics.15,16 Small molecule metabolites may, however, permeate the 
BBB, though acute changes in tissue metabolite content are significantly more detectable 
than are alterations in plasma.17 Blood lipid levels are expected to reflect brain 
pathophysiology, given the close proximity of the CSF and the brain, the lipophilic nature 
of the endothelial cells comprising the BBB, the ease of transport of small lipids, and the 
similarity of lipid content in the CSF and extracellular fluids.18,19 Lipids are therefore more 
likely to translate to clinically successful TBI biomarkers than are proteins, especially in 
readily accessible biofluids such as blood or urine. Exploration of lipid metabolites as 
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potential biomarkers of TBI is still in its infancy compared to protein-based markers, yet it 
holds promise given the high lipid content of the brain and its vulnerability to oxidative 
lipid damage.20-22 
The dysregulation of lipids after TBI is well documented,23-27 and identification of 
altered lipids in the serum may reveal novel biomarker candidates.20,28 Elevated levels of 
PUFAs and redox transition metals as well as the high rate of oxygen consumption in the 
brain make it highly vulnerable to free radical attack.29 Free radical mediated damage from 
ROS and RNS is initiated acutely following the primary insult but can persist in the hours 
and days following injury, overwhelming antioxidant defenses and mediating damage to 
vital cell structures such as membranes and mitochondria.30,31 The study of volatile urinary 
metabolites also offers promise for the detection of inflammatory processes resulting from 
neurological disorders such as TBI.32  
Many existing studies into lipid biomarkers have utilized targeted profiling of a 
handful of specific molecules, which has the disadvantage of being biased toward known 
pathways and not necessarily revealing the optimum biomarker candidates that can be 
found with discovery-based approaches.33 A high-coverage survey of the lipid profile 
changes associated with TBI can thus help to guide biomarker discovery while providing 
additional mechanistic understanding of the role of specific lipid-related molecular 
effectors in TBI pathophysiology. Therefore, the objective of this study was to determine 
which lipids, or classes of lipids, were dysregulated following moderate TBI in rats using 
a high-coverage, non-targeted lipidomics approach, ultimately selecting an optimized 
panel of lipid biomarkers that has the potential to objectively differentiate injured from 
uninjured Sprague-Dawley rats, which often serve as a suitable pre-clinical model for 
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human disease.34 Currently there are no Food and Drug Administration (FDA) approved 
biomarkers for the diagnosis of TBI, but consideration for the inclusion of lipids in the 
development of biomarker panels may aid in translation to clinical success.35 
 
2.3 Experimental Details 
2.3.1 Injury Protocol 
All procedures involving animals were performed according to the guidelines set 
forth in the Guide for the Care and Use of Laboratory Animals (U.S. Department of Health 
and Human Services, Pub no. 85-23, 1985) and were approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee (protocol #A15013). The study 
was not pre-registered. Male Sprague-Dawley rats (8 weeks old; Charles River) were kept 
on a 12-h light–dark cycle, and food and water were available ad libitum. Thirty-four 
animals weighing 300-400 g were randomly assigned to the following groups using a 
computer based randomization algorithm: (1) naïve (n=10), (2) sham-operated (n= 8; n=4, 
3 days post-surgery; n=4, 7 days post-surgery), and (3) TBI (n=16; n=7, 3 days post-injury; 
n=9, 7 days post-injury). Sham-operated animals were employed to ensure that the stress 
of surgery did not play a role in sample classification based on lipid profiles, while naïve 
samples were taken from a subset of animals prior to sham or TBI procedures.  
Unilateral contusions of the lateral frontoparietal cortex were created using a CCI 
device (Pittsburgh Precision Instruments, Pittsburgh, PA) following published 
procedures.36,37 Rats were anesthetized (induction, 5% isoflurane; maintenance 2-3% 
isoflurane), mounted in a stereotaxic frame, and a 6 mm craniectomy was made over the 
left frontoparietal cortex (center: -3.0 mm AP, +2.0 mm ML from bregma). A pneumatic 
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piston (tip diameter=5 mm; positioned 15 degrees from vertical in the coronal plane) 
impacted the cortical tissue to a depth of 2 mm (velocity=4 m/s, duration=200 ms), values 
consistent with a moderate TBI insult.38 Following the injury, the wound cavity was 
thoroughly cleaned and all bleeding stopped before a layer of 2% SeaKem agarose (Lonza, 
MD) was applied to the injury site and the scalp sutured.39,40 The bone flap was not replaced 
as per standard CCI protocols.37 Animals received sustained release buprenorphine (1mg 
kg-1) and were placed on a heating pad during recovery, at which time they were returned 
to their home cage and singly housed. Sham-operated animals were subjected to the same 
procedures described above, but did not receive an impact, while naïve animals were not 
subjected to surgical procedures. 
2.3.2 Blood Sampling 
The serum lipidome of rats was analyzed at 3- and 7-days following moderate CCI 
injury in order to identify potential biomarker candidates. During the afternoon, 
approximately 200 µL of whole blood was collected from a tail vein punctured by 20-gauge 
Precision Glide needles (Beckton Dickinson) and stored on ice. Whole blood samples were 
allowed to coagulate at room temperature for 45 minutes, and all sample collection 
followed literature guidelines for limiting the potential for hemolysis.41,42 Samples were 
then centrifuged at 4 °C for 15 min at 2500 x g, and serum was collected in 50 μL aliquots 
and stored at -80 °C. 
2.3.3 Sample Preparation 
Prior to analysis, lipids and small non-polar metabolites were separated from 
proteins in blood using IPA for protein precipitation, shown to be advantageous over the 
Folch or Bligh and Dyer methods for a variety of experimental considerations.43-46 For 
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protein precipitation purposes, serum samples were thawed on ice for 1 h and serum was 
mixed 1:3 v/v with IPA. Samples were centrifuged at 16,000 x g for 7 min, and the 
supernatant was collected. Samples were stored at -80 °C until analysis. LC-MS analysis 
confirmed excellent coverage of various expected lipid classes (Figure A1). 
2.3.4 UPLC-MS Analysis 
A Waters ACQUITY UPLC quaternary solvent manager system was employed 
for chromatographic separations. Both ionization modes utilized identical mobile phases, 
though different chromatographic gradients were employed (Table A1A). Mobile phase 
A was 40:60 water: acetonitrile (ACN) and mobile phase B was 10% ACN in IPA. Both 
mobile phases included 10 mM ammonium formate (Sigma Aldrich, >99.995%) and 
0.1% formic acid (Fluka Analytical) additives to improve peak shape and ionization 
efficiency. All solvents used were of LC-MS grade and provided by Sigma Aldrich (IPA) 
or J.T. Baker (ACN). The column used was an ACQUITY UPLC BEH C18 1.7 μm, 2.1 x 
50 mm, operated at 60°C, while samples were maintained at 5° C throughout the analysis. 
Injection volumes of 5μL and 10 μL were used in positive and negative ion modes, 
respectively. Run order was randomized, and samples were acquired in duplicate. A 
Waters Xevo G2 quadrupole time-of-flight (QTOF) mass spectrometer with an ESI 
source was used for lipidomic analysis of all samples. MS parameters are provided in the 
appendix (Table A1B). The mass spectrometer was calibrated with a sodium formate 
solution, and data were acquired in the 50-1200 Da range with leucine enkephalin used 







Most MS/MS experiments were performed in the Xevo G2 QTOF mass 
spectrometer (4 different collision energies, ranging from 10 V to 40 V). For low 
abundance markers that required higher sensitivity, MS/MS experiments were performed 
in a Q-Exactive (QE) HF Orbitrap mass spectrometer (Thermo Fischer Scientific) at a 
normalized collision energy (NCE) setting of 10, 30 and 50, and combined into a single 
spectrum by the instrument software. Table A2 details the specific instrument used to 
acquire the MS/MS data for each respective lipid as well as the annotation of each species. 
Spectral interpretation of lipid fragmentation patterns was performed either manually or by 
comparison to entries in the Lipid Metabolites and Pathways Strategy (LIPID MAPS), 
human metabolome database (HMDB), and Metlin databases.47-49 The LIPID MAPS 
MS/MS prediction tool for glycerophospholipids was also used for the assignment of 
fragment ion species. 
2.3.5 Sample Size Calculation 
Minimum sample size to achieve statistical significance was determined by a priori 
power analysis using G*Power 3.1 statistical software.50 For each metabolomic feature, 
Cohen’s effect size (d) was estimated at d=1 using pilot data, producing the desired 
statistical power (1-β = 0.80) and type I error probability (α = 0.05) with a sample size of 
n=34. 
2.3.6 Data Mining 
Chromatographic alignment, de-isotoping, deconvolution, normalization, and peak 
picking were accomplished using Progenesis QI software. Sets of 1669 and 622 spectral 
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features, defined as unique pairs of RT and exact mass to charge ratio (m/z), were obtained 
for positive and negative ion modes, respectively. Filters were applied to remove peaks 
detected as background contaminants and peaks in which the instrumental variation, or the 
coefficient of variation measured (CVm), approached the biological coefficient of variation 
(CVb) through the use of solvent blanks and quality control (QC) pooled samples. Any 
features detected above the noise threshold in solvent blank runs or with high CVm in 
pooled QC runs were removed from the datasets. Features detected in fewer than 75% of 
samples in TBI and control groups were also removed prior to binary classification. The 
remaining 727 feature abundances (413 positive and 314 negative mode) were exported as 
a single matrix combining both ionization modes to omniClassifier for multivariate 
analysis.  
2.3.7 Feature Selection and Classification 
Post-processed feature abundances were log2 normalized to create an 
approximately Gaussian distribution prior to binary classification. OmniClassifier was 
utilized to develop an initial model to predict TBI based on lipidomics data.51 As a first 
approximation to model the data, sham-operated and naïve animals were collectively 
grouped as “controls” in a single class, while 3- and 7-day post-injury time points were 
collectively labeled as “TBI”. This was done to increase the total number of samples in 
each class, prevent overfitting, and increase model statistical significance. Using nested 
cross-validation (CV), prediction models were optimized using four different classifiers 
bundled within omniClassifier: Bayesian, KNN, Logistic Regression and SVMs. Ten 
iterations of three-fold nested CV were applied to the training data to estimate prediction 
performance, resulting in 4x10x3 = 120 total tested models. Subsequently, non-nested CV 
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was applied to the training data to optimize a final prediction model. Blinding was utilized 
in the data analysis CV stage, where a subset of samples was removed from the training 
set, blinded and predicted for each tested model. 
A single iteration of nested CV produced three prediction performance values, 
which were averaged into a single performance quantity. This entire process was repeated 
for ten iterations, resulting in ten averaged CV performance quantities. After nested CV, a 
final prediction model was chosen. When choosing a final prediction model, the same CV 
optimization procedure as previously used in the nested CV step was followed but applied 
to the entire training data set. Subsequently, the final model parameters were used to select 
features and train the classifier.  
Each classifier was optimized over several parameters. Bayesian classifiers 
included nearest centroid, diagonal linear discriminant analysis, spherical discriminant, and 
uncorrelated discriminate classifiers.52 KNN classifiers were optimized over ten values of 
K (K=1-10). The linear SVMs were optimized over ten cost values (i.e. 1 to 10). Feature 
selection was accomplished using the minimum redundancy, maximum relevance 
(mRMR) method, choosing optimal feature sizes from within the range of 1 to 100.53 The 
mRMR feature selection method identified an optimal set of features that minimized the 
correlation among features while maximizing mutual information between features and 
class labels. Following omniClassifier analysis, more granular models were created using 
orthogonal partial least squares-discriminant analysis (oPLS-DA) for each of sham-
operated or naïve vs. TBI samples (MATLAB, R2015a, The MathWorks, Natick, MA with 
PLS-Toolbox, version 8.0, Eigenvector Research, Inc., Manson, WA) with Venetian blinds 
CV.54,55 Prior to oPLS-DA, features were autoscaled. Abundances of features with 
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significant changes (TBI vs. control) were analyzed at 3- and 7-days post-injury using a 
one-way analysis of variance (ANOVA) with p < 0.05 considered significant. 
2.4 Development of a Lipid Biomarker Panel for the Classification of Moderate 
TBI 
 Overall, 2288 features were detected, this was and further reduced to 727 based on 
frequency criteria. PCA of this dataset (Figure 2.1A) showed that pooled samples grouped 
together and accurately represented the average composition of both TBI and non-injury 
(naïve + sham-operated) samples analyzed. Initially, each sample was projected into linear 
space so that the relationship across all variables could be visualized in two dimensions. 
However, the lack of distinct clustering in the PCA scores plot revealed that accurate 
discrimination of TBI would require the selection of specific features that directly reflected 
TBI pathophysiology using supervised classification approaches. We initially combined 
the injured groups in order to use robust binary classification schemes to find potential 
lipids that could distinguish injured from non-injured rats. Using a non-targeted lipidomics 
approach, we examined features that were able to distinguish TBI samples from controls.  
This feature set was then processed using a total of 120 multivariate omniClassifier models 
of controls (sham-operated + naïve) vs. TBI by testing a combination of various classifiers 
and comparing inner and outer CV values. In all cases, inner CV area under the curve 
(AUC) values approximately matched outer CV values, indicating lack of overfitting 
(Figure A2). Recursive selection within the 727-feature set simplified these classification 
models by reducing data dimensionality while preserving only features that resulted in high 
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Table 2.1 shows the performance of the best models produced by each of the four 
classifiers tested. All four models performed similarly well, with the number of features 
utilized ranging from 9 to 31 and AUC values ranging from 0.80 to 0.84 under CV. As 
expected, AUC performance on the whole dataset approached unity for these four best 
models, but the cross-validated AUC values were chosen as more representative of a 
scenario in which unknowns would be predicted. Interestingly, the smallest set of 9 features 
selected by the optimized Bayesian classifier using mRMR feature selection was conserved 
across all classifiers, lending support for the underlying biological basis of this multivariate 
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classification. The optimized KNN classification model, containing 31 metabolite features, 
was selected for chemical annotation of the features so as not to ignore any useful TBI 
biomarker that might reflect unique network level alterations.  Of those 31 features, 5 
eluted with the chromatographic solvent front where measured ion intensities are unreliable 
due to ion suppression effects.56 As their removal from the multivariate model did not result 
in a significant decrease in classification accuracy, these features were excluded from 
further consideration.  Following establishment of a subset of distinguishing features, we 
identified the molecules and examined changes in relative abundance at each of the post-






Figure 2.1: A) Principal component analysis (PCA) scores plot for the subset of 314 
negative mode features obtained following filtering and prior to feature selection across 
each class. The distribution of samples in this plot reveals no clustering amongst samples. 
by class Pooled quality control samples, represented by yellow circles, clustered towards 
the center of the plot, indicating they are an accurate representation of the average sample 
analyzed. B) Orthogonal Partial Least Squares Discriminant Analysis (oPLS-DA) scores 
plot depicting clustering of samples separated into five classes by day of sample collection 
and injury status using the 26-feature model. Variance between classes is captured across 
the X-axis. C) oPLS-DA scores plot depicting clustering of samples separated into a binary 
model, with the y-axis acting as a separation boundary between classes. Samples are 





Figure 2.1B depicts an oPLS-DA scores plot for the optimized 26-feature lipid 
panel with all sample classes treated individually. Here, it becomes clear that the samples 
can be roughly split into two classes, with negative scores on latent variable (LV) 1 
generally corresponding to TBI samples and positive scores on LV1 being more 
representative of controls, irrespective of day of collection. In a binary representation of 
the data, differences between all control samples and TBI samples were also modeled using 
oPLS-DA and leave-one-out CV (Figure 2.1C). Control samples separated from injured 
samples with no significant overlap, again with negative scores on LV1 corresponding to 
TBI samples and positive scores indicative of controls. The sensitivity, specificity and 
overall accuracy were 93.7 %, 77.8 % and 85.3 %, respectively. More detailed binary 
comparisons (sham-operated vs. TBI, naïve vs. TBI, all controls vs. TBI) were also 
performed using the same panel of 26 metabolites and oPLS-DA, a standard multivariate 
classification tool (Figure 2.2). The classification accuracy in all cases exceeded 90%, with 
a sensitivity of 93.8% and specificity of 87.5-100%. These results indicated that lipid 
alterations observed in the 26-feature panel can be attributed solely to TBI and were not a 




Figure 2.2: oPLS-DA cross validated class prediction plots based on the optimized 26 
feature panel comparing A) sham + naïve controls vs. TBI, B) sham vs. TBI and C) naïve 
vs. TBI samples. For all plots, TBI samples are represented by red diamonds and 
correspond to a predicted class value of 0 while the various control samples are represented 
by green squares and correspond to a predicted value of 1. Accuracy, sensitivity and 
specificity values are given for each model. The red dashed line represents a decision 
boundary between classes. The oPLS-DA model details were as follows: A) 34 samples, 
venetian blinds CV, 5 splits, 3 latent variables (LVs); B) 24 samples, venetian blinds CV, 





2.5 Identification of Lipid Metabolites 
With an average mass error of 1.4 ppm, the elemental formulae and head groups 
were determined for all but two lipids, and all species were annotated where possible. Table 
2.2 details the identity of the lipids included in the 26-feature panel determined by both 
high-resolution mass spectrometry (HRMS) and MS/MS experiments, while Table A2 
provides the level of confidence obtained for each identification. Two of the 26 species in 
the panel likely corresponded to a mixture of at least two lipids, which co-eluted in the 
UPLC dimension and were isobaric in the MS dimension, therefore being unavoidably co-
isolated for MS/MS experiments. Distinction of these species was beyond the scope of this 
study, and would require an additional dimension of either liquid-phase or gas-phase 
separation, such as ion mobility.57,58 Table 2.2 also depicts p-values and abundance fold 
changes (FC) for each species. Positive FC values correspond to species with increased 
abundance in injured samples, while negative values indicate higher abundance in controls. 
When considered univariately, 15 of the 26 lipid species showed p-values at or below 0.05 
(p-value range=0.000354-0.0156) for a binary comparison between controls and TBI, 
though it must be taken into account that the panel as a whole was utilized for classification 
purposes, so the changes within an individual lipid species are less significant when 
alterations are investigated at a systems level. Of these 15 lipid species, 13 remained 
statistically significant when compared against time-matched sham controls only (naïve 
samples were removed from the control class) for p-value calculations, further verifying 
that the lipidome alterations observed were due to injury and not to surgery. Ionization 
efficiency varies widely between lipid classes, so only abundances of lipids belonging to 
the same class can be compared directly.59 Calculation of absolute abundance values for 
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each lipid was beyond the scope of this paper, as it requires extraction of serum samples 
with all relevant internal standards.60 This must therefore be performed prior to analysis 




Table 2.2. Annotation of lipids in 26-feature panel for the classification of moderate TBI. Retention time (RT), observed exact 
mass with Xevo instrument (and observed mass error), adduct, predicted elemental formulae, p-value comparing average 
abundances between all controls and TBI samples (and p-value comparing abundances between sham and TBI), and fold change 
(FC) values are included. Positive FC values correspond to species with increased abundance in injured animals, while negative 
values indicate higher concentrations in controls. Fatty acid chain information was included only when MS/MS experiments 
were possible, which required a minimum precursor ion abundance and no chemical overlaps with other species. SN1/SN2 
stereochemistry was not determined. For those unidentified species, please refer to Table A2 for additional information on the 
identity of detected fragments. Abbreviations- PE: phosphatidylethanolamine; PC: phosphatidylcholine; Cer: Ceramide; DG: 













24 9.86 738.5081 
0.27 
[M-H]- C41H74NO8P PE(20:4_16:0) 0.236 
0.619 
-1.58 
41 5.38 303.2323 
-2.31 
[M-H]- C20H32O2 Arachidonic acid (AA) 0.0138 
0.0134 
1.35 
58 11.32 666.6038 
-0.60 
[M+HCO2]- C40H79NO3 Cer(d18:1_22:0)) 0.252 
0.000168 
-1.11 
61 7.21 465.3035 
-1.93 





64 10.61 858.6225 
-0.58 
[M+HCO2]- C46H88NO8P PC(20:2_18:0) 0.00280 
0.380 
-1.21 
103 10.12 778.5594 
-1.28 
[M+HCO2]- C40H80NO8P PC(16:0_16:0) 0.0606 
0.0639 
-1.50 












128 10.35 711.5221 
-0.70 
[M+HCO2]- C43H70O5 DG(22:6_18:1) 0.00169 
6.92E-05 
2.23 
129 10.37 818.5912 
-0.57 
[M+HCO2]- C43H84NO8P Not identified 0.0544 
0.147 
-1.18 
245 0.54 262.8846 Not identified Not identified Not identified 0.00449 
0.0235 
2.88 
271 10.02 709.5041 
-1.13 
[M+HCO2]- C43H68O5 DG(22:6_18:2) 0.000354 
7.54E-06 
2.49 
272 5.91 329.2483 
-0.91 








Table 2.2 (continued). 
277 10.47 687.5197 
-1.16 
[M+HCO2]- C41H70O5 DG(20:4_18:1) 0.00156 
0.0057 
2.61 
289 5.02 283.2642 
-0.35 
[M-H]- C18H36O2 FFA(18:0) 0.0153 
0.000241 
3.02 
292 0.53 297.0985 Not identified Not Identified Not identified 0.0552 
0.153 
-10.8 
314 1.48 295.2274 
0.27 
[M-H]- C18H32O3 FFA(18:2 + 1 O)c 0.0560 
0.0071 
-2.55 
357 9.35 813.617 
6.64 
[M+NH4]+ C45H82NO8P PE(18:0_22:4) 0.00835 
0.387 
-1.28 
377 10.29 785.656 
3.69 
[M+H]+ C45H89N2O6P SM(d18:1/22:1)) 0.00241 
0.000247 
-1.37 
409 1.32 548.3713 
0.36 
[M+H]+ C28H54NO7P LysoPC(20:2) 0.549 
0.00147 
-1.08 
479 0.44 784.4746 
-1.66 
[M+H]+ C42H74NO10P PS(16:0_20:4) 0.159 
0.155 
1.21 
656 9.78 684.558 
2.78 
[M+NH4]+ C43H70O5 DG(22:6_18:1) 0.00104 
0.000213 
2.67 
665 10.93 746.5693 
-0.13 
[M+H]+ C41H80NO8P Not identified 0.219 
0.0492 
-1.38 
680 8.57 682.5402 
-0.44 
[M+NH4]+ C43H68O5 DG(22:6_18:2) 0.000489 
0.000125 
2.60 
698 7.14 822.60 
-0.85 
[M+H]+ C47H84NO8P Not identified 0.370 
0.0161 
-1.36 
699 0.92 582.3147 
-0.17 
[M+2Na-H]+ C26H52NO8P LysoPC(18:2 + 1 O) 0.0144 
0.0076 
1.65 
719 10.86 840.6465 
-1.43 
[M+H]+ C48H90NO8P Not identified 0.0103 
0.426 
-2.65 
a No matching database hits to expected fatty acid chain length from fragmentation experiments with PC headgroup. 
b A co-eluting species at m/z 262.9005 was co-selected by the quadrupole in all attempted MS/MS experiments, 
preventing accurate annotation via fragmentation. 
c The notation indicates that the position of the oxygen atom as well as the number of double bonds in the lipid structure 
are unclear at this stage. It could be an epoxide group or some other type of oxidized species.
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Among the lipids identified as potential TBI biomarkers, PUFAs and PUFA-
esterified DGs were found to increase in TBI samples. Also, a decrease in SM(d18:1_22:1) 
was observed in the TBI group, which was accompanied by a corresponding decrease in a 
related ceramide, Cer(d18:1_22:0). Injury-specific changes in abundance were also found 
for a variety of other membrane lipids (e.g. PCs, PEs, and a PS) as well as for CS. The PE 
membrane lipid containing esterified AA- PE(20:4_16:0)- was more abundant in controls, 
while the relative abundance of PS(20:4_16:0) was slightly increased in the TBI cohort 
following injury. Additionally, all PCs identified by the 26-feature model were of lower 
relative abundance in TBI samples, while the lysophosphatidylcholine (lysoPC) species 
observed showed an increase following injury. 
In addition to the 26-lipid panel described in Table 2.2, other lipids were frequently 
selected by the 120 multivariate models built using omniClassifier but were not part of the 
optimum panels highlighted in Table 2.1. Figure A3 details the topmost 30 features in the 
120 unique individual multivariate models based on their frequency of selection, which 
was related to the feature’s ability to discriminate between classes. Only 7 features (#30, 
34, 35, 227, 311, 475 and 701) were not covered in the 26-feature panel discussed above. 
Box plots and chemical annotations for the most significant additional features are shown 
in Figure A4. These were identified by both MS and MS/MS as eicosapentaenoic acid 
(EPA), DHA, lysoPE(20:4), PE(32:0), and PC(40:4). 
 
2.6 Overview of Broad Changes in the Serum Lipidome 
In order to visualize the entire set of relevant features simultaneously, a volcano 
plot was used to represent changes in individual species. Figure 2.3 provides a broad 
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overview of the most salient lipidome alterations following TBI as a function of p-value 
and fold change. Boundaries are drawn to illustrate features with FC absolute values > 2 
and p < 0.05. Features in the upper left and upper right regions satisfy both of these 
requirements and are most likely to be good candidate biomarkers of TBI if a single species 
was more desirable, although it is known that biomarker panels are more robust than assays 
based on single species.62,63 The lipids contained in the 26-feature model are indicated by 
red circles, with 9 of the 15 individually-significant features contained in those volcano 
plot regions. Additionally, most of the frequently selected features not in the panel, 
represented by blue X’s in the plot, fell above the significance boundary, further validating 
the feature selection method. As shown, not all the selected features were significant or 
near significant individually; however, when combined into a multivariate panel, all 





Figure 2.3: Volcano plot of processed metabolomic data set. Each point represents one 
feature. Features with fold change < 2 are colored in grey. Features in optimized 
classification panel are colored in red. Features frequently selected to build models but not 
in final classification panel are colored in blue. Positive fold change values correspond to 




Box plots describing these trends in dysregulation and normalized relative 
abundances for a variety of lipid species from the classification panel are shown in Figure 
2.4. As observed in panels A1-A3, FFA concentrations (18:0, 20:4 and 22:5) were all 
significantly elevated in TBI samples. The same trend held for DGs- DG(20:4_18:1) and 
DG(22:6_18:2)- as shown in panels A5 and A6. Panels B1-B3 illustrate decreases in 




Figure 2.4: Example box plots showing significantly dysregulated species used by 
optimized model for classification of samples. A1-A6 show species that increased and B1-
B3 show species that decreased following injury. A1) FFA 18:0, [M-H]- = 283.2644;  
A2) arachidonic acid, [M-H]- =303.2330; A3) docosapentaenoic acid, [M-H]- = 329.2483; 
A4) m/z = 262.8846; A5) DG(20:4_18:1), [M+HCO2]- = 687.5197;  
A6) DG(22:6_18:2), [M+HCO2]- = 709.5041; B1) Cholesterol Sulfate, [M-H]- = 465.3035;  







Altered lipids were subdivided into groups by describing their trend as increased, 
decreased, or no significant change at the 3- and 7-day time points following injury (Figure 
2.5). No significant differences were observed compared to controls at either time point for 
five features, indicating that these alone are unlikely to translate to successful biomarkers. 
Approximately half (10/21) of the remaining features were significant across both time 
points when compared to controls, while 10 more showed significant differences at only 3- 
or 7-days post-injury (Figure 2.5A-B). Most features in the panel, all except for 2, did not 
show significant differences between 3 and 7 days, (Figure 2.5C). The remaining 
differences, however, could be attributed to reduced sample size for each pair-wise 
comparison or type I errors stemming from multiple comparisons. Additionally, many 
features showed temporal patterns supporting a return towards control levels at 7 days, 
warranting further study and inclusion of more acute time points to determine the time-




Figure 2.5: Boxplots showing time profile changes of samples at 0, 3 and 7 days following 
TBI. Features are divided into 3 groups: A) Features 14, 128, 271, 272, 277, 699, 289, 245, 
656, 680 and 479 showed an initial increase following TBI; B) features 719, 61, 357, 103, 
377, 64, 129, 292 and 314 that decreased following TBI and continued to decrease or 
started to return to baseline at 7 days; C) features 24, 118, 409, 665 and 698 that showed 
no significant differences between timepoints. †Not identified; *Adduct differences; 






We utilized a broadband, discovery approach to identify novel lipid biomarkers of 
moderate TBI in the serum of adult male rats at 3- and 7-days post-injury. These subacute 
time points correspond with ongoing secondary cell degradation, as well as the time-course 
of post-traumatic inflammatory and oxidative stress cascades.31,64-70 Through the 
combination of HRMS methods and rigorous data-driven classification models (feature 
selection algorithms: Bayesian, KNN, Logistic Regression and SVMs), we determined a 
26-feature lipid panel that consistently separated TBI samples from sham-operated and 
naïve controls with over 85% accuracy. Many of the lipids prominent in the panel were 
PUFAs and PUFA-containing DGs, as well as oxidized phospholipids, sphingolipids, and 
other lipophilic moieties. These dysregulated lipid species warrant further investigation 
and consideration for inclusion in a TBI biomarker panel. While it is expected that a 
biomarker panel will increase specificity over a single biomarker, 15 of the 26 lipids in the 
panel distinguished injury from control when considered individually, demonstrating the 
potential of this approach to identify TBI-specific changes in single lipid species. 
2.7.1 Biological Relevance of the Identified Lipid Panel 
Among the lipids identified as potential TBI biomarkers, PUFAs were found to 
increase after TBI. Specifically, FFAs such as FFA(18:0), FFA(20:4, AA), FFA(22:5, 
docosapentaenoic acid, DPA), and FFA(22:6, DHA) all showed significantly increased 
relative abundances following TBI, while the abundance of oxidized fatty acid species 
FFA(18:2 + 1 O) decreased. Similarly, elevated levels of AA have been found in rat serum 
following TBI using gas chromatography-mass spectrometry (GC-MS) at 1 and 5 days 
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post-injury.71 FFA increases have also been observed in the rat brain following CCI26 as 
well as in the CSF of TBI patients.72,73 
An increase in FFAs is known to accompany cellular injury events such as 
uncoupling of oxidative phosphorylation, exacerbating the disruption of ion balance and 
aggregation of oxidative metabolites.74 The disruption of calcium ion homeostasis in 
combination with energy depletion in the brain following injury leads to the activation of 
PLA2 and PLC, which causes the release of FFAs from membrane phospholipids.75,76 The 
activation of PLA2 in particular causes the liberation of AA, DPA, EPA, DHA, and other 
FFAs, enabling their detection in serum post-TBI. Increases in phospholipase activity have 
been observed as early as 15 minutes post TBI,77 and the levels of FFAs have been reported 
to remain elevated at least 35 days post-injury.25 Evidence of fatty acid oxidation as well 
as disrupted amino acid metabolism has also been reported in patients presenting with 
severe blunt head trauma.78. 
While PUFAs are elevated following injury, FFA turnover is an essential process 
for membrane homeostasis and synaptogenesis,79 and these changes may be associated 
with post-injury repair attempts. The downstream metabolites of AA have been cited as 
potential biomarkers of inflammation, albeit for both pro- and anti-inflammation 
cascades.66 Specifically, AA is metabolized to eicosanoids through the COX pathway, as 
well to as anti-inflammatory lipoxins through the lipoxygenase (LOX) pathway, which are 
associated with the resolution phase of inflammation.80 
Fatty acids can also undergo LP as a result of ROS and RNS imbalances once 
cleaved from membrane phospholipids, leading to the formation of α,ß-unsaturated 
aldehydes including MDA, 4-HNE and acrolein.81 We observed a decreased abundance for 
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the oxidized FFA (18:2 + 1 O) and a lysoPC of the same species, lysoPC(18:2 + 1 O). The 
enzyme lipoprotein associated phospholipase A2 (Lp-PLA2) hydrolyzes oxidized 
phospholipids within LDL to generate oxidized lysoPC molecules, which are known to 
induce inflammation.82 However, the resolution phase following injury is not reached if 
the oxygen supply in the brain is not re-established, possibly explaining the decrease in 
observed oxidized FFAs.83 The decreased relative abundance of these oxidation products 
in TBI samples may thus indicate a lack of effective controlled clearance of damaged 
cellular membranes following TBI, possibly due to an imbalance in PUFA concentrations. 
Necrotic cell death also stimulates the release of ROS and cytokines, the activation of 
phospholipase and sphingomyelinase, and phospholipid hydrolysis, all of which occur in 
TBI.84 Furthermore, the CNS has a high level of lipid content, providing abundant 
substrates for oxidative attack by ROS.85 Neurons are particularly vulnerable to ROS due 
to reduced glutathione levels, with the high degree of polyunsaturation of brain lipids 
providing many sites for the propagation of LP reactions.86 
We also found that PUFA-esterified DGs changed significantly following TBI. TBI 
stimulates the activation of phospholipases C and D, resulting in increased abundances of 
DGs.87 In our study, DGs- specifically those containing PUFA residues (22:6 or 20:4)- 
were significantly increased in relative abundance following TBI. It has been shown 
previously that DGs in rat brains were increased immediately following CCI and remained 
elevated a month later compared to controls.26 
While FFAs and DGs were increased in response to injury, all PCs and PEs 
identified in the classification panel were decreased in abundance after TBI. The majority 
of these lipids were esterified by PUFAs such as AA, including PE(20:4_16:0), PE 
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(22:4_18:0), and PC(20:2_18:0), which were all decreased in TBI samples, while the 
relative abundance of PS(20:4_16:0) was slightly increased. Although lipid species 
containing only saturated fatty acids followed the same trend, none achieved statistical 
significance individually.  
A recent study showed decreased levels of cortical and cerebellar PCs and PEs 
following CCI in the rat, while hippocampal PC and PE levels were elevated. Levels of 
overall PC, PE, and SM were lower in plasma following injury, and ether PE levels were 
lower in the cortices and plasma of injured mice relative to controls.24 In addition to 
preclinical evidence, phospholipid dysregulation has been observed in the CSF of human 
subjects following TBI. Clinical evidence for the disruption of CNS phospholipids has been 
observed within the first days following TBI, with PCs and PEs elevated to the highest 
concentration by day four.88 Similarly, both PCs and PEs were dramatically increased as 
early as one day following TBI, though levels decreased with time for survivors, falling 
below control levels by day six.89 Total PS concentrations were elevated at all measured 
time points, in agreement with the observed trend for the AA-containing PS molecule 
identified in the 26-feature panel above. Clinical evidence supports the initial increase of 
membrane phospholipids upon injury, followed by a decrease to levels below controls, 
likely indicative of ongoing hydrolysis of PC and PE species.85 Activation of 
phospholipases results in the hydrolysis of PUFAs esterified to membrane phospholipids, 
leading to decreased concentrations of PUFA-containing PC and PEs. The same 
pathophysiology resulting in the increased formation of FFAs also leads to a decreased rate 
of phospholipid re-synthesis, and our results follow previous observations regarding 
phospholipid dysregulation following TBI.  
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Injury-specific changes in abundance were found for a variety of membrane lipids 
(e.g. PCs, PEs, and PSs) as well as for CS, which was significantly decreased in the TBI 
cohort. CS is an end product in the cholesterol metabolic pathway and may play a 
stabilizing role in cell membranes.90 The decrease in CS may also indicate a possible 
disturbance in AA regulation, a vital pathway in the secondary injury cascade.91 
Additionally, while both cholesterol and CS play key roles in lipid organization, CS is often 
found in high abundance in DHA rich membranes.92 DHA was increased following 
moderate injury, though CS was significantly decreased, potentially decreasing membrane 
permeability due to less efficient packing. 
2.7.2 Limitations 
There are some limitations to the present study that should be acknowledged.  
While we focused on time-points that are known to reflect secondary injury changes, 
exploration of earlier time points may help to guide biomarker panel development in the 
acute period for diagnostics measures.  Furthermore, we did not examine possible 
correlations between biomarker levels and histopathological or behavioral changes post-
TBI.  While such correlation is not straightforward 93,94 it will be pertinent to examine 
histopathologic correlates.  As the lipid panel is refined, it would also beneficial to study 
not only other outcome measures, but also how addition of other fluid biomarkers, such as 
GFAP or UCH_L1, might improve specificity and sensitivity of diagnosis. 
Additional lipid changes after both experimental and clinical TBI have been 
observed. Gangliosides such as GM2, have been shown to increase in the hippocampus, 
thalamus and hypothalamus of mice following blast TBI, accompanied by a corresponding 
decrease in ceramides.27 Brain CLs have been shown to be selectively oxidized following 
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TBI, 21,95,96 though none were detected in this study due to their low abundance in plasma 
resulting from localization within the mitochondrial membrane, as well as possible ion 
suppression effects.97-99 Also DGs and CEs have been found to increase, while PCs, PEs, 
PIs, and cholesterol decrease in rat brains following CCI.23 Phospholipids esterified with 
PUFAs have been found to increase in the CSF of TBI patients.24 Similarly, levels were 
higher in patients with TBI who died within days after injury compared to those who 
survived.89,100 The results of our study thus lend support to previously identified lipidome 
alterations resulting from TBI and introduce a host of new potential biomarker candidates 
warranting further validation. 
 
2.8 Conclusion 
In addition to providing novel lipid biomarker candidates for TBI, the untargeted 
nature of our study also provides an in-depth exploration of the metabolic processes in the 
subacute post-TBI period. Overall, many of the altered lipids are known to be involved in 
secondary injury pathways and would be expected to cross the BBB regardless of injury 
severity, increasing their likelihood of being detectable in serum, a readily accessible 
matrix with clinical relevance. The identified lipids may serve as prognostic biomarkers 
for TBI in the rat model, and it is expected that many of the same lipids could be detectable 
in both rodent and human blood. However, due to differences in the genome, proteome and 
subsequently the metabolome between rodents and humans, this specific diagnostic panel 
is unlikely to have direct clinical utility. Therefore, further discovery and validation studies 
are needed to assess the viability of this panel in detecting TBI in human patients. The 
metabolism of lipids is both complex and interwoven, but this study serves as a foundation 
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for future validation studies of TBI biomarkers. Comprehensive biomarker panels for TBI 
diagnosis and clinical management should consider inclusion of lipid-based molecules.  
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CHAPTER 3: ACUTE PHASE SERUM LIPIDOME ALTERATIONS 






Following the development of a high accuracy multivariate classification panel to 
detect moderate traumatic brain injury at the post-acute phase (t= 3-7 days), we proposed 
to study a mild injury model at an earlier acute time point (t=24 h). Using a matched pair 
study design to improve statistical power, a panel of 16 lipid metabolites was developed 
with a classification accuracy of 88.5%, a modest improvement from the previous study 
despite the use of a less complex metabolite panel (reduction of the number features 
utilized for classification) and the occurrence of a milder form of injury in which the 
average effect size of lipid alterations was reduced. These promising results demonstrate 
the feasibility of utilizing non-targeted lipidomics to detect mild, concussive events in 
serum samples. MS/MS analysis of the target panel reveals similar trends with respect to 
alterations in lipid classes to those observed in the first study of moderate TBI, here 
indicating that phosphatidylcholines (PCs) were increased in TBI samples, while a lysoPC 
was decreased in abundance compared to controls. Again, cholesterol sulfate was identified 
as a biomarker candidate, exhibiting a significant (1.27-fold) decrease in abundance across 
mTBI samples, while a DHA-containing CE showed a relative increase (1.48-fold). Time-
matched sham controls were included to indicate that changes in lipid profiles were a direct 
consequence of the injury. Control samples including pre-injury baseline, sham baseline, 
and sham 24-hour samples were nearly identical experimentally, except for the time and 
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method of collection as well as total duration of anesthesia exposure. Specificity must still 
be demonstrated in other co-occurring environments to be applicable to return to play 
considerations (e.g. stress, exercise, inflammatory diseases, or orthopedic injury). 
 
3.2 Introduction 
3.2.1 Traumatic Brain Injury Epidemiology 
The widespread occurrence of TBI in the military, general public and athletics has 
led to heightened awareness of an ongoing public health crisis, in which more than 50 
million injuries are estimated to occur worldwide each year.1 Including both direct and 
indirect healthcare expenses, the total economic burden of brain injuries exceeds $400 
billion USD annually, accounting for approximately 0.5% of the global output.2,3 TBI is 
especially prevalent in young adults, as more than 30% of people have experienced some 
form of TBI by age 25, while more than half of the world’s population will sustain a TBI 
at some point in their lifetime.1,4 TBI is also the leading cause of mortality in young 
adults and is among the leading causes of injury related death and disability across all 
populations.5  
TBI is typically stratified into three broad categories (mild, moderate, and severe) 
based on a patient’s level of consciousness using the GCS.6 However, this simple grading 
scheme fails to capture the heterogeneity associated with different primary and secondary 
injury mechanisms. Variance within the affected clinical population, including age, sex, 
and genetic differences as well as previous history of injury, may also have an influence 
on outcome.7,8 Until recently, most research focused on severe TBI, which accounts for 
only approximately 3% of the documented injuries worldwide. However more than 70-
90% of TBI occurrences are classified as mild, or mTBI. Synonymous with concussions, 
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these milder injuries were initially viewed as insignificant, with patients being discharged 
immediately without any recommended follow up.9 However, it is now understood that 
even mild brain trauma can lead to significant neurological alterations, post-traumatic 
amnesia, and other concussive symptoms, which may persist for days, weeks or even 
years in some instances.10,11 Mild brain injuries are often diagnosed based on the presence 
of these subjective self-reported symptoms, which has led to many going undetected or 
unreported.12 Thus, a substantial gap remains between basic science efforts and clinical 
implementation of more objective injury assessments in the setting of mTBI. Concerted 
research efforts must be focused on the study of individual responses in the midst of 
heterogeneity in order to develop diagnostic tools capable of providing objective 
measures of brain injury status. 
3.2.2 The Use of Biomarkers for TBI Diagnostics 
Blood-based biomarkers are gaining traction as a possible solution to this 
problem, as they have the potential to objectively monitor injury status and provide a key 
to understanding the pathophysiological responses to TBI.13,14 Biomarkers can be 
measured in a variety of sample sources. For TBI, the ideal sample type would be the 
brain tissue directly affected by injury, but since this can only be sampled post-mortem, 
other clinically relevant sample sources must be explored. CSF is the fluid source closest 
to the tissue and bathes the brain and spinal cord. However, collection of CSF is not 
commonly clinically feasible and can be a painful procedure. Therefore human samples 
can be especially difficult to obtain.15 Additionally, available CSF volume and total lipid 
concentration in CSF are low in comparison to other readily available biological 
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matrices.16 Thus blood, either serum or plasma, is the ideal sample type for biomarker 
studies, as it can be easily collected in both animal and human subjects.  
The majority of existing biomarker research has focused on a few brain-specific 
proteins and peripheral markers of BBB dysfunction that are up-regulated as a 
consequence of brain injury.17 For example, tau protein is expressed in axons, and 
concentrations in ventricular CSF have been shown to correlate well with lesion size and 
clinical outcome following TBI.18,19 Without adequate clearance, aggregates of misfolded 
proteins, composed primarily of tau and amyloid-beta (Aβ) that have been associated 
with the onset of AD and chronic traumatic encephalopathy (CTE), form in the brain. 
Thus, TBI may be a risk factor for the development of neurogenerative disorders due to 
the resulting buildup of such proteins.20 GFAP is also cited within the literature as a 
candidate biomarker for the diagnosis of TBI, as astroglial cells produce more GFAP in 
response to brain injury, while levels of the protein do not spike without brain injury even 
when other injuries are present.21 Recent research efforts have successfully utilized the 
combination of multiple markers into a single panel to improve sensitivity and specificity 
of diagnosis, as Banyan Biomarkers took a major step forward when their Brain Trauma 
Indicator, a panel of UCH-L1 and GFAP, gained FDA approval for determining the need 
for CT scan in the presence of injury.22  
Peripheral markers of BBB disruption have also been suggested as biomarkers of 
TBI, the most commonly cited being CSF/serum albumin ratio.23 The elevation of this 
ratio indicates that albumin has passed from the blood to CSF.17 While an increase in this 
ratio has been discovered in cases of severe TBI, similar alterations have not been 
observed in studies of mTBI, indicating a lack of BBB breach.24,25 Thus, in cases of 
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mTBI, BBB efflux transporters are likely required for brain-specific biomarkers 
including proteins to reach systemic circulation, perhaps explaining the lack of pre-
clinical to clinical translation within existing protein biomarkers to date. 
Lipid biomarker research is more limited but offers promising leads as well. 
Recently, a panel of 6 lipids was shown to discriminate between athletes with TBI and 
non-injured teammates at <6 h, 2d, 3d, and 7d post-mTBI.26 The ability of these 6 lipids 
to classify injury in both the initial college athlete cohort as well as a separate 
independent cohort indicates the utility of lipid biomarkers to detect changes associated 
with TBI and make predictive assessments of TBI using objective methods. Additionally, 
a number of targeted studies have looked at changes in gangliosides, ceramides, and SMs 
as these lipids are much more highly concentrated in the CNS.27,28 Increases in circulating 
FFAs and DGs have also been shown to occur as a consequence of TBI.29,30 Previously, 
using non-targeted lipidomics in a rodent TBI model, we identified a panel of 26 lipid 
metabolites capable of differentiating moderate TBI serum samples from controls.31 In 
this study, we aimed to utilize the same methods to determine which lipids are affected at 
the onset of mild, closed-head TBI. 
 
3.3 Methods and Materials 
3.3.1 Injury and Blood Sampling 
All procedures involving animals were performed according to the guidelines set 
forth in the Guide for the Care and Use of Laboratory Animals (U.S. Department of 
Health and Human Services, Pub no. 85-23, 1985) and were approved by the Georgia 
Institute of Technology Institutional Animal Care and Use Committee (protocol 
#A15088). The study was not pre-registered. Male Sprague-Dawley rats (8 weeks old; 
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Charles River) were kept on a 12-h light–dark cycle, and food and water were available 
ad libitum. Thirty-eight animals weighing between 300 and 450 g were randomly 
assigned to the following groups using a computer-based randomization algorithm: (1) 
TBI, n=30 and (2) sham (no injury, n=8). The 30 TBI animals were further subdivided 
into four groups based on the type of foam used to support the head during injury: (1) 
closed-cell (C, n=7), (2) polyurethane (P, n=8), (3) yellow generic in-house foam (Y, 
n=7) and (4) Marmarou (M, n=8). A pre-procedure baseline was taken just before injury 
(during isoflurane exposure), such that each sample was acquired in matched pairs (0 and 
24 h). Sham-control animals were employed as time-matched controls to ensure that the 
differences in lipid metabolite abundances were due primarily to injury status rather than 
anesthesia exposure duration or other confounding effects.  
Mild, closed-head injury was induced using a CCI device (Pittsburgh Precision 
Instruments, Pittsburgh, PA). Rats were anesthetized (induction, 5% isoflurane; 
maintenance 2-3% isoflurane) prior to all procedures, and injury was induced 30 s after 
removal of the isoflurane supply. A pneumatic piston fitted with a 1.6cm diameter 
silicone tip (Yield House Industries) impacted the dorsal surface of the head directly 
above the center of the cortex (head displacement = 5 mm, velocity=5 m/s, duration=100 
ms), modifying literature protocols to simulate mTBI insult.32,33,34 Animals were placed 
on a heating pad during recovery, after which they were singly housed in their home 
cage. Sham-control animals were subjected to the same procedures described above but 
did not receive an impact. 
For baseline samples, approximately 200 µL of whole blood was collected during 
the afternoon from the tail vein punctured by 22-gauge Precision Glide needles (Beckton 
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Dickinson) and stored on ice. The matched pair 24 h samples were collected directly 
from the heart upon sacrifice. Whole blood samples were allowed to coagulate at room 
temperature for 45 min., and all sample collection followed literature guidelines for 
limiting the potential for hemolysis.35,36 To isolate the lipophilic portion of the serum 
lipidome, sample preparation was conducted as previously described.31 
3.3.2 UPLC-MS Analysis 
 Reversed-phase chromatography was employed to separate the components of 
serum using a Waters Acquity UPLC quaternary solvent manager system using 
previously established methods for LC separation and MS acquisition settings.31 Solvents 
and additives were obtained from Fisher Chemical (ACN), Honeywell (IPA), CovaChem 
(formic acid, LC-MS grade) and Sigma Aldrich (ammonium formate, purity > 99.995%).  
Tandem MS experiments were performed in a QE HF mass spectrometer (Thermo 
Fischer Scientific) using three distinct NCE values (10, 30 and 50), which were then 
averaged and combined into a single spectrum. Spectral interpretation of lipid 
fragmentation patterns was performed either manually or by comparison to entries in the 
LIPID MAPS, HMDB, and Metlin databases.37-39 Lipid Search software was also used in 
order to verify identifications.40 Additionally, for low abundance metabolites, a more 
sensitive instrument was required to obtain pertinent MS/MS information. These 
experiments were conducted on a Thermo IDX mass spectrometer with the instrument 
programmed to perform a full scan every second and internal mass calibration activated. 
During free injection time, the instrument was programmed to target ions of interest, as 
determined by the use of an inclusion list containing pertinent adducts of the target ions. 
The method utilized both Orbitrap (OT) and ion trap (IT) detectors, while OT data 
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collection was given priority. If an ion in the inclusion list was detected, it was 
fragmented by higher-energy collisional dissociation (HCD) and the fragment ions were 
measured in the OT. Then the parent was fragmented by Collision-induced dissociation 
(CID) and the ions were measured in the OT. If time permitted, the second priority scan 
was initiated, and the targeted parent ion was fragmented by CID while the ions were 
collected in the IT. HCD and orbitrap DDA data were collected with an isolation window 
of 1.2 m/z, resolution of 15,000, and collision energy of 10, 30, and 50, which were again 
averaged into a single spectrum. CID data were acquired at a collision energy of 32 V 
with the same isolation window and resolution.  
3.3.3 Data Mining 
 Chromatographic alignment, de-isotoping, deconvolution, normalization, and 
peak picking were accomplished using Progenesis QI software. Sets of 1805 and 826 
spectral features, defined as unique pairs of retention time (RT) and exact mass to charge 
ratios (m/z) corresponding to unidentified lipid metabolites, were obtained from positive 
and negative ion mode data, respectively. Filters were applied to remove peaks detected 
as background contaminants and peaks in which the instrumental variability exceeded 
20% through the use of solvent blanks and pooled QC samples.41 Features detected in 
fewer than 75% of samples in both TBI and control groups were also removed prior to 
binary classification. The relative abundances for the remaining 841 features (564 
positive mode and 277 negative mode) were exported as a single matrix combining both 
ionization modes into MATLAB (R2018b, The MathWorks, Natick, MA with PLS-




3.3.4 Feature Selection and Classification 
The procedure for multivariate feature selection is described in Figure 3.1. 
Briefly, a matrix was created containing the relative feature abundances across each 
sample. A scheme was developed within MATLAB using the iPLS-DA internal feature 
selection algorithm, which selected the single feature that minimized cross-validation 
error (CVE) and iteratively added features until an optimized model was developed. To 
begin, the 62 samples were randomly stratified into random CV sets, using 7 or 8 data 
splits. This way, a portion of the data were used to select features, while others were 
withheld to cross-validate the predictive model. The use of random subsets CV ensured 
that different samples were used for the feature selection process as well as for the 
external CV step in each model built, an effort to avoid overfitting the data, a common 
problem that commonly plagues PLS-DA studies.42,43 Each iteration of the process 
generated a model comprised of approximately 5-10 features with classification accuracy 
approaching 90%. The features used to build all 20 of these models were then sorted by 
frequency of selection and the most commonly selected features were retained within the 





Figure 3.1: Schematic overview of the feature selection process for determining an 
optimized classification model used to differentiate TBI samples (red) from controls 
(green). A) Matched pair data (n=31) were imported into Matlab as a 62x841 matrix 
containing relative feature abundances for each sample. B) Samples were randomly 
stratified into 7 or 8 data splits so that a different portion of the data were withheld to build 
each model using random subsets cross-validation. C) Using the iPLS-DA feature selection 
algorithm, a classification model was built by iteratively adding the feature that contributed 
to the lowest total error of cross-validation. This process was repeated 10 times using 7 
data splits and 10 times using 8 data splits. D) The features selected most frequently within 
the 20 classification models were combined to build an optimized classification panel 




3.4.1 Preliminary Data Overview 
 The serum lipidome of 38 Sprague-Dawley rats was analyzed at 24 h post-injury 
following closed-head CCI injury in order to identify potential biomarker candidates of 
mTBI, with each animal’s pre-injury baseline sample serving as a matched pair control. 
During sample processing, two samples (Y7 baseline and M4 baseline) were discarded 
following rupture of the Eppendorf tube in the centrifugation process. Five additional 
samples (C7 baseline, C2 post-injury, C3 post-injury, Y1 baseline and S8 post-
anesthesia) were noted for possible evidence of hemolysis, and these samples were 
excluded as outliers during analysis using T2 and Q residual values to identify outliers in 
the multivariate analysis. Therefore, the matched pair samples associated with the above 
were all also excluded in order to maintain a robust matched pair study design, leaving a 
total of 62 samples for analysis (31 baseline control samples and 31 24 h post-injury 
samples with the distribution of animals within groups as described in Table 3.1.  
 
 
Table 3.1. Experimental design for subset of 31 animals including number of animals (n) 
sampled per group and the density of each different type foam subtype.  
Foam Type n Foam Density 
Closed-cell (C) 4 0.046 g/cm3 
Marmarou (M) 7 0.017 g/cm3 
Polyurethane (P) 8 0.036 g/cm3 
Yellow (Y) 5 0.031 g/cm3 
Sham (no injury) 7 N/A 




All anticipated classes of lipids were detectable as determined by the use of base 
peak intensity chromatograms (BPI, Figure 3.2). However, no differences in the 
abundance of these lipids were observed within the BPI traces when sorted by type of 
sample (TBI, matched-pair baseline control or sham), indicating that advanced 
multivariate techniques were necessary for the discrimination of TBI samples from 
controls. Overall, 2631 features with signal intensity above background were detected, 
and this total was further reduced to 841 based on filtering criteria. These features were 
imported into MATLAB, in order to determine which lipids were most critical to the 





Figure 3.2: Offset base peak intensity (BPI) traces for aligned chromatographic 
separations of rodent serum samples in A) negative ionization mode and B) positive 
ionization mode. Colors correspond to individual sample subtypes: TBI samples are 
colored in red, pre-injury control samples are colored in light blue, and sham control 
samples are colored in green. The top black trace corresponds to a mean BPI trace of all 
samples analyzed during the experiment. Lipid classes are labeled by anticipated time of 
elution, and the classes of lipids labeled above correspond to the retention time across the 




3.4.2 Development of Multivariate Models for the Classification of Mild 
Traumatic Brain Injury 
PCA of the lipidomics dataset indicated that the effect of mTBI was relatively 
more subtle than what was detected in Chapter 2 (Figure 3.3A). While TBI samples 
trended towards negative scores on principal component one, there was still broad 
overlap between TBI and control samples using unsupervised techniques on the entire set 
of features. For supervised classification, in which class information was incorporated 
into the data, an oPLS-DA model was created using the relative abundances of all 
features to attempt to classify TBI samples from all controls (Figure 3.3B). This 
multivariate model performed with an overall accuracy of 83.9%, specificity of 92.1% 
and sensitivity of 70.8%. While this model performed well in terms of overall accuracy, it 
had a tendency to underperform in the ability to accurately predict TBI samples, as 
numerous false negatives were produced in the initial classification. In the field of 
concussion diagnostics, there is a tendency to underestimate the existence of mTBI due to 
lack of perceived symptoms (i.e. false negative). However, it is safer to overestimate (i.e. 
false positive) the number of injuries than risk subsequent injury due to second impact 
syndrome, which could lead to post-concussive symptoms.44,45 Therefore, future 
iterations were optimized to select just those features which contributed to the improved 
classification sensitivity and overall accuracy, leading to the development of a 
classification panel containing 16 unique lipid metabolites which were capable of 
classifying mTBI samples from controls with an accuracy of 88.5%, sensitivity of 87.5%, 
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and specificity of 89.5% (Figure 3.3C). The features contained within this classification 
panel are included in Table 3.2.  
 
Figure 3.3: Classification model performance comparisons with and without feature 
selection illustrating accuracies of developed classification models to used discriminate 
between TBI samples, represented by red diamonds, and control samples, represented by 
green squares. A) PCA scores plot containing all features; B) oPLS-DA model containing 
all features; C) oPLS-DA scores plot for 16 feature model showing performance of 
classification of all 62 samples, including sham controls. Sample numbers 1-24 correspond 
to baseline control samples, 25-38 indicate sham control samples, and 39-62 represent TBI 
samples; D) oPLS-DA model showing performance of 16 feature classification model on 
48 matched pair samples, excluding shams. Sample numbers 1-24 correspond to baseline 
control samples and 25-48 represent TBI samples. For plots A-C, the line at 0.5 on the y-




3.4.3 Performance of the Classification Models 
When the same model was used to classify TBI samples against only their 
matched pair baseline control samples, a model with accuracy of 97.9%, sensitivity of 
95.8%, and specificity of 100% was generated, indicating that much of the CVE stemmed 
from the misidentification of sham control samples in the multivariate classification 
scheme. While this may be attributed in part to overfitting of the data, or non-injury 
related differences within sample subtypes, it is further evidence that pre-injury baseline 
samples offer the clearest path to identification of mTBI following injury. 
 Additionally, much of the power of the multivariate classification model was due 
to only differences in a handful of these 16 features. Comparing loadings, levels of 
significance and fold changes between sample types, the panel of 16 could be reduced to 
a simpler model including only 5 lipid metabolites capable of classifying mTBI with 
nearly the same accuracy (Figure 3.4). While this simpler model again performed very 
well on the matched pair samples, accurately predicting 47/48 samples (Figure 3.3D), it 
also had a tendency to misclassify a number of the sham samples as injuries. In this and 
other similar prediction models, each of the multivariate models systematically 






Figure 3.4: Performance of the 5-feature oPLS-DA model. Performance accuracy of 
developed classification models to discriminate between TBI samples, represented by red 
diamonds, and control samples, represented by green squares. A) oPLS-DA model for 5 
feature model, including only features 56, 380, 448, 456, and 623, showing performance 
of classification of all 62 samples, including sham controls. Sample numbers 1-24 
correspond to baseline control samples, 25-38 indicate sham control samples, and 39-62 
represent TBI samples; B) oPLS-DA model showing performance of 5-feature 
classification model on 48 matched pair samples, excluding shams. Sample numbers 1-24 
correspond to baseline control samples and 25-48 represent TBI samples. The line at 0.5 
on the y-axis represents the decision boundary between TBI samples and control samples. 
 
 
3.4.4 Possible Confounding Factors 
 The inability of the multivariate classification model to accurately predict the 24 h 
sham samples as controls may be attributed to a number of confounding factors. The 
effect size of mTBI on the features was small compared to previously published data on 
moderate TBI.31 Thus, minor differences may also exist within the sham samples that 
affected the serum lipidome with a similar effect size to that of the mild injury. Isoflurane 
was used to anesthetize rats during collection of blood, and this has been shown to affect 
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the metabolome as well, inducing changes in protein phosphorylation with durations as 
low as 30 minutes.46 Use of isoflurane as an anesthetic also led to increased 
concentrations of lactate and glutamate in the rodent hippocampus and parietal cortex 
compared to animals anesthetized with propofol, though these increases were 
independent of blood lactate concentrations.47 Additionally, plasma samples of patients 
sedated with propofol showed different metabolic profiles when compared to patients 
treated with etomidate. The primary differences observed included a general decrease in 
metabolite concentrations due to slowed metabolism while under anesthesia, decreased 
branched amino acids such as leucine and isoleucine coupled to increased ketones such as 
acetone, acetoacetate and 3-hydroxybutyrate, while others could be attributed to 
differences in drugs administered to patients, such as cefuroxime, an antibiotic.48 
Prolonged exposure to sevoflurane, another anesthetic agent, has also been shown to alter 
lipid metabolism, leading to disruption of cellular membranes and subsequent neuronal 
dysfunction and damage in developing brains.49,50 Therefore in studies utilizing anesthetic 
agents, the distinction between association of brain injury with lipidome alterations must 
be interpreted in light of the potential confounding effects of anesthesia exposure.  
Additionally, the collection of the baseline sample and subsequent matched pair 
sample, at 24 h for sham and mTBI, were done via different procedures, as the 24 h 
samples were collected from the heart upon sacrifice of the animal. Though differences in 
circulating blood should have normalized by this time, it is possible that the method or 
time of collection contributed to more similarities within the lipidome of 24 h sham and 
TBI samples than their baselines, which again favors the collection of pre-injury 
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baselines samples for later comparison to injuries, as has been done in other biomarker 
studies.51,52  
 While the foam was initially intended to provide support for the head during 
injury, it also may have served the purpose of cushioning the skull from impact by 
absorbing and dampening some of the force directed by the pneumatic piston. Due to the 
densities and cell structures of the foams, the dispersion of forces was unique to each 
foam subtype. If the foam support sufficiently dissipated the force of impact, the presence 
of injury in these TBI samples would be partially mitigated and such samples may be 
modeled more similarly as sham controls. To investigate this hypothesis, we temporarily 
changed the class membership of the samples taken from each foam type from TBI to 
control, generating new classification models to see how cross-validated accuracy was 
affected. 
 For three of the foams (Marmarou, closed-cell, and polyurethane), this led to a 
dramatic decrease in performance accuracy of the 5-lipid model (0.174, 0.219, and 0.203 
CVE respectively), indicating that the samples were still correctly predicted as TBI, as 
they were subsequently misclassified in each of the newly generated multivariate models. 
However, yellow, in-house lab foam showed similar classification accuracy in both cases 
(Figure 3.5). Alteration of class membership of TBI samples to controls from the yellow 
foam group adjusted the separation boundary between classes and improved classification 
accuracy of 24 h sham samples. While overall performance was slightly decreased 
(89.3% to 87.5%), this indicates that the effect on the selected lipids was even more 




Figure 3.5. Cross-validated class prediction values using 5-lipid classification model when 
yellow foam TBI samples are defined as A) TBI (class = 1) and B) control (class = 0). 
Sample numbers 1-24 correspond to baseline control samples, 25-38 indicate sham control 
samples, and 39-62 represent TBI samples. 
 
 
3.4.5 Disruption of Cholesterol Metabolic Pathways 
 While the combination of multiple lipids into a multivariate classification panel 
led to the accurate distinction of TBI and control samples, changes on the univariate level 
can be mapped to known pathophysiology, helping to explain the importance of the 
features used for classification. For instance, a significant decrease (p < 1.0E-9) in the 
level of CS was observed across TBI samples. CS, a sterol sulfate present in human 
plasma in µg/mL levels as well as in tissue including the epidermis, plays a stabilizing 
role in cellular membranes and serves as a precursor in the synthesis of other sulfonated 
adrenal steroids such as pregnenolone sulfate.53,54 Levels of plasma CS may increase by 
an order of magnitude in association with disease states such as cirrhosis of the liver and 
hypothyroidism.55,56 CS has been shown to have a significant on lipid metabolism, acting 
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via a number of mechanisms including inhibiting the esterification of cholesterol.57 
Conversely, decreased supply of both cholesterol and sulfate have been associated with 
impaired autophagy and insulin resistance.58 The observed decrease in CS in this study 
(FC = -1.27) followed the same trend as previously observed in the study of moderate 
TBI in rodents, and was of a slightly higher magnitude (FC = -1.20 for the moderate TBI 
study).31 These findings indicate that CS may also be potential novel biomarker of TBI 
ranging across multiple severities. Additionally, a significant increase (p < 1.5E-4) in the 
abundance of the DHA-containing cholesteryl ester CE(22:6) was observed following 
mTBI (Figure 3.6). Similar trends have been discovered in the rodent brain following 
TBI induced by CCI, revealing that CE(22:6) and other CEs were not detected in control 
brains but were increased in the injury site at timepoints corresponding decreases in 
cholesterol in the same region (3 and 7 days).59 One hypothesis for the increased 
formation of CEs stems from a lack of CS in the brain following injury, which fails to 
inhibit of the esterification reactions forming CEs, leading to increased circulation of 
these lipids in the serum. Thus, these dietary lipids may also serve a purpose as 






Figure 3.6: Boxplots of selected features from 16-lipid classification panel showing 
relative abundances corresponding to: A) Cholesterol Sulfate: [M-H]- = 465.3035; B) 
CE(22:6): [M+NH4]+ = 706.6345; C) PC(41:2): [M+H]+ = 856.6821; D) PC(38:5): [M+H]+ 
= 808.5873; E) PC(39:6): [M+H]+ = 820.5851; F) PC(40:4), [M+H]+ = 838.632.. Dots in 
the center of the boxes indicate the mean while the line represents the median value for 
each sample subtype; p-values were calculated as matched pairs. 
 
 
3.4.6 Dysregulation of Membrane Phospholipids 
The boxplots in Figure 3.6 also show the distribution of changes in membrane 
phospholipids, specifically PUFA-containing PCs. The largest decrease was observed for 
PC(38:6), though all four species showed related decreases in abundance following TBI. 
Two of the lipids, PC(41:2) and PC(39:6) are not expected to be found in large quantities 
endogenously, as they represent odd chain fatty acid (OCFA)-containing lipids. Other 
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PUFA-containing PCs such as PC(18:1_22:6), PC(20:0_20:5) and PC(18:0_22:4) showed 
non-significant increases, indicating that systemic alterations of the membrane lipids was 
not observed. Decreased abundance of PUFA-containing PCs was previously related to 
increased hydrolysis of these lipids, which also led to increased formation of associated 
FFAs and lysoPCs. Here, AA and lysoPC(22:4) were both decreased, suggesting that 
mTBI does not simply lead to lower magnitude changes in the serum lipidome, but that 
novel metabolic alterations are induced, at least at the early timepoint studied here (24 h).  
3.4.7 Limitations 
 A number of limitations within the experimental design must be acknowledged. 
Tandem MS experiments were employed in order to identify which lipid species were 
associated with the induction of mTBI. Due to experimental difficulties including low ion 
abundances of the selected features and inadequate separation of some lipid classes, 
including ceramides, a few of the features were not identified. For these species, a 
characteristic headgroup or elemental formula is listed, where possible. Where MS/MS 
data were collected, the esterified fatty acids chains are listed. The lipid biomarkers 
included within the classification panel may also represent markers of general 
inflammation, so their specificity to the brain or brain injury must be determined in future 
experiments.60 This would require a study of lipid fluxes between brain and blood, which 
is assumed to operate primarily via the BBB, but could also include glymphatic clearance 
and other efflux routes.61,62  
 Additionally, some lipids containing OCFAs are expected to be present based on 
the precursor mass and adducts determined, as in PC(41:2) and PC(17:0_22:6). While 
ECFAs compose >99% of all fatty acids present in plasma, four OCFAs, C15:0, C17:0, 
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C17:1 and C23:0, also exist in small but detectable amounts.63,64 These OCFAs have been 
hypothesized to originate primarily from dietary fats, specifically dairy, due in part to 
high levels of their production by rumen microbial fermentation.65,66 It is now believed 
that altered metabolic pathways may also allow for the production of such OCFAs 
endogenously. Fatty acids are normally metabolized by β-oxidation, but an alternative 
mechanism (α-oxidation) is necessary when fatty acids cannot undergo β-oxidation, as in 
the case of β-branched chain fatty acids.67 When the α-oxidation process acts on straight 
chain fatty acids, OCFAs may be produced.68,69 OCFAs increase membrane fluidity and 
have been found in lower levels in AD patients, indicating their potential utility as 
biomarkers in TBI, which operates via similar mechanisms of neurodegeneration.70,71 
Tandem MS experiments confirmed the fatty acyl chains of PC(17:0_22:6).  
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Table 3.2: Identification of candidate biomarkers and annotation of lipids in 16-feature panel for the classification of mTBI. 
Feature number, retention time (RT), observed exact mass (m/z) with Xevo instrument mass error, observed adduct, predicted elemental 
formulae, p-value for differences between matched pair control (MPC) and TBI samples, and fold change (FC) values are included. 
Positive FC values correspond to species with increased relative abundances in injured animals, while negative values indicate higher 
relative abundances in controls. SN1/SN2 stereochemistry was not determined.  












(TBI vs MPC) 
FC 
(TBI/MPC) 
17 1.05 311.1684 
N/A 
N/A N/A Not identified 0.078 -1.65 
56 7.18 465.3035 
-1.93 
[M-H]- C27H46O4S Cholesterol Sulfate (CS) 4.42*10-9 -1.27 
102 9.57 876.5729 
--3.54 
[M+HCO2]- C48H82NO8P PC(18:1_22:6) 0.249 -1.06 
244 11.29 698.6297 
-1.00 
[M+HCO2]- C41H83NO4 Cer* 3.70*10-5 -1.21 
249 11.34 856.6874 
1.05 
[M+HCO2]- C48H93NO8 HexCer(d18:1_24:0) 0.385 1.08 
253 11.44 706.6345 
-1.42 
[M+HCO2]- C43H83NO3 Cer* 0.161 -1.11 
296 14.43 714.6206 
3.26 
[M+NH4]+ C49H76O2 CE(22:6) 1.53*10-4 1.48 
307 10.69 864.6488 
1.27 
[M+H]+ C50H90NO8P PC(20:0_22:5) 0.182 1.15 
324 7.26 844.5282 
3.43 
[M+K]+ C46H80NO8P PC(16:0_22:6) 2.2*10-4 1.24 
380 9.49 808.5873 
2.72 
[M+H]+ C46H82NO8P PC(16:0_22:5) 
PC(18:1_20:4) 
9.34*10-6 1.27 
448 10.68 838.6312 
-0.95 
[M+H]+ C48H88NO8P PC(18:0_22:4) 0.075 1.07 
456 12.42 856.6821 
3.62 
[M+H]+ C49H94NO8P PC(41:2) 0.00727 1.31 
579 7.72 820.5823 
-3.41 
[M+H]+ C47H82NO8P PC(17:0_22:6) 0.0044 1.12 
608 16.04 940.833 
0.21 
[M+NH4]+ C60H106O6 TG(57:5) 5.48*10-5 -1.32 
623 2.72 305.2463 
-3.91 
[M+H]+ C20H32O2 Arachidonic Acid (AA) 1.01*10-6 -2.63 
764 1.77 572.3689 
-3.84 




 Non-targeted lipidomic techniques were utilized to identify a number of novel 
biomarker candidates for the identification of mTBI in rodent serum samples using a 
matched pair study design. A multivariate classification model was built that was capable 
of discriminating mTBI from control samples with close to 90% using only the relative 
abundances of a panel 16 lipids. A model generated using a subset of 5 of these lipids 
performed with nearly equivalent accuracy, indicating that many of the initial lipids 
identified were not critical to the classification accuracy of the model. Among the 
univariate changes observed within the species selected to build the classification panel, 
cholesterol sulfate was decreased in TBI samples, while a DHA-containing cholesterol 
ester was increased in the TBI cohort, indicating that cholesterol metabolic pathways play 
a role in injury pathophysiology. Additionally, membrane lipids, primarily PCs 
containing PUFAs, were generally of higher relative abundance in the TBI samples. The 
robust matched pair study design enabled high classification accuracy due to the use of 
pre-injury baseline controls; however, these experiments must be replicated to determine 
if statistical overfitting contributed in part to the high accuracy of classification. 
Additionally, a similar study involving the use of human samples to identify which 
specific lipids are capable of detecting the presence of mTBI would be more clinically 
relevant, as differences exist within the lipidomic profile of rodent and human serum that 
would invariably lead to altered patterns of lipid metabolism following injury. 
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CHAPTER 4: KARENIA BREVIS ALLELOPATHY COMPROMISES 
THE LIPIDOME, MEMBRANE INTEGRITY, AND 
PHOTOSYNTHETIC EFFICIENCY OF COMPETITORS 
 
 
Portions reprinted with permission from:  
Poulin, R. X., Hogan, S., Poulson-Ellestad, K. L., Brown, E., Fernández, F. M., & 
Kubanek, J. (2018). Karenia brevis allelopathy compromises the lipidome, membrane 






 Karenia brevis is a bloom-forming species of algae that can reduce the growth of 
phytoplankton competitors through the release of allelopathic chemicals. The sub-lethal 
effects of allelopathy on competitors vary based on patterns of cohabitation, as some 
species such as Asterionellopsis glacialis may have developed an evolved resistance 
during periods of co-occurrence with K. brevis while other non-resistant competitors such 
as Thalassiosira pseudonana, having had no such previous exposure, show diminished 
cell membrane integrity and reduced photosynthetic capabilities in addition to reduced 
growth rates when grown in the presence of K. brevis. Lipidomics, the study of all lipid 
metabolites contained within an organism, can be a useful tool to understanding the 
changes associated with allelopathy. Here, MS- and NMR-based lipidomics experiments 
identified a variety of fatty acids, phospholipids, glycolipids, sulfolipids and amino acid-
related metabolites as significantly dysregulated as a result of K. brevis exposure. 
Mapping these changes to systems pathways may be critical in understanding and 





4.2.1 Bloom Forming Algae 
The accumulation of high concentrations of microscopic algae that release or 
exude toxic compounds leads to the formation of harmful algal blooms (HABs), which 
pose a threat to marine and ultimately human life due to transfer of these toxins up the 
food chain.1 One such dinoflagellate, Karenia brevis, often forms blooms in the Gulf of 
Mexico and the Southeastern Atlantic Ocean. As the pigments contained within these 
phytoplankton cause a red color to form within the water, these dense congregations of K. 
brevis are commonly referred to as red tides.2 K. brevis releases a suite of polyether 
neurotoxins called brevetoxins.3 Shellfish and filter-feeding organisms can accumulate 
high concentrations of these toxins, ingestion of which causes neurotoxic shellfish 
poisoning.4 Exposure to these toxins can thus be fatal and often leads to massive fish kills 
in marine ecosystems.5 
4.2.2 Impact of K. Brevis Allelopathy 
Additionally, when K. Brevis forms HABs, it is able to out compete or exclude 
other plankton species through allelopathy, the release of chemicals that inhibit the 
growth of competitors.6 However, brevetoxins have not been shown to be responsible for 
such effects.7 Instead, allelopathic compounds are suggested to be unstable aromatic or 
unsaturated hydrocarbons, possibly derived from fatty acids, though complete 
characterization has eluded researchers to date.8 As K. brevis allelopathy results in sub-
lethal changes within competitors including suppressed growth rates, diminished 
photosynthetic activity and reduced membrane integrity, the response to allelopathic 
stress can be studied within living competitors, making this an attractive target for 
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metabolomic analysis.9 Metabolomics provides an instantaneous view of all the small 
molecule metabolites contained within an organism and reflects the chemical 
transformation of such metabolites caused by isolated treatment effects.10 Determining 
which metabolites are most affected by K. brevis allelopathy may thus provide insight 
into the mechanisms responsible for such physiological responses. 
4.2.3 Changes Discovered in the Polar Metabolome of Marine Phytoplankton 
Previously, proteomic and metabolomic analysis was conducted in order to 
compare the responses within the polar metabolome of two distinct competitors to K. 
brevis exposure.11 One competitor, Asterionellopsis glacialis, cohabitates in geographical 
regions with K. brevis and has likely developed a resistance to exposure in order to 
survive. Other competitors such as Thalassiosira pseudonana have had no such periods 
of co-occurrence and therefore may be more susceptible to K. brevis allelopathy. As 
hypothesized, T. pseudonana cell extracts showed altered levels of protein expression 
indicating increased cell membrane permeability, inhibited osmoregulation, decreased 
photosynthetic capability and increased levels of oxidative stress.11 In addition, increased 
synthesis and β-oxidation of fatty acids and significant changes in concentrations of a few 
vital lipid membrane constituents were also discovered, indicating that effects of K. 
brevis allelopathy may also extend to the lipophilic portion of the diatom metabolome.  
4.2.4 The Use of Lipidomics to Discover Changes in the Non-Polar Metabolome 
The objectives of this study thus were to determine which specific lipids in T. 
pseudonana were significantly altered as a consequence of K. brevis exposure and to 
determine how this response differed from that of A. glacialis. Using established 
lipidomics techniques to assess variations in the response of competitors A. glacialis and 
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T. pseudonana to K. brevis allelopathy, several lipids were identified through high-
resolution mass spectrometry (HRMS) and tandem MS techniques that relate to 
hypothesized physiological changes induced by interactions with K. brevis. Based on the 
complementary nature of the techniques, NMR was also used to characterize changes 
within a different subset of lipophilic compounds in the diatoms of interest. 
The exclusive study of lipid metabolites, referred to as lipidomics, is a newly 
expanding field under the umbrella of metabolomics.12 Lipids play keys roles in cellular 
physiology, regulating processes such as signal transduction, energy storage, and 
membrane integrity.13 Like plants, marine phytoplankton contain a unique mix of lipids, 
distinct from those typically observed in mammallian cells.14 Commonly occuring lipids 
such as triacylglycerols (TGs), FFAs and polyunsaturated aldehydes (PUAs) in addition 
to a vairety of phospholipids such as PEs, PCs, and PGs have been found in these 
organisms.14,15 Marine plankton also contain a diverse family of other polar glycerolipids, 
the most abundant class of lipids in the sea, that compose the bulk of eukaryotic 
microbial cell membranes.16 These include glycolipids such as 
monogalactosyldiacylglycerols (MGDGs), digalactosyldiacylglycerols (DGDGs) and 
sulfoquinovosyldiacylglycerols (SQDGs) as well as betaine lipids such as diacylglyceryl 
trimethyl homoserines (DGTSs), diacylglyceryl hydroxymethyl trimethyl-β-alanines 
(DGTAs), and diacylglyceryl carboxyhydroxymethylcholines (DGCCs). The range of 
concentrations of these polar glycerolipids in the ocean is relatively small, spanning the 
order of hundreds to thousands of pmol/L.14  
A total of nine distinct classes of polar glycerolipids thus exist within marine 
phytoplankton, primarily derived from FFAs, which have previsouly served as 
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biomarkers in ocean science research.17,18 More recently, it has been discovered that 
changes in concentrations of lipids such as sulfolipids and betaine lipids may serve as 
indicators of nutrient induced stress in conditions when sources of phosphorus, nitrogen 
or sulfur are limited.19,20,21 ROS also serve as source of stress in biological systems 
including plants. Developed to identify and annotate products of ROS stress in diatoms, 
the lipid and oxylipin biomarker screening through adduct hierarchy sequences 
(LOBSTAHS) database served as a useful tool for identifying the diverse array of lipids 
found within the studied marine diatoms and was critical in identifying metabolic 
changes brought about by such stressors.15  
 
4.3 Experimental Methods 
4.3.1 Preparation of Cellular Extracts 
Changes within polar metabolites of diatoms undergoing stress from competition 
with K. brevis were previously reported by Poulson-Ellestad et al. (2014), with growth of 
diatom cultures and exposure to K. brevis as previously described.11 For the subsequent 
analysis of non-polar metabolites, lipid metabolites within dried extracts were dissolved 
in a biphasic mixture of 9:10:15 water/methanol/chloroform to induce phase separation. 
The more lipophilic layer was removed and washed twice with 9:10 water/methanol, 
dried and stored at -80° C until analysis. For the current work, the lipid-soluble fractions 
were analyzed by 1H NMR spectroscopy and UPLC-MS metabolomics. The cellular 
extracts of all samples were reconstituted in 200 µL IPA prior to MS analysis. Methods 
for NMR sample preparation and data acquisition can be found within the published 
manuscript, as previously reported.22 
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4.3.2 UPLC-MS Data Collection 
 Lipid extracts (n=13 per group) were reconstituted in 200 μL IPA. Quantitative 
metabolomics data were acquired using a Waters Xevo G2 QTOF mass spectrometer. 
The instrument was operated in negative mode ESI with a capillary voltage of -2.0 kV 
and a sampling cone voltage of 30 V. The source temperature of 90 °C was maintained 
throughout the experiment. Nitrogen was used as a desolvation gas at 250 °C with a flow 
rate of 600 L/h. The mass spectrometer was calibrated across the 50-1200 Da mass range 
using a sodium formate solution. Leucine enkephalin was infused at a flow rate of 2 
μL/min and acquired as a lockmass correction. Run order was randomized and samples 
were acquired in duplicate. Pooled QC samples were acquired after every twelfth sample 
injection to monitor instrumental drift and minimize batch effects. 
Chromatographic separation was accomplished using a Waters Acquity UPLC 
quaternary solvent manager system fitted with a Waters ACQUITY UPLC BEH C18 
column (1.7-μm particle size, 2.1 × 50 mm), with an injection volume of 10 μL. The 
column was operated at 60 °C, while the autosampler tray was maintained at 5 °C. 
Mobile phase A contained 40:60 water: ACN and mobile phase B contained 10% ACN in 
IPA. A flow rate of 300 μL/min was used with the following gradient: 0-1 min, 70% B; 
1-3 min, 75% B; 3-6 min, 80% B; 6-10 min, 90% B; 10-14 min, 100% B. Both mobile 
phases included 10 mM ammonium formate (Sigma Aldrich, >99.995%) and 0.1% 
formic acid (Fluka Analytical) additives to improve peak shape and ionization efficiency. 
All solvents used were of LCMS grade and provided by OmniSolv (water, ACN) or 
Honeywell (IPA).  
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4.3.3 UPLC-MS Data Processing 
Data were imported into Progenesis QI for chromatographic alignment, de-
isotoping, adduct deconvolution, normalization, and peak picking. Peaks detected in the 
sample blanks at greater than 10% of the average sample intensity were removed as 
potential contaminants. The corresponding normalized intensities across each sample for 
every feature, defined as a temporarily unidentified m/z and RT pair, were imported into 
MATLAB for multivariate analysis.  
4.3.4 Multivariate Statistical Analysis 
Prior to multivariate modeling, NMR and MS spectral data were preprocessed. 
PCA and oPLS-DA models were generated to investigate the effect of K. brevis 
allelopathy on algal lipidomes (MATLAB and PLS Toolbox, version 8.1, Eigenvector 
research). Spectral features with discriminatory power in NMR-based models were 
annotated using HMDB and Chenomx Profiler while MS-based features were annotated 
using LOBSTAHS, Kyoto Encyclopedia of Genes and Genomes (KEGG), LIPID MAPS, 
and Metlin databases15,23-27. Pooled extracts of each species were used to collect 2D NMR 
spectral data including: correlation spectroscopy (COSY), heteronuclear single quantum 
coherence (HSQC), and heteronuclear multiple bond correlation spectroscopy (HMBC) 
to aid in annotation.  
PCA and oPLS-DA plots were constructed using PLS Toolbox version 8.1 in 
Matlab. For PLS-DA, plots were orthogonalized such that the maximum variance 
between classes was produced across the first LV, with all other LVs explaining within 
class variance. Data were autoscaled and the model containing the fewest LVs that 
produced the lowest cross-validated error was selected. Venetian blinds CV was 
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employed with six data splits for analysis of treatment/control effects of each cell type, 
while eight data splits were used when comparing all samples (n=61) including pooled 
QCs. Significant peaks, defined as p<0.05/n (number of features) were identified using a 
2-tailed t-test with unequal variance following the use of the Bonferroni correction for 
multiple comparisons.  
4.3.5 Metabolite Annotation 
Tandem MS experiments were performed on Thermo Q-Exactive HF quadrupole-
Orbitrap mass spectrometer using the top 10 Data-dependent acquisition (DDA) method 
to select and fragment all ions of interest with resolution=30,000, automatic gain control 
(AGC) = 1e5, maximum injection time = 30 ms, and a stepped NCE ranging from 10 to 
50. 
 All features with significant differences between control and treatment groups 
within each cell type were analyzed by MS/MS to elucidate structure. Following adduct 
analysis, elemental formulae were determined based on exact mass and isotopic 
distribution. Features with exact masses corresponding to matches in the LOBSTAHS 
database were tentatively identified, with identities confirmed by matching headgroup 
fragments and fatty acid chains from the MS/MS spectra to tentative identities.15 For 
those features without LOBSTAHS matches, identifications were performed by hand 
using known lipid fragmentation patterns and cross-checked against other the KEGG, 




4.4.1 MS Analysis Reveals Broad Changes in Phytoplankton Lipidome 
MS-based analysis was conducted in negative mode using a Waters Xevo G2-
QTOF mass spectrometer operated with an electrospray ionization source. Use of 
negative ionization mode enabled the detection of a wide variety of fatty acids, primary 
fatty acid amides (PFAAs), and a number of sulfolipids, which included SQDGs and 
other lipids containing sulfate functional groups. Polar glycolipids such as MGDGs and 
DGDGs were also detected and identified in negative ionization mode. Although easier to 
ionize in positive mode, PCs and PEs were detected here as formate adducts [M+HCO2]-, 
and the use of negative mode allowed for the precise annotation of esterified fatty acid 
chains in the detected lipids of interest.  
A total of 13 samples from each of four groups were analyzed: T. pseudonana 
control, T. pseudonana treatment, A. glacialis control and A. glacialis treatment. 
Treatment groups were exposed to K. brevis allelopathy for six days, while control 
samples remained unexposed. A total of 1546 features detected within all samples, 
including pooled QCs, were imported into Matlab to conduct qualitative interpretation of 
the alterations within the lipidomes of each phytoplankton competitor. PCA is an 
unsupervised analysis technique that reduces dimensionality in the data in order to 
visualize multivariate matrices in a linear space.28 It can be helpful in observing 
clustering patterns in the data without the potential overfitting imposed by imparting class 
information. A number of interesting trends can be visualized by decomposing the data 
into lower dimensional space, with each sample represented by a single point in a PCA 
scores plot. First, pooled QC samples, obtained by alloquoting an equivalent portion of 
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each sample contained within the study, were resampled over the duration of the 
experiment. As expected, these samples, represented by pink stars in Figure 4.1, clearly 
clustered together towards the center of the scores plot, indicating the reliablity of the 
analysis conducted over time. Next, clear distinction between the lipidomic profile of the 
two species was seen, with T. pseudonana samples possessing negative scores on PC1 
and A. glacialis samples having positive scores on PC1. More interestingly, the two 
classes of T. pseudonana samples clustered distinctly from each other, with control 
samples exhibiting negative scores on PC2 while treatment samples showed a distinct 
trend towards positive scores. No such separation existed for the A. glacialis samples, 
with both treatment and control samples generally overlapped, indicating that changes 






Figure 4.1: Principal Component Analysis (PCA) scores plot prior to feature selection. 
Pools, closely clustered together in the center of the plot, were successful representations 
of the combination of all classes of samples analyzed and can be used for quality control 
purposes. No initial separation of A. glacialis treatment (green square) and A. glacialis 
control (red diamond) samples was observed. A clear separation of T. pseudonana 
treatment (light blue) and T. pseudonana control (dark blue) samples could easily be 
approximated by the blue ellipses. This indicates that larger differences exist in the 






4.4.2 Comparison of Lipidomic Changes Within Individual Phytoplankton Species 
Peak lists were also processed and compiled separately for each of the two model 
systems being investigated in order to distinguish between features that were unique to 
each species. A total of 320 features were detected in T. pseudonana samples, following 
filters to remove low abundance, high variance, and contaminant peaks detected within 
experiments, while 358 were detected in the cellular extracts A. glacialis. Using 
univariate techniques to assess the extent of lipidomic variation caused by exposure to K. 
brevis, changes within 171 of the 320 species detected in the T. pseudonana lipidome 
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were considered statistically significant (p < 0.05) compared to only 91 of the 358 peaks 
detected in A glacialis samples. Applying the Bonferonni correction for multiple 
comparisons, the difference in response of each species’ respective lipidome was even 
more pronounced. While almost half (80/171) of the features remained statistically 
significant (p < 0.05/n) in T. pseudonana samples, only 6 of the 91 features found in A. 
glacialis samples remained above this same threshhold. The identifications for 
significantly altered metabolites are included in Tables 4.1 and 4.2 respectively. 
Additionally, of those 6, all were contained within the set of 80 statistically significant 
peaks in the T. pseudonana samples, indicating that lipidomic changes within T. 
pseudonana samples were more pronounced, and that the negative effects of allelopathy 
could be understood by studying the lipidomic changes assocaited exclusivly within this 




Table 4.1: Identification of metabolites from T. pseudonana whose concentrations are significantly altered when exposed to K. brevis. 
Observed m/z and mass error (ppm), adduct, elemental formula, and molecular composition (full fatty acid chain information) are 
provided where possible. Fold change (FC) values are positive when relative abundance of metabolite increased when T. pseudonana 
was exposed to allelopathy. Annotation confidence (conf.) ranges from 1-3. Confidence level 1: observed MS/MS data consistent with 
predicted spectrum AND LOBSTAHS exact mass match to corresponding lipid class; 2: observed MS/MS data consistent with predicted 
spectrum; 3: observed exact mass match to LOBSTAHS database and/or partial MS/MS structural determination. 






ID FC p-value Conf. Lipid Class 
563.3986 
0.71 
[M-H]- C30H60O7S Tetradecanoyl 
Sulfohydroxy-palmitic acid 
>25* 2.39E-05 2 Other (sulfur containing) 
577.4146 
1.39 
[M-H]- C31H62O7S Myristoyl sulfohydroxy-
heptadecanoic acid 
>25* 3.83E-06 2 Other (sulfur containing) 
591.4308 
2.20 
[M-H]- C32H64SO7 Pentadecanoyl 
sulfohydroxy-
heptadecanoic acid 
>25* 1.88E-06 2 Other (sulfur containing) 
379.2148 
7.12 
[M-H]- C21H32O6 FFA(21:5 + 4 O) >25* 4.25E-5 
 
3 Free fatty acid 
607.4243 
1.81 





2 Other (sulfur containing) 
619.4249 
0.81 
[M-H]- C33H64SO8 Hydroxy-pentadecanoyl 
sulfooleic acid 
>25* 1.96E-05 2 Other (sulfur containing) 
572.4354 
0.87 
[M-H]- C32H63NO5S Pentadecanoyl sulfate  
heptadecenamide 
>25* 5.77E-07 2 Other (sulfur containing) 
367.2127 
1.63 
[M-H]- C20H32O6 FFA(20:4 + 4 O) >25* 2.75E-05 
 
3 Free fatty acid 
575.4356 
1.91 
[M-H]- C32H64O6S Pentadecanoyl 
sulfoheptadecanoic acid 
>25* 4.38E-07 2 Other (sulfur containing) 
592.4942 
0.17 
[M-H]- C36H67NO5 N-heptadecenoic acid 
oleamide 





Table 4.1 (continued). 
665.5117 
3.31 
[M-H]- C35H74N2O7S Hexadecenoyl N-
sulfanediol dihydroxy-
nonadecanediamide 
>25* 3.04E-06 2 Other (sulfur containing) 
257.2125 
3.11 
[M-H]- C15H30O3 FFA(15:0 + 1 O) >25* 7.05E-05 
 
3 Free fatty acid 
616.4615 
0.65 
[M-H]- C34H67NO6S N-sulfo, N-pentadecanoyl 
nonadecanamide 
>25* 1.0E-08 2 Other (sulfur containing) 
561.4194 
0.89 
[M-H]- C31H62O6S Myristoyl sulfo-
heptadecanoic acid 
>25* 1.9E-06 2 Other (sulfur containing) 
787.5583 
0.76 





[M-H]- C32H65NO5S Pentadecanoyl sulfate 
heptadecanamide 
14 9.71E-08 2 Other (sulfur containing) 
578.4790 
1.04 
[M-H]- C35H65NO5 N-palmitoleic acid 
oleamide 
8.5 2.14E-06 2 Fatty acid amide 
564.4639 
1.95 
[M-H]- C34H63NO5 N-pentadecenoic acid 
oleamide 
7.1 7.94E-07 2 Fatty acid amide 
566.4792 
1.41 
[M-H]- C34H65NO5 N-pentadecanoic acid 
oleamide 
7.0 6.79E-08 2 Fatty acid amide 
686.4778 
1.75 
[M-H]- C37H70NO8P PE(16:1_16:1) 6.5 3.54E-05 1 Phosphatidylethanolamine 
550.4480 
1.64 
[M-H]- C33H61NO5 N-pentadecenoic acid 
heptadecanamide 
5.8 9.45E-06 2 Fatty acid amide 
682.5090 
1.47 
[M-H]- C39H73NO6S N-sulfo, N-octadecanoyl 
heneicosanamide 
5.5 4.23E-05 2 Other (sulfur containing) 
651.4958 
3.68 
[M-H]- C34H72N2O7S Pentadecenoyl N-
sulfanediol dihydroxy-
nonadecanediamide 
3.3 3.48E-04 2 Other (sulfur containing) 
653.5117 
3.37 
[M-H]- C34H74N2O7S Pentadecanoyl N-
sulfanediol dihydroxy-
nonadecanediamide 
1.7 0.0276 2 Other (sulfur containing) 
793.5113 
3.53 






Table 4.1 (continued). 
763.4646 
1.83 
[M+HCO2]- C41H66O10 MGDG(16:3_16:3) -2.1 4.05E-05 1 Monogalactosyldiacylglycerol 
791.4988 
0.38 
[M-H]- C41H76O12S SQDG(16:0_16:1) -2.2 4.52E-05 1 Sulfoquinovosyldiacylglycerol 
771.5272 
1.04 
 [M+HCO2]- C41H74O10 MGDG(16:1_16:1) -2.5 2.6E-06 1 Monogalactosyldiacylglycerol 
719.4879 
1.39 
[M-H]- C38H73O10P PG(16:0_16:1) -2.6 4.89E-07 1 Phosphatidylglycerol 
737.4527 
1.63 
[M-H]- C37H70O12S SQDG(14:0_14:0) -2.6 7.99E-08 1 Sulfoquinovosyldiacylglycerol 
779.4988 
0.38 
[M-H]- C40H76O12S SQDG(15:0_16:0) -2.6 7.16E-06 1 Sulfoquinovosyldiacylglycerol 
813.4798 
3.07 
[M-H]- C43H74O12S SQDG(16:0_18:4) -2.7 1.79E-06 1 Sulfoquinovosyldiacylglycerol 
765.4723 
1.44 
[M-H]- C42H71O10P PG(16:1_20:5) -2.8 2.33E-02 1 Phosphatidylglycerol 
769.5111 
0.39 
[M+HCO2]- C41H72O10 MGDG(16:0_16:3) -2.8 1.30E-03 1 Monogalactosyldiacylglycerol 
977.5477 
0.20 
[M+HCO2]- C51H80O15 DGDG(16:3_20:5) -2.8 1.07E-02 1 Digalactosyldiacylglycerol 
759.4368 
1.19 
[M-H]- C39H68O12S SQDG(14:0_16:3) -2.9 1.42E-02 1 Sulfoquinovosyldiacylglycerol 
751.4681 
1.20 
[M-H]- C38H72O12S SQDG(14:0_15:0) -3.1 2.93E-08 1 Sulfoquinovosyldiacylglycerol 
765.4796 
3.53 
[M-H]- C39H74O12S SQDG(14:0_16:0) -3.2 1.69E-08 1 Sulfoquinovosyldiacylglycerol 
691.4565 
1.30 
[M-H]- C36H69O10P PG(14:0_16:1) -3.2 9.85E-07 1 Phosphatidylglycerol 
819.5268 
0.49 
[[M+HCO2]- C45H74O10 MGDG(16:1_20:5) -3.3 9.7E-05 1 Monogalactosyldiacylglycerol 
791.4989 
0.51 
[M-H]- C41H76O12S SQDG(14:0_18:1) -2.2 4.52E-05 1 Sulfoquinovosyldiacylglycerol 
745.5114 
1.61 




Table 4.1 (continued). 
748.5145 
2.14 
[M+HCO2]- C38H74NO8P PC(14:0_16:1) -3.7 2.59E-06 1 Phosphatidylcholine 
761.4489 
3.41 
[M-H]- C39H70O12S SQDG(14:0_16:2) -3.9 9.06E-06 1 Sulfoquinovosyldiacylglycerol 
799.4681 
1.13 
[M-H]- C42H72O12S SQDG(15:0_18:4) -3.9 7.44E-05 1 Sulfoquinovosyldiacylglycerol 
743.4965 
2.69 
[M+HCO2]- C39H70O10 MGDG(14:0_16:2) -4.0 1.75E-05 1 Monogalactosyldiacylglycerol 
802.5609 
1.37 
[M+HCO2]- C42H80NO8P PC(16:1_18:1) / 
PC(16:0_18:2) 
-4.0 9.41E-06 1 Phosphatidylcholine 
907.5639 
0.33 
[M+HCO2]- C45H82O15 DGDG(14:0_16:1) -4.0 4.9E-06 1 Digalactosyldiacylglycerol 
762.5017 
35.1 
[M+HCO2]- C39H76NO8P PC(15:0_16:1) -4.0 8.47E-06 3 Phosphatidylcholine 
822.5293 
0.24 
[M+HCO2]- C44H76NO8P PC(16:1_20:5) -4.1 4.57E-08 1 Phosphatidylcholine 
841.5108 
3.92 
[M-H]- C45H78O12S SQDG(36:4) -4.2 1.24E-05 3 Sulfoquinovosyldiacylglycerol 
935.5961 
1.28 
[M+HCO2]- C47H86O15 DGDG(16:0_16:1) -4.2 1.8E-07 1 Digalactosyldiacylglycerol 
757.4210 
1.06 
[M-H]- C39H66O12S SQDG(14:0_16:4) -4.4 5.19E-06 1 Sulfoquinovosyldiacylglycerol 
820.5129 
0.61 
[M+HCO2]- C44H74NO8P PC(16:2_20:5) -4.4 3.36E-06 1 Phosphatidylcholine 
583.3129 
1.89 
[M-H]- C30H48O11 MGDG(21:4+1 O) -4.5 1.23E-06 3 Monogalactosyldiacylglycerol 
773.5427 
0.78 
[M+HCO2]- C41H76O10 MGDG(16:0_16:1) -4.5 8.48E-07 1 Monogalactosyldiacylglycerol 
795.5265 
0.13 
[M+HCO2]- C43H74O10 MGDG(16:0_18:4) -4.5 6.45E-06 1 Monogalactosyldiacylglycerol 
829.4763 
1.09 
[M-H]- C43H74O13S SQDG(34:4 + 1 O) -4.8 0.000138 3 Sulfoquinovosyldiacylglycerol 
818.4976 
0.24 
[M+HCO2]- C44H72NO8P PC(16:3_20:5) / 
PC(18:4_18:4) 




Table 4.1 (continued). 
850.5604 
0.00 
[M+HCO2]- C46H80NO8P PC(18:1_20:5) -5.3 4.66E-06 1 Phosphatidylcholine 
870.5292 
0.11 
[M+HCO2]- C48H76NO8P PC(20:5_20:5) -5.3 6.87E-07 1 Phosphatidylcholine 
796.5138 
1.13 
[M+HCO2]- C42H74NO8P PC(14:0_20:5) / 
PC(16:1_18:4) 
-6.3 3.49E-07 1 Phosphatidylcholine 
824.5454 
0.85 
[M+HCO2]- C44H78NO8P PC(16:0_20:5) -6.4 1.25E-08 1 Phosphatidylcholine 
896.5448 
0.11 
[M+HCO2]- C50H78NO8P PC(20:5_22:6) -6.7 3.46E-07 1 Phosphatidylcholine 
800.5449 
0.25 
[M+HCO2]- C42H78NO8P PC(16:0_18:3) -6.9 4.77E-05 1 Phosphatidylcholine 
798.5286 
0.63 
[M+HCO2]- C42H76NO8P PC(16:0_18:4) -7.8 5.7E-05 1 Phosphatidylcholine 
844.5135 
0.12 
[M+HCO2]- C46H74NO8P PC(18:4_20:5) -8.5 1.41E-05 1 Phosphatidylcholine 
848.5448 
0.12 
[M+HCO2]- C46H78NO8P PC(18:2_20:5) / 
PC(16:1_22:6) 
-8.5 5.3E-06 1 Phosphatidylcholine 
821.5427 
1.46 
[M+HCO2]- C45H76O10 MGDG(36:5) -9.3 2.82E-06 3 Monogalactosyldiacylglycerol 
843.5266 
0.24 





Table 4.2: Identification of metabolites from A. glacialis showing significantly altered relative concentrations when exposed to K. 
brevis. Observed m/z and associated mass error (ppm), adduct, elemental formula, and molecular composition (full fatty acid chain 
information) are provided where possible. Fold change (FC) values are positive when relative abundance of metabolite increased when 
A. glacialis was exposed to allelopathy. Annotation confidence (Conf.) ranges from 1-3. Confidence level 1: observed MS/MS data 
consistent with predicted spectrum AND LOBSTAHS exact mass match to corresponding lipid class; 2: observed MS/MS data 






ID FC p-value Conf. Lipid Class 
591.4308 
2.37 





4.24E-06 2 Other (sulfur containing) 
607.4243 
1.81 
[M-H]- C32H64O8S Pentadecanoyl 
sulfodihydroxy-
heptadecanoic acid 
4.9 1.66E-05 2 Other (sulfur containing) 
616.4615 
0.65 
[M-H]- C34H67NO6S N-sulfo, N-pentadecanoyl 
nonadecanamide 
13.8 5.55E-05 2 Other (sulfur containing) 
578.4790 
1.04 
[M-H]- C35H65NO5 N-palmitoleic acid 
oleamide 
12.2 7.2E-06 2 Fatty acid amide 
651.4958 
3.68 
[M-H]- C34H72N2O7S Pentadecenoyl N-
sulfanediol dihydroxy-
nonadecanediamide 
12.5 1.42E-05 2 Other (sulfur containing) 
653.5117 
3.37 
[M-H]- C34H74N2O7S Pentadecanoyl N-
sulfanediol dihydroxy-
nonadecanediamide 




These same observations held true when interpreting oPLS-DA plots of both MS 
and NMR data for each of the two studied species (Figure 4.2). oPLS-DA is a powerful 
supervised classification tool, useful for maximizing the separation of two or more 
distinct classes using multivariate data dimensionality reduction.29 Optimized models 
incorporating data obtained from both MS and NMR showed that treatment and control 
samples from each of the two species studied could in fact be separated with a high 
degree of accuracy. However, the distinction between T. pseudonana treatment and 
control samples was more prounounced, as LV1 explained 79.2% of the variance within 
samples for MS data, while LV1 only captured 21.9% of the variance within A. glacialis 
samples analyzed by MS. Additionally, the classification model separating T. 
pseudonana treatment and control samples, built using the 80 significant features 
previously discussed, perfomed with 100% accuracy, sensitivty and specificity, in 
comparison to 88.5%, 92.3%, and 84.6% for the MS-based A. glacialis model, 
respectively. Similar patterns were observed within the NMR classification models, again 






Figure 4.2: oPLS-DA models reveal that lipidomes of T. pseudonana and A. glacialis are 
disrupted by Karenia brevis allelopathy. Filled symbols represent lipidomes of algae 
exposed to K. brevis through molecule-permeable but cell impermeable membranes, 
empty symbols represent lipidomes from unexposed algae (controls). oPLS-DA model 
generated from A) 1H NMR spectral data and B) from UPLC-MS metabolic features 
from lipidomes of T. pseudonana (blue squares). oPLS-DA model generated from C) 1H 
NMR spectral data and D) from UPLC-MS metabolic features from lipidomes of A. 
glacialis (yellow circles). NMR data were collected and interpreted and figure produced 
by Dr. Remington Poulin.22 
 
 
4.4.3 Identification of Altered Lipid Species within T. Pseudonana 
The direction of change for these features was visualized using a volcano plot 
(Figure 4.3). Volcano plots are intended to give a broad overview of the association 
between p-value and fold change (FC) for datasets containing a large number of 
variables, with the highly significant points with large FCs appearing in the upper left and 
upper right corners of the plot. Here it was clear that a vast majority of the A. glacialis. 
data remained below the significance threshold, while many T. pseudonana features were 
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highly significant. Allelopathy led to reductions in relative abundances for a total of 47 of 
these features within T. pseudonana samples, while the remaining 33 statistically 
significant features were increased within the treatment group as a result of exposure. All 
six of the significantly altered features detected within A. glacialis samples displayed 
increased relative abundances in the treatment group, though the relative FC was 
generally less than that observed for the same features detected in T. pseudonana samples 
(Table 4.2). This evidence supports the hypothesis that A. glacialis has evolved a pattern 
of resistance to K. brevis allelopathy, as displayed by the relatively minor changes 
observed within the lipidome of this species following exposure to K. brevis. Meanwhile, 
a substantial fraction of all lipids found within T. pseudonana were statistically different 
upon treatment with K. brevis, and the changes within the lipidome of this competitor 





Figure 4.3: Volcano plot summarizing the differences in the lipidomic responses of T. 
pseudonana (blue) and A. glacialis (yellow) when exposed to K. brevis allelopathy. The 
relative abundances of 80 metabolites were significantly different (p < 0.05 after 
Bonferroni correction) in T. pseudonana samples upon exposure to K. brevis allelopathy. 
Red lines indicate log2 fold differences of ±1.  
 
 
Of the 80 species identified to be significantly dysregulated in cell extracts of T. 
pseudonana, a total of 70 lipid metabolites were confidently identified using tandem MS 
fragmentation patterns, class specific characteristic headgroup fragments and fatty acid 
chain lengths (see Table 4.1 for full annotation). These lipid species belonged to nine 
classes, with each class generally showing the same trend regardless of fatty acid chain 
length (Table 4.3). Therefore lipid class was far more correlated with physiological 
effects associated with allelopathy than was fatty acid chain length.  
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Table 4.3: Lipid classes identified by MS-based oPLS-DA model as having significantly 
different concentrations in T. pseudonana based upon exposure to K. brevis allelopathy.  
Common adducts detected, the number of detected compounds, and the average fold 
change (FC) are included for each lipid class. The average FC is an average of the 
individual FCs for each lipid identified in a class. Classes of lipids identified include: 
phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), phosphatidylglycerols 
(PGs), sulfoquinovosyldiacylglycerols (SQDGs), digalactosyldiacylglycerols (DGDGs), 
monogalactosyldiacylglycerols (MGDGs), primary fatty acid amides (PFAAs), free fatty 










PC [M+HCO2]- 15 -5.8 
SQDG [M-H]- 14 -3.3 
DGDG [M+HCO2]- 3 -3.3 
PG [M-H]- 3 -2.9 
MGDG [M+HCO2]- 12 -2.8 
PE [M+HCO2]- 1 6.5 
PFAA [M-H]- 5 25 
FFA [M-H]- 3 >25* 
SULF [M-H]- 14 >25* 
*Fold change value uncertain due to extremely low concentration of metabolites in control samples 
 
 
Each class of lipid was identified by a characteristic neutral loss or parent ion 
scan, often indicative of the lipid headgroup. Previous studies have identified and 
quantified these classes of lipids using diagnostic scans in positive mode,14 but the use of 
negative mode allowed for the distinction of isobaric lipids by exact fatty acid 
composition, giving rise to a weath of information about underlying chemisty related to 
metabolomic changes within phytoplankton. PCs, PEs and PGs were identified using the 
characteristic headgroup fragments of 224.07, 196.04 and 227.03 Da respectively. 
MGDGs and DGDGs each contained a minor peak at 235.08 Da and were distinguished 
by the number of attached sugar molecules and exact mass, while SQDGs contained a 
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unique fragment at 225.01 Da. PFAAs were tentatively identified by the presence of a 
74.02 Da fragment, while sulfolipids showed a characteristic 80.96 Da fragment 
representing the HSO3- ion. FFAs were identified with exact mass only and matched to 
the LOBSTAHS database.15 
4.4.4 Alterations in Free Fatty Acids and Related Small Molecules 
Fatty acids are small molecules found within cells that play a role in energy 
production and serve as intermediates in metabolism. A basic building block of more 
complex lipids, they exist as free carboxylic acids or may be esterified as in wax esters, 
phospholipids, and other similar molecules.30 Following exposure to K. brevis, the 
relative abundance of three fatty acids, each containing some degree of oxidation, was 
dramatically increased (FC > 25) within T. pseudonana cell extracts. The largest increase 
was observed for FFA(21:5 + 4 O), which showed a 1000-fold increase due to minimal 
initial relative abundance found within the control samples. Fatty acid amides, consisting 
of an acyl chain and carboxamide group, are formed from the conversation of a fatty acid 
and an amine and often play a role in cell signaling.31,32 Ammonium is likely the source 
of nitrogen in such metabolic reactions.33 For all non-sulfur containing PFAAs, a 
similarly large increase was observed. A nearly 100-fold increase was observed for one 
species (n-heptadecenoic acid oleamide), while the four other molecules identified 
showed more modest increases in relative abundance (average FC = 7.1).  
4.4.5 Identified Sulfolipid Alterations 
The term sulfolipid has been used to describe compounds containing sulfonic acid 
(C-SO3H) functional groups, and sulfolipids have been discovered within all 
photosynthetic organisms.34 Two main types of sulfur-containing molecules exist in such 
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organisms: alkyl sulfates and SQDGs.35 The alkyl sulfates observed in the cellular 
extracts of T. pseudonana largely consisted of molecules with a sulfonated fatty acid or 
alcohol esterified to another fatty acid. A total of 14 species within this class (SULF, or 
non-SQDG sulfonated lipids) were significantly different in K. brevis treated samples. 
Each of the compounds within this class exhibited large increases in relative abundance 
(FC > 25). Conversely, SQDGs showed a moderate decrease in relative abundance 
resulting from K. brevis exposure (FC = -3.3), and all 14 statistically significant SQDGs 
identified were more abundant in T. pseudonana control samples than in the treatment 
group. SQDGs compose a minor level of lipids found within the thylakoid membrane of 
chloroplasts in marine plankton.36 They are involved in the maintenance of photosystem 
II activity, and the observed decrease in SQDGs may be associated with the decrease in 
photosynthetic efficiency which has been observed within competitors exposed to K. 
brevis allelopathy.9 The changes may also be the result of nutrient induced stress 
conditions brought about by sulfur deficiency.37 
4.4.6  K. Brevis Exposure Leads to Lower Levels of Phospholipids 
Dramatic changes in phospholipid concentrations were also observed in T. 
pseudonana samples resulting from exposure to K. brevis allelopathy. Phospholipids 
including PCs, PEs and PGs are all lipids commonly found in cellular membanes. In this 
study, compared to T. pseudonana cells grown in culture alone, the number of cells with 
damaged membranes was increased as a result of co-culture with K. brevis, indicating 
that allelopathy decreased the permeability of cell membranes.22 The large decrease in 
PCs (FC = -5.8) and moderate decrease in PGs (FC = -2.9) was likely associated with the 
observed decrease in membrane integrity. A single PE species, PE(16:1_16:1), was found 
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to be significantly increased in the treatment group. However, PCs and PGs were more 
prone to systems level alterations than were PEs, indicating that changes within these two 
classes of phospholipids may be associated with the observed alterations in cell 
membrane permeability.  
4.4.7 Allelopathy Also Leads to Significant Alterations in Glycolipids 
 Similarly, decreased abundance of MGDGs (FC = -2.8) and DGDGs (FC = -3.3) 
was also observed within T. pseudonana cell extracts following K. brevis exposure. 
These are the most abundant lipids in chloroplast membranes, over 80%. Thus, decreased 
concentrations of these lipids is likely associated with the decreased photosynthetic 
activity observed in these experiments. The increased membrane permeability could also 
be a result of decreased MGDGs and DGDGs, which compose over 80% of total lipid 
content in chloroplasts.36  
4.4.8 NMR Identifies Complementary Alterations within T. Pseudonana 
A wealth of complementary information can be obtained by incorporating 
orthogonal techniques such as NMR into metabolomics experiments. In addition to the 
lipids identified above, NMR metabolomics led to the discovery of aconitic acid, malonic 
acid, methyl guanidine, N-acetyl cysteine, and N-acetyl glutamine as compounds whose 
concentration was significantly suppressed in T. pseudonana samples by K. brevis 
allelopathy.22 Aconitic acid is an intermediate in the tricarboxylic acid (TCA) cycle, 
while malonic acid is an intermediate in fatty acid synthesis. The decrease in relative 
abundance of these metabolites may be explained by increased catabolism of these 
molecules as starting materials and intermediates or reduced anabolism.38,39 The 
suppression of three methylated and acylated amino acids also suggests the alteration of 
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amino acid metabolism induced by allelopathy. None of these five compounds could be 
identified using MS-based analysis, highlighting the highly complementary nature of 
information obtained by these techniques.  
 
4.5 Conclusion 
Initial exposure to the red tide dinoflaggellate K. brevis resulted in substantial 
changes within the lipidome of T. pseudonana cell extracts, as determined by the use of 
MS and NMR as complementary analytical techniques. Meanwhile, smaller often 
insigificant changes were observed in A. glacialis, likely based on the development of an 
evolved resistence in this competitor due to previous periods of co-habitation with K. 
brevis, reducing the effects of allelopathy. The study of the lipidomic response in T. 
pseudonana cell extracts may give rise to a more thorough understanding of the effects of 
allelopathy on non-resistent competitors, which displayed reduced growth rates, reduced 
cell membrane integrity, and decreased photosynthetic activity as a result of exposure. 
Significant decreases in complex lipids such as PCs, PGs, MGDGs, DGDGs and SQDGs 
were observed, while the relative abundance of a variety of smaller lipid metabolites 
including fatty acids, PFAAs and sulfolipids was increased in T. pseudonana treatment 
samples. Ultimately, these systems level alterations offer unique insight into the 
metabolic changes associated with K. brevis allelopathy in both resistant and non-
resistant phytoplankton competitors.  
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The primary focus of this thesis centers around the examination of lipids to aid in 
the diagnosis, prognosis, and mechanistic understanding of traumatic brain injury (TBI). 
Lipids are important signaling molecules and play a critical role in energy storage as well 
as membrane structure and organization. Using mass spectrometry (MS) based methods 
to perform non-targeted metabolomic experiments with a focus on extraction of lipid 
metabolites, a rodent model is investigated to explore the feasibility of developing lipid 
biomarker panels to classify injury post-hoc across multiple severities. The developed 
methods are then used to study another biological system in order to show the broad 
applicability of lipidomics by investigating the effect of Karenia brevis allelopathy on 
two phytoplankton competitors. Additionally, suggestions for potential future directions 
of the projects and improvements upon experimental limitations are included within this 
chapter. 
 
5.2 Use of High-Resolution Mass Spectrometric Metabolomics to Determine 
Lipidome Alterations Following Traumatic Brain Injury of Differential Severity 
 
5.2.1 Summary of Accomplishments 
In order to measure the changes in relative abundances of circulating serum lipids 
resulting from the induction of TBI in rats, a CCI device was used to generate moderate 
TBI in rats. A subsequent study utilized the same techniques to detect differences in 
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serum abundances in the setting of mTBI. Protocols for the extraction of serum lipids 
were established and multivariate modeling techniques were used to classify TBI and to 
discover potential novel biomarker candidates of TBI. The developed LC-MS methods 
were used to separate, detect, identify and provide relative quantification for many unique 
lipid metabolites that may ultimately serve as biomarkers of TBI.  
In the first study, thirty-four animals weighing 300-400 g were randomly assigned 
to the following groups: (1) naïve (n=10), (2) sham-operated (n= 8; n=4, 3 days post-
surgery; n=4, 7 days post-surgery), and (3) controlled cortical TBI (TBI, n= 16; n=7, 3 
days post-injury; n=9, 7 days post-injury). A panel of 26 metabolites was created using 
omniClassifier to conduct rigorous feature selection across four unique classifiers 
(Bayesian, K-nearest neighbors, logistic regression and support vector machines), which 
performed classification of injured vs. non-injured samples with 85% accuracy.1 Both 
inner and outer cross-validation were utilized to avoid overfitting. Using the same 26-
feature model, binary comparisons of sham-operated vs TBI and naïve vs. TBI each 
performed with greater than 90% accuracy, indicating that the serum lipidome alterations 
were associated directly with injury and were not attributable to another confounding 
factor. Some minor differences in lipid abundances existed between the 3- and 7- day 
timepoints, though injury was the main discriminating factor, not time of sampling.  
Several trends could be observed based on the classes of lipids selected for 
inclusion in the multivariate classification panel. Increases in all measured and identified 
FFAs such as AA, DHA and EPA as well as corresponding decreases in a variety of 
membrane phospholipids such as PE(20:4_16:0), PE(18:0_22:4), and PC(20:2_18:0) 
were observed. These changes were likely the result of the activation of phospholipase 
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A2, which causes the liberation of AA, DHA, EPA and other FFAs from membrane 
phospholipids. An increase in DGs was also observed, specifically those containing 
PUFA residues (22:6 or 20:4). TBI is known to stimulate the activation of phospholipases 
C and D, resulting in increased abundances of PUFA-containing DGs.2 Finally, the 
relative concentration of cholesterol sulfate (CS), a unique metabolite in the cholesterol 
and steroid hormone biosynthesis pathway, was decreased following induction of TBI.  
A follow-up study was conducted to determine how the severity of injury affected 
serum lipidome alterations stemming from mTBI. Using a closed-head injury model, the 
same CCI device was used to induce mTBI in another cohort of adult male Sprague-
Dawley rats using a matched pair study design (n=30). A separate multivariate 
classification panel was generated to distinguish between mTBI and control samples, 
which performed with an accuracy of 88.5%, sensitivity of 87.5%, and specificity of 
89.5%. While the majority of features selected within the two classification panels were 
different, CS was selected as a novel biomarker of injury in both studies of mild and 
moderate TBI, displaying a significant decrease in the TBI cohort.  
5.2.2 Moving Forward 
The work presented in chapters 2 and 3 demonstrates the utility of lipids as 
biomarkers for the detection of TBI in the serum of rodents across multiple injury 
severities. Additional studies are warranted to independently validate the proposed 
biomarkers and to address several limitations within the design of experiments. The 
following studies are recommended in order to fully characterize the lipidomic alterations 
stemming from TBI: 
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1. The work contained within this thesis focused on the development of a lipid-based 
biomarker panel for the diagnosis of TBI in a homogeneous cohort of adult male 
Sprague-Dawley rats. While the use of this population minimized the number of 
independent variables being examined experimentally, it did not capture the 
heterogeneity of the population incurring TBI clinically. Future studies must consider 
how the lipidomic response to TBI varies based on sex, strain, and age of the animals to 
account for inherent population heterogeneity. Additionally, the use of orthopedic 
controls (i.e. musculoskeletal injuries), or control subjects with injuries to tissues other 
than the brain, is needed to demonstrate whether the alterations in serum lipids associated 
with TBI stem from biochemical changes within the brain or general inflammation.3  
2. While it has been demonstrated that the abundances of certain lipid species are 
altered following TBI, this association does not indicate the source (i.e. brain or 
peripheral tissues) of these biochemical changes. For example, if the source was the brain 
molecules would have to exit the brain to be detectable in the blood. The BBB normally 
acts to prevent diffusion of molecules between the brain and the blood, but this 
membrane has been shown to be disrupted, particularly in the case of severe TBI.4 
Increased permeability of the BBB has also been shown in cases of mTBI, though such 
changes are often much shorter in duration.5 Additionally, lipophilic molecules may 
diffuse through an intact BBB, though proteins require alternative transport mechanisms 
for the clearance of molecular effectors into systemic circulation.6,7  
Lacking lymphatic circulation, the brain instead possesses a glial lymphatic 
(glymphatic) system, which has recently been investigated as a means of clearance for 
proteins.8 Therefore, future studies must investigate the nature of efflux of potential 
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biomarkers of TBI in order to determine whether their clearance is via BBB-only 
transport or potentially through multiple efflux routes.9 For example, pilot studies were 
conducted in which injection of small volumes of AlexaFluor594 dye, a small fluorescent 
tracer, into the lateral ventricle, were subsequently detected in the blood 30 min after 
injection using high resolution MS. While these experiments demonstrated the utility of 
this approach to examine efflux of surrogate biomarkers, they must be further expanded 
upon. We have also examined tracer efflux using IR imaging of lymph and peripheral 
circulation, which allows us to measure the kinetics of tracers and determine if the route 
is brain to lymph to blood, or directly into the blood. Alexis Pulliam, a graduate student 
in Dr. LaPlaca’s research group, has begun experiments investigating the glymphatic 
system as a potential clearance route for molecules from the brain. Determining the major 
efflux pathways of lipid effectors from the brain to blood would help to establish how 
these markers reach systemic circulation and aid in questions regarding specificity. 
In order to determine the efflux routes for biomarker clearance, the sampling of 
different biological fluids must be incorporated into the experimental design. Measuring 
the concentrations of biomarkers, or specified molecular effectors that model biomarker 
candidates, in CSF, interstitial fluid (ISF), saliva, urine and blood could enable the 
development of a closed-system model accounting for total lipid metabolism.  
3.  A variety of time-points were sampled throughout the presented studies. Serum 
lipid profiles measured at both 3- and 7- days following moderate injury were each easily 
distinguished from control samples. The study of mTBI showed that changes in lipid 
abundances were present as early as 24 h post injury. Future work must demonstrate how 
the differences in lipid abundances vary based on the time-point sampled post-injury. 
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Additionally, more detailed temporal profiles should be generated to determine the 
earliest time at which TBI can be objectively diagnosed using either the proposed panel 
of biomarkers or a similar, independently validated set of biomarkers. Thus, serial 
sampling at regular intervals such as 1 h, 6 h, 24 h, 72 h, and 168 h post-injury would aid 
in biochemically determining the optimal time to measure specific biomarkers for the 
diagnosis and tracking of recovery from injury, such as when the difference between 
control and injured samples is the greatest and when levels return to baseline. In order to 
conduct such experiments, blood vessel cannulation can be used to avoid multiple needle 
entries into a single site to minimize pain and stress in the animals.10 This method also 
improves reproducibility of blood collection and accurately limits the volume of blood 
collected to levels within guidelines set forth by the National Institutes of Health.11,12,13,14 
The metabolism of the detected substances must also be considered to account for 
molecular degradation,  processing, diffusion or excretion, which may mask primary 
biochemical changes. 
4. While major research efforts have focused on determining the pathophysiological 
response to single impact injury as previously discussed, outcomes stemming from 
repeated blows to the head can be even more devastating.15,16 It is well known that boxers 
suffer from progressive neurological deterioration as a result of repetitive brain 
trauma.17,18 Buildup of diffuse amyloid plaques are a hallmark of this disease, now 
referred to as CTE.19 CTE has been associated with mood and behavioral changes, 
memory impairment and Parkinsonism, as well as speech and gait abnormalities.20 
Additionally, CTE develops in at least 17% of individuals who suffer from repeated 
mTBIs.21 While advanced imaging techniques may aid in the detection of Aβ plaques, 
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autopsy is still required to confirm diagnosis of CTE.22 Approaches such as those 
described in this thesis may be useful to study the progression of neurological 
dysfunction by examining lipid alterations as a potential component of underlying 
mechanisms that may lead to neurodegeneration stemming from repetitive concussive or 
subconcussive events. 
MALDI-MS utilizes the energy of a laser to induce ionization of molecular targets 
co-crystallized with an energy absorbing matrix with minimal fragmentation. The advent 
of the RapifleX MALDI Tissue-typer (Bruker Daltonics) instrument has substantially 
reduced anticipated analysis time, minimizing time needed to for sample acquisition 
through the introduction of a high frequency 10,000 Hz laser. To this end, we have 
initiated the use of MALDI-MS to rapidly assess the entire brain of injured rats and 
reconstruct a 3D image using the lipid distribution acquired during analysis in an effort to 
understand the pathophysiology of repeated impacts to the head, which commonly occur 
during practice sessions in the days following sporting events. Time-matched sham 
animals will be used to examine differences in the brain lipidome resulting from either 
single impact injury or repeat (5x) injury while controlling for duration of anesthesia 
exposure. Many of the necessary methods, including matrix deposition and MS 
acquisition setting optimization are being developed using 2D image generation. Dr. 
Clint Alfaro, a post-doc in the Fernandez research group, and Eric Gier, a graduate 
student, have begun experiments to investigate the alterations in lipids directly in brain 
tissue using the Bruker RapifleX instrument for speed of acquisition and potential for 3D 
imaging, while a SolariX 12 Tesla FT-ICR (Bruker Daltonics) instrument will be used to 
provide enhanced resolution of biochemical species being investigated.  
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5.2.3 Limitations of the Current Work 
A few limitations of the experiments conducted should be acknowledged. Best 
practice protocols for LC-MS based non-targeted lipidomics experiments include a 
spiked internal standard (IS) to provide a reference for quantification of lipid 
metabolites.23 While it would be impractical to include a standard for each of the 
thousands of individual compounds being analyzed simultaneously, one or more 
standards per lipid class expected should be spiked into the samples at levels 
approximating endogenous concentrations during each stage of sample processing. To 
quantify lipids, it is a common practice to normalize the individual molecular ion-peak 
intensities using an IS for each lipid class. The calculated ratio of analyte and IS is then 
multiplied by the concentration of the IS to obtain the concentration of a particular 
analyte. The IS must be included prior to sample extraction to accurately measure 
concentrations in blood while correcting for extraction efficiency of the lipids.24,25 While 
typical ESI-MS instruments cover 3-4 orders of magnitude, the lipid concentrations can 
vary in tissue by 1012 or more (from millimolar levels of TGs to attomolar concentrations 
of eicosanoids).26,27 Additionally, species in non-polar lipid classes and other neural lipids 
(e.g., CEs, DGs, TGs, etc.) do not have a dominant ionizable head group. Species in these 
lipid classes do not exhibit identical response factors even in a very low concentration 
region.28 For accurate quantification, response factors of individual non-polar species 
must be pre-determined in relation to their acyl chain length and unsaturation.  
The use of a two-phase extraction such as the Bligh and Dyer (BDE) or Folch 
extraction may be warranted in order to analyze all lipid subtypes for discovery studies, 
though these experiments may be limited by throughput due to the involvement of 
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multiple steps in the extraction protocol.29,30 In 2008, Matyash et al. introduced a novel 
sample-extraction procedure employing MTBE as an alternative solvent to chloroform.31 
The method involves addition of MeOH and MTBE (1.5:5, v/v) to the sample and 
followed by phase separation induced by adding water. The advantage of MTBE 
extraction over conventional two-phase chloroform-containing solvent systems comes 
from the low density of the lipid-containing organic phase that forms the upper layer 
during phase separation, greatly simplifying collection and minimizing sample loss. 
Furthermore, compared with chloroform, MTBE is non-toxic and non-carcinogenic, 
which reduces the environmental burden as well as the health risks for exposed 
personnel.32  
Additionally, one potential limitation of the studies may stem from a bias towards 
the detection of the easily ionizable phospholipids such as PCs and PEs, which will 
suppress the ionization of less abundant lipid classes.33 These low abundance lipids, 
including but not limited to eicosanoids, phosphoinositol phosphates, prostaglandins and 
backbone sphingolipid molecules, are often signaling molecules or metabolites of more 
abundant lipids.34,35 Similar issues arise when detecting CLs due to their localization 
within the mitochondrial membrane.36 The accurate detection and quantification of these 
low abundance lipids would lead to a more comprehensive assessment of changes in the 
global lipidome, specifically for a variety of lipid classes which hold promise for TBI 
biomarker research. Furthermore, the use of non-polar solvents such as IPA is well suited 
for the extraction of hydrophobic lipids including FFAs, TGs, and CEs, though more 
polar lipids such as PIs and sulfatides are better extracted with other solvent systems.31 
Additionally, gangliosides, unlike the majority of all other lipids, are soluble in aqueous 
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environments, so the use of a biphasic extraction and subsequent analysis of both 
fractions may be necessary for the determination of all relevant changes in the biological 
system of interest.37 These factors must be considered when designing non-targeted 
lipidomics experiments in order to accurately assess all possible metabolic pathways that 
may be disrupted in association with disease onset and progression. 
Additionally, a number of the proposed lipid biomarker candidates, such as DGs, 
TGs and CEs, could be influenced by dietary intake. An overall decrease in food intake 
following blast TBI has been observed previously.38 Additionally, we conducted a study 
showing that food intake is decreased in rodents following repetitive injury, though the 
differences were most pronounced in the first day following injury and results were not 
significant given the small sample size. Nevertheless, studies involving overnight fasted 
animals are recommended to definitively demonstrate that changes in circulating lipids 
are primarily the result of injury status rather than simply associated with changes in food 
intake. Similarly, the minor effect of mTBI on the serum lipidome could be confounded 
by a number of variables such as the previously discussed anesthesia duration, location of 
blood draw and circadian variation in circulating lipids.39,40 Controlling for these 
variables will be a critical aspect of future experimental design.  
Ultimately, the research into lipid biomarkers of TBI must be translated clinically 
through the use of human samples. While rats commonly serve as pre-clinical models for 
TBI, there are a number of fundamental differences between rats and humans. The 
biggest distinction between rat and human brains is based on size differences. Humans 
brains are large (1300 g), have increased cortical size due to the development of language 
skills and thus possess sulci or gyri for increased surface area.41 However, rat brains are 
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much smaller (~2 g), are lissencephalic and possess little white matter, which contains 
more than double the mass content of lipids relative to proteins compared to grey 
matter.42 The human brain also expresses a much larger number of genes and encodes 
more complex DNA.43 Due to these inherent differences, and difference in the lipid 
composition of the brains of humans and rodents, it is expected that a novel set of 
biomarkers will be required for the accurate classification of brain injury in human 
samples.  
The field of lipidomics is rapidly expanding and offers unique insight into 
pathophysiological changes associated with disease states such as TBI. The use of 
lipidomics for the discovery of novel biomarkers of TBI fills a gap within the literature, 
which has to date yet to effectively diagnose mTBI by objective measures and relies 
heavily on the presence of self-reported symptoms. Comparison of proposed lipid 
biomarkers with the gold standard protein biomarkers such as GFAP, NSE and UCH-L1, 
among others, is needed to build off current literature. This would allow for the 
introduction of combined lipid and protein biomarker panel for the purposes of injury 
diagnosis, prognosis of outcome, and response to treatment for TBI. The use of NP 
testing, advanced imaging modalities, and other related measures have also proven 
effective in adding objectivity to mTBI diagnosis. In the future, it is likely that a 
diagnostic tool combining multiple biochemical and pathophysiological detection 




5.3 Karenia brevis Allelopathy Compromises the Lipidome, Membrane Integrity, 
and Photosynthetic Efficiency of Competitors 
5.3.1 Summary of Accomplishments  
The same analytical methods used to study TBI lipidomics can also be used to 
understand different biological systems, such as the response of phytoplankton 
competitors to exposure to the red-tide forming dinoflagellate, Karenia brevis. We aimed 
to study the effects of K. brevis allelopathy on the lipidomes of two different 
phytoplankton competitors: Asterionellopsis glacialis and Thalassiosira pseudonana, 
using NMR spectroscopy and MS-based metabolomics. Both species are phytoplankton 
competitors, though only A. glacialis co-exists in nature with K. brevis in the Gulf of 
Mexico. Likely due to a developed resistance to K. brevis allelopathy, A. glacialis 
maintained a more robust metabolism following exposure whereas T. pseudonana 
exhibited significant alterations in lipid synthesis, cell membrane integrity, and 
photosynthetic activity. 
MS-based metabolomics analysis of phytoplankton lipidomes led to the 
identification of 80 distinct lipid metabolites whose concentrations differed significantly 
in T. pseudonana following exposure to K. brevis allelopathy. These 80 metabolites 
represent nine major lipid classes, of which members of five (PCs, SQDGs, MGDGs, 
DGDGs, and PGs) were generally less abundant when T. pseudonana was subjected to K. 
brevis allelopathy, whereas members of four classes (non-SQDG sulfonated lipids, FFAs, 
PFAAs, and PEs) were generally more abundant. Multivariate models generated using 
oPLS-DA were capable of differentiating T. pseudonana treatment samples from controls 
with 100% accuracy, with latent variable 1 explaining nearly 80% of the between class 
176 
 
variance, using only these features. In contrast, for the other competitor, A. glacialis, 
concentrations of only six metabolites were significantly affected by allelopathy. Similar 
multivariate modeling approaches were still capable of differentiating A. glacialis 
treatment samples from controls, albeit with lower accuracy (88%) and LV1 explaining 
only 21% of the between class variance, reinforcing the hypothesis that A. glacialis 
maintains a more robust metabolism in response to K. brevis allelopathy due to an 
evolved resistance stemming from prior co-habitation. 
A majority of lipids formed (PFAA, FFA, and SULF) by allelopathic exposure are 
either metabolic breakdown products or metabolic precursors of PCs and SQDGs. These 
findings suggest that A) the stress of allelopathic exposure leads to the degradation of 
complex lipids into their less complex components; or, B) allelopathic compounds 
exuded by K. brevis inhibit the biosynthetic enzymes within T. pseudonana that are 
responsible for the anabolic synthesis of complex lipids from more simple building 
blocks, resulting in a build-up of biosynthetic precursors (PFAA, FFA) and a loss of more 
complex lipids (SQDG, PC). 
 Globally, concentrations of membrane-associated lipids (MGDG, DGDG, 
SQDG, PC) were significantly suppressed for T. pseudonana exposed to allelopathy, 
leading membranes of living cells to become more permeable and therefore damaged. 
Increased membrane permeability as well as decreased photosynthetic capability both 
likely evolved due to decreases in the concentrations of membrane- and thylakoid-
associated lipids. K. brevis allelopathy appears to target lipid biosynthesis affecting 
multiple physiological pathways suggesting that exuded compounds have the ability to 
significantly alter competitor physiology, giving K. brevis an edge over sensitive species. 
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5.3.2 Moving Forward 
The identification of a number of the lipid metabolites observed in this study was 
aided by the use of the LOBSTAHS databases, which was based on exposure of the 
Phaeodactylum tricornutum diatom to oxidative stress.44 To fully annotate the lipids of 
interest, similar software should be developed for the marine diatoms being studied. 
Additionally, most diatoms have no pattern of co-occurrence with K. brevis and the 
response of each unique species can be compared to that of a number of marine 
phytoplankton competitors which do co-occur with K. brevis, such as Skeletonema 
grethae, Odontella aurita, and Stephanopyxis turris, and may therefore have developed a 
similar pattern of resistance to allelopathic effects.45 Such experiments would enable the 
determination of whether the described patterns of lipid dysregulation are common to 
phytoplankton or are species specific. This represents just one such application of 
lipidomics, which can be broadly applied to any biological system utilizing lipids as an 
energy source to solve a number of other related biological questions, such as 
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Figure A1. Representative base peak intensity chromatograms for pooled serum samples. 
Figure A2. Inner vs. outer cross validation performance plot. 
Figure A3. Frequency of selection of peaks within prediction models. 
Figure A4. Frequently selected peaks as box plots. 
Table A1. Chromatographic gradients and MS acquisition parameters. 
Table A2. Detailed chemical (MS/MS) annotation of the 26-feature panel. 
 
 
Figure A1: Lipid coverage following protein precipitation with isopropyl alcohol. 
Representative Base Peak Intensity (BPI) chromatograms for pooled serum samples from 
moderate TBI experiments analyzed in A) negative ion mode or B) positive ion mode. 






Figure A2: Estimated nested cross validation performance of TBI prediction modeling. 
Inner cross validation performance is similar to outer cross validation performance, 
meaning inner cross validation AUC is an unbiased estimate of outer cross validation 
AUC. Each point represents one iteration of cross validation. The large X’s represent the 
average performance of each of the four classifiers. The region around 0.8 AUC is 





Figure A3: Most commonly selected features to build models for classification of 
moderate TBI sorted by frequency selected– 120 maximum. Features were selected to 




Figure A4: Box plots depicting alterations in features not contained in the 26-feature 
model for the classification of moderate TBI but that were still selected with high 
frequency by omniClassifier. A) eicosapentaenoic acid, [M-H]- = 301.217, #34; B) 
docosahexaenoic acid, [M-H]- =327.2322, #35; C) LysoPE(20:4), [M-H]- = 500.278, 





Table A1. Methods information. A) Chromatographic gradients for positive and negative 
mode separations: mobile phase A- water: acetonitrile (40:60) and mobile phase B- 10% 
acetonitrile in isopropyl alcohol, each with 10 mM ammonium formate and 0.1% formic 



















 Negative mode Positive Mode 
Source capillary voltage -2.0 kV 3.0 kV 
Sampling cone voltage 30 V 40 V 
Extraction cone voltage 3 V 4 V 
Source temperature 90° C 80° C 
Desolvation temperature 250° C 150° C 
Desolvation gas flow rate 600 L/h 600 L/h 
Cone gas flow rate 50 50 
 
  
Negative Mode Positive Mode 
Time (min) % A % B Time (min) % A % B 
0 95 5 0 70 30 
1 95 5 1 70 30 
3 90 10 3 60 40 
5 80 20 5 54 46 
6 58 42 6 52 48 
10 26 74 10 45 55 
11 10 90 11 30 70 
12 0 100 15 26 74 
14 0 100 18 0 100 
   20 0 100 
187 
 
Table A2. Detailed chemical (MS/MS) characteristics of the panel of 26 metabolic features that distinguished moderate TBI from 
control samples. The fragment ions are listed in the table were obtained using the corresponding collision energy (CE). The ions 
selected for fragmentation are underlined. Each metabolite was identified according to the following four rigor levels: 1) identified 
compounds matched to authentic compound using standards (accurate mass, isotopic abundances, fragmentation spectrum and 
retention time matched); 2) putatively annotated compounds (accurate mass, isotopic abundances, and fragmentation spectrum 
matched to databases or consistent with expected fragmentation patterns); 3) putatively characterized compound classes (accurate 
mass matched to Lipid Maps, HMDB or Metlin database entry, and/or fragmentation showing a few matching characteristic fragment 
ions, such as lipid head group); and 4) unknown compound. 

































[M – H]- 
NL FA 16:0 
Loss of FA 20:4 as ketene 
NL FA 20:4 
[FA 20:4 – H]- 



























[M – H]- 
[M – H – H2O]- 










































[M + HCO2]- 
[M – H]- 
[M – HCHO]- 
[M – HCHO – H2O]- 
NL 240.2 (sphingosine base) 
NL 256.2 (sphingosine base) 
[FA 22:0 – H]- 
[FA 22:0 – H2O]- 
C18 sphingosine fragment 
C18 sphingosine fragment 
Consistent with 
predicted spectrum 




















































[M + HCO2]- 
[M – CH3]- 
Loss of Choline & HCO2 
- 
Loss of FA 20:2 as ketene 
- 
[FA 20:2 – H]- 
[FA 18:0 – H]- 
[GPC – CH3 – H2O]- 
Phosphocholine – CH3 




































[M + HCO2]- 
[M – CH3]- 
Loss of FA 16:0 as ketene 
- 
[FA 16:0 – H]- 
[GPC – CH3 – H2O]- 






















































Loss of FA 18:2 as ketene 
[FA 18:0 – H]- 





[M – CH3]- 
Loss of FA 18:2 as ketene 
NL FA 18:2 – CH3 
[FA 18:2 – H]- 
[FA 16:0 – H]- 
[GPC – CH3 – H2O]- 
Phosphocholine – CH3 
































[M + HCO2]- 









































[M + HCO2]- 
[M – CH3]- 
Loss of FA 18:1 as ketene 
Loss of FA 20:0 as ketene 
NL FA 20:0 – CH3 
[FA 22:4 – H]- 
[FA 20:4 – H]- 
[FA 18:1 – H]- 
[FA 18:0 – H]- 
[FA 17:0 – H]- 
[FA 16:0 – H]- 
[GPC – CH3 – H2O]- 




















































[M + HCO2]- 
























[M – H]- 
[M – H – H2O]- 



























[M + NH4]+ 
[M + H]+ 
[M + H – H2O]+ 
- 
NL FA 18:1 + NH3 
NL FA 20:4 + NH3 
FA 20:4 [RC=O]+ 
FA 18:1 [RC=O]+ - H2O 
Consistent with 
predicted spectrum 
















[M – H]- 























































FFA(18:2 + 1 O) 
HCD 30 

















[M – H]- 
[M – H – H2O]- 






































[M – H]- 
Loss of FA 18:0 as ketene 
NL FA 18:0 
[FA 22:4 – H]- 
[FA 20:4 – H]- 
[FA 18:0 – H]- 
- 
[GPC – CH3 – H2O]- 
PE headgroup 
Phosphocholine – CH3 
Glycerol-3-phosphate – H2O 
[PO3]- 
PE species matched 
to predicted 
spectrum [2], # 




















[M + HCO2]- 
[M – CH3]- 
Loss of FA 22:1 as ketene 





























[M + HCO2]- 
[M – CH3]- 
[FA 20:2 – H]- 
Loss of FA 20:2 as ketene 
[GPC – CH3 – H2O]- 
Phosphocholine – CH3 





































Loss of serine 
Loss of FA 20:4 as ketene 
NL FA 20:4 
[FA 20:4 – H]- 
[FA 18:2 – H]- 
[FA 16:0 – H]- 
- 
































[M + NH4]+ 
[M + H]+ 
NL FA 18:1 + NH3 
NL FA 22:6 + NH3 
FA 22:6 [RC=O]+ 
FA 22:6 [RC=O]+ – H2O 
Consistent with 
predicted spectrum 

































[M + HCO2]- 
[M – CH3]- 
Loss of FA 15:0 as ketene 
NL FA 18:1 
NL FA 17:1 
Loss of FA 18:1 as ketene 
[FA 18:1 – H]- 
[FA 17:1 – H]- 
[FA 16:0 – H]- 
[FA 15:0 – H]- 
[GPC – CH3 – H2O]- 




























[M + NH4]+ 
[M + H]+ 
[M + H – H2O]+ 
NL FA 18:2 + NH3 
NL FA 22:6 + NH3 
FA 22:6 [RC=O]+ 
FA 22:6 [RC=O]+ – H2O 
FA 18:2 [RC=O]+ 
FA 18:2 [RC=O]+ – H2O 
Consistent with 
predicted spectrum 





































[M + HCO2]- 
[M – CH3]- 
- 
Loss of FA 20:4 as ketene 
- 
[FA 22:5 – H]- 
[FA 20:4 – H]- 
[FA 19:0 – H]- 
[FA 17:0 – H]- 
[C19H32]- 
[GPC – CH3 – H2O]- 
Phosphocholine – CH3 
[PO3]- 
Consistent with 
multiple possible PC 
structures [3], # 
699 
 
LysoPC(18:2 + 1 O) 
HCD 30 

















[M + HCO2]- 




[FA 18:2 + 1 O – H]- 
[GPC – CH3 – H2O]- 




























[M + HCO2]- 
[M – CH3]- 
Loss of FA 18:2 as ketene 
NL FA 18:2 
[FA 22:1 – H]- 
[FA 18:2]- 
[GPC – CH3 – H2O]- 
Phosphocholine – CH3 
[H2PO4]- 
 Consistent with 
predicted spectrum 
(Lipid Maps) - [2], # 
196 
 
Table A2 (continued). 
 
1http://www.lipidmaps.org/tools/structuredrawing/GP_p_form.php  
2Fragment ions observed were consistent with PC(16:0_16:0), however, fragment ions corresponding to arachidonic acid (20:4) were 
also observed in the spectrum, suggesting possible co-selection of precursor ions. 
3The high resolution of the QE HF instrument reveled two precursors under feature # 118 detected with the lower 
resolution Xevo instrument. Each was examined individually and matched a specific lipid species.   
4Although this feature could only be assigned a level 3 confidence based on negative ion mode measurements, it is “paired” to another 
feature in the panel detected in positive ion mode with a higher level of confidence (feature #656).   
5Although this feature could only be assigned a level 3 confidence based on negative ion mode measurements, it is “paired” to another 
feature in the panel detected in positive ion mode with a higher level of confidence (feature #680).   
*Accurate mass matched in negative mode, fragmented in positive mode for FA chain and headgroup info 
# Accurate mass matched in positive mode, fragmented in negative mode for FA chain and headgroup info 
 
